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Abstract
The present work is on the total synthesis of the natural 
compounds and/or analogues of Bengamides, Gummiferol and 
Depudecin. The target molecules, selected in virtue of their prominent 
biological activity as antibiotic and antitumor agents are featured by the 
presence of one or two epoxide groups and were synthesized by 
application of a novel methodology of asymmetric epoxidation based on 
the use of a new class of chiral sulfur ylides. The synthetic routes 
described in this thesis employed cheap and readily available starting 
materials and all the targeted molecules were reached in a moderate to 
good overall yield, except for the case of Depudecin, whose final step has 
not yet been accomplished.
Keys words: chiral sulfur ylides, epoxides, total synthesis, 
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1.1. Natural Products in Organic Synthesis
Selection of a particular target molecule for total synthesis is 
frequently motivated by potential properties of the final product such as 
physical qualities, biological activity or medicinal applications (Figure 
1.1). For those target molecules with an interesting biological or medicinal 
profile, Nature remains an important source of inspiration;1 given the 
infinite efficiency of biologically active compounds, Natural Products 
might be then considered as "privileged structures", because of their 
characteristics of high chemical diversity, biochemical specificity and other 
molecular properties that make them suitable as lead structure for drug 
discovery.1
__________________________________________
Natural products have been widely used to study the cellular 
functions of proteins in several ways. Identification of the 
cellular receptors led to discover new proteins with functions 
linked to the effects that natural products have on cells.
______________________________________________
Playing an important role in drug discovery, nowadays, more than 
50 percent of FDA-approved drugs were NPs or NP derivatives.2 This fact 
might be due to several “quantifiable” advantages that must be 
highlighted.3,4
(i) NPs offer unmatched chemical diversity with structural 
complexity and biological potency. Although it is certainly difficult to 
calculate the scope of this advantage, a recent review estimates a ~100-
fold higher hit rate for NPs over synthetic compounds.5
(ii) When compared with synthetic compounds, NPs databases 
contain not only more scaffolds, but also an important source of 
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Figure 1.1. Chemical process for natural products discovery1
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(iii) NPs compounds serve as drugs as well as templates for drugs, 
leading to the discovery and better understanding of targets and pathways 
involved in the disease process.
As an example of the above mentioned advantages, the Table 
1.13 illustrates a list of some anticancer agents isolated from natural 
sources undergoing clinical development.
Table 1.1. Natural products of microbial origin undergoing clinical development as 
anticancer agents3
Compound Source Status
Becatecarin Rebeccamycin from Lechevalieria aerocolonigenes Phase III
CKD-732 Fumagillin from Aspergillus fumigatus Phase II
ECO-4601 Micromonospora sp. Phase I
Elsamitrucin unidentified actinomycete strain Phase II
Irofulven Illudin S from Clitocybe illudens Phase II
Ixabepilone Epothilone B from Sorangium cellulosum Phase III
KOS-953 Geldanamycin from Streptomyces hygroscopicus Phase II
NPI-0052 Salinipora tropica Phase I
NPI-2358 Halimide from Aspergillus sp. Phase I
Romidepsin Chromobacterium violaceum Phase II
Vorinostat Trichostatin from Streptomyces hygroscopicus Phase II
Temsirolimus Sirolimus from Streptomyces hygroscoicus Phase III
Given the determining role of natural products in the discovery 
and development of drug-like compounds, and taking into account the 
availability of new reagents and synthetic methods, it seems worthy 
appropriate to dedicate our efforts to the synthesis of novel natural 
products and analogues, exhibiting an intriguing biological profile.6
1.2. Total synthesis of Natural Products
Organic synthesis involves the assembly of complex molecules 
(usually containing the elements: C, H, O, N, S, P, B and halogens) from 
relatively simple starting materials and reagents through the formation 




Traditionally, organic synthesis is divided into method-oriented 
synthesis and target-oriented synthesis, which is more commonly referred 
to as total synthesis.7 The main issue of method-oriented synthesis is the 
invention, discovery and development of new synthetic reactions, reagents 
and catalysts. In contrast, the ultimate goal of total synthesis is the 
construction of a defined target molecule via a sequence of consecutive 
reactions (Figure 1.2).
As rightly discussed by Nicolaou and Sorensen in "Classics in 
Total Synthesis",7 although at the beginning the purpose of a total 
synthesis was to confirm the molecular structure of a natural product, 
nowadays, other reasons for total synthesis have emerged. Among the 
most important are: (a) the challenge of synthesizing a naturally occurring 
substance of novel architecture; (b) the opportunity to discover and 
develop new synthetic chemistry; and (c) the ability to make contributions 
in biology by providing the natural substance as well as designed molecules 

















Figure 1.2. Organic synthesis in perspective7
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Indisputably, total synthesis has indeed contributed to advances in 
a number of adjacent fields. In fact, almost half of the drugs on the 
market are natural products or derivatives thereof. Nevertheless, in the last 
decade, research on natural products by the pharmaceutical industry has 
declined. This is mainly due to a strategic shift toward combinatorial 
library synthesis of small organic molecules in combination with high-
throughput screening for lead discovery as well as optimization.3 However, 
the latest insights indicate that the generation and screening of a large 
number of synthetic compounds can at best complement but certainly not 
replace lead discovery via investigation of natural products, which have 
been carefully selected by evolutionary pressure.1
1.3. Epoxide in Organic Chemistry
Among the different functional groups, the oxirane group 
represents one of the most versatile and useful in Organic Chemistry, due 
to its capability of transformation into 1,2-bifunctional compounds, which 
are extremely appreciated in drugs and natural products synthesis, by 
means of  ring opening reactions with nucleophiles.8
Moreover, the oxirane ring can be found in a wide range of 
natural products containing epoxides in their structures. Relevant 
examples of natural products containing one oxirane ring and with 
prominent cytotoxic activities are depicted in Figure 1.3. This is 
currently the case of epothilone B, isolated from Sorangium cellulosum 
cultures and that promotes the polymerization of tubulines.9 Another such 
example is (-)-laulimalide, a potent antitumoral agent due to its potent 
microtubule-stabilizing properties that also inhibits the P-glycoprotein, 
which is active against multiple-drug resistance tumor cells.10 A few other 
shining examples are cryptophycin 1, a cytotoxin possessing very potent 




factor NF-kB in 3T3 mouse cells,12 or N1999-A2 that exhibits antitumor 
and antibacterial activities (Figure 1.3).13
Equally remarkable is the case of eponemycin14 a novel antibiotic 
with specific activity against B16 melanoma, isolated from Streptomyces 
hygroscopic us No. P247-71.
On the other hand, the occurrence of a diepoxide system is not so 
usual as the monoepoxide-containing natural products. Then it is worthy 
to mention (±)-leucomalure, a major sex pheromone component of the 
Satin moth Leucoma salicis L. (Lepidoptera: Lymantriidae)15 or squalene 




















































Figure 1.3. Some examples of  epoxide groups in natural products
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Among those striking examples exhibiting a promising biological 
activity, certain antitumor metabolites isolated from the fungus Nattrassia 
mangiferae (Sch 49210, Sch 53514 and Sch 53516),17 or the complex 
metabolite Spatol, produced by a marine tropical alga, which displays a 
potent cytotoxicity against skin and brain tumour cells, by complete 
inhibition of cell division in human T242 Melanoma and 224C 
Astrocytoma neoplastic cell lines (Figure 1.4-C).18-20
It should be also mentioned the polyketide depudecine, an histone 
deacetylase inhibitor (HDAC) isolated from the fungus Alternaria brassicicola 
(Figure 1.4-C).21,22
Finally, a novel inhibitor of angiogenesis, rhizoxin, a microbial 
metabolite that contains two epoxide groups and exhibits anti-tubulin 
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1.4. Asymmetric Epoxidation Methodologies
In the realm of asymmetric synthesis, methods that are directed 
towards the stereoselective construction of an oxirane ring constitute an 
important area of research, owing to the versatility and usefulness of this 
functional group.8
Chief among the different methodologies of epoxidation it is 
worth stressing those generating the oxirane ring from carbonyl 
compounds either from Wittig olefination followed by enantioselective 
oxidation of the prochiral olefin (oxidative methods) or by use of ylides, 
carbenes or Darzen's reagents (non oxidative methods) through 
enantioselective cycloaddition to a prochiral carbonyl group (Scheme 
1.1).24,25
Among the flurry of asymmetric methods that have been 
developed to date, there is no doubt that the Sharpless asymmetric 
epoxidation reactions,26 which rendered its inventor the Nobel Prize, has 



















Figure 1.4-C. Metabolites containing diepoxide systems
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important and most powerful reactions in organic synthesis by virtue of its 
high efficiency and generality for the enantiocontrolled synthesis of 
oxirane rings.
However, oxidative methodologies present some structural 
requirements (allylic alcohols, cis-alkenes, enones, etc.) and drawbacks 
(long reaction time, moderated enantiomeric excess, continue addition of 
oxidants, etc.). Nonetheless all these methods are synthetically valid for the 
synthesis of  enantiomerically pure epoxides.
Scheme 1.1. Main asymmetric epoxidation methodologies
WITTIG OLEFINATION














































Sharpless: TBHP, Ti(Oi-Pr)4, DET, -20ºC
Jacobsen-Katsuki: NaOCl, Mn (III)-Complex
Yamamoto: TBHP, Va catlysts
Julia: H2O2, NaOH, poly-L-aminocid
Shi: Oxone, Chiral ketones, K2CO3
Enders: O2, Et2Zn, N-methylpseudoephedrine
Jackson: TBHP, Bu2Mg, DET

































In the exploration of new methods for asymmetric epoxidation, 
chiral sulfur ylides have emerged as efficient synthetic tools not only for the 
asymmetric synthesis of epoxides,27,28 but also for aziridines29-32 and 
cyclopropanes.33-38 In this sense, the contributions by Aggarwal's group39-41 
have reaped the benefits of this type of reagent in the synthesis of natural 
products42-44 and drug-like compounds.45-48
To this aim, amide-stabilized sulfur ylides49-55 are particularly 
valuable for three reasons: i) they only require very mild conditions and 
simple procedures for their reactions with carbonyl compounds, ii) they 
show high diastereocontrol in favor of the trans epoxides, and 3) the 
synthetic potential of the resulting glycidic amides, which displays 
exquisite regiocontrol for the C2 position in reactions with nucleophiles.
56-59
In the case of amide-stabilized sulfur ylides, the chirality can be 
introduced in the amide fragment (type A), or in the sulfur fragment (type 
B). A third case, which has not been studied so far, can be represented by 
cyclic sulfur ylides of type C, which in our own experience render a high 
degree of diastereoselection in their reactions with carbonyl compounds 
owing to the presence of  a chiral bicyclic system (Scheme 1.2).57
These new chiral sulfur ylides should yield epoxy amides of the 
type C depicted in Scheme 1.2 and offer diverse synthetic possibilities, 
including oxirane ring-opening reactions that are combined with the 
reduction or hydrolysis of  the amide functionality.57
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Our experience with the synthesis of glycidic amides via amide-
stabilized sulfur ylide51,56,57,60 prompted us to consider the asymmetric 
version via this new potential class of chiral sulfur ylides (type C) which 
where succesfully synthesized from the corresponding commercially 
available amino acids. Thus, for the synthesis of the sulfonium salts 4 and 
6, which are precursor of sulfur ylides 1 and 2, L- and D-methionines 
were subjected to treatment with LiAlH4, followed by reaction with 
acetone under acidic catalysis with camphorsulfonic acid (CSA). The 
subsequent treatment with 2-chloroacetyl chloride furnished 2-
chloroacetamides 3 and 5, which were not isolated and were treated with 
sodium perchlorate in acetone to obtain, after crystallization, cyclic 
sulfonium salts 4 and 6 in 70% overall yields from L- and D- methionines, 
respectively (Scheme 1.3).






































It is important to highlight that sulfonium salts 4 and 6 were 
isolated as single diastereoisomers, which was essential for obtaining high 
asymmetric induction in their reactions with aldehydes.54
With regard to the reactivity, in situ preparation of ylides 1 and 2 
by treatment of their corresponding sulfonium salts (4 and 6) with an 
aqueous solution of NaOH in tBuOH, followed by the addition of the 
aldehyde (one-phase method) or with an aqueous solution of NaOH in 
CH2Cl2-H2O (two-phase method)61 when the aldehyde was basic sensitive, 
afforded their corresponding epoxy amides, isolated as single 
diastereoisomers, which indicated an excellent level of stereochemical 
control. These epoxyamides were easily converted into the epoxy alcohols 
or epoxy aldehydes, as appropriate (Scheme 1.4).
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The high asymmetric induction provided by sulfonium salts 4 and 
6, together with the resulting stereochemistry was tentatively justified 
based on the structure of these sulfonium salts, by which the configuration 
at the sulphur atom might be established. In these previous studies, this 
configuration assignement was achieved by a combination of 
spectroscopic and theoretical studies since X-rays of these compounds 
were not possible to be obtained during those studies. Recently, we were 
able to obtain the X-rays of both 4 and 6 and the results demonstrated 
that we failed in our initial configuration assignments.*  As showed in 
Schemes 1.5-A and 1.5-B, the configurations at the sulphur atoms were 
the opposite in a conformation that could be match with the NOE 
correlations found during the spectroscopic studies.































(9) (de > 98%)




















* X-ray experiments were registered on a Nonius Kappa CCD diffractometer by Dr. John 
Davies in collaboration with Prof. S. V. Ley. Department of Chemistry, University of 
Cambridge, Lensfield Road, Cambridge (CB2 1EW)
Assuming that the stereochemistry at the sulphur atom of the 
ylide remains the same with respect to its sulfonium salt precursor, as we 
experimentally demonstrated by the formation of sulphur ylide and 
Scheme 1.5-A. Demonstration of the stereochemistry at the sulfur atom of sulfonium 













Scheme 1.5-B. Demonstration of the stereochemistry at the sulfur atom of sulfonium 


































4b (X = AcO)
Me MeX NaOH, tBuOH
AcOH, 0˚ C (quant.)
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quenching with acetic acid that afforded sulfonium salt with similar 
diastereomeric purity, we then rationalized the resulting stereoselectivity as 
described in Scheme 1.6. This rationale would then support a concave 
approach as the most favourable pathway, in contrast to the transition state 
that is derived from a convex approach that would exhibit an important 
steric hindrance between the starting aldehyde with the methyl group at 
the sulphur atom. Combining this concave approach with a preferred 
cisoid arrangement between the reactants, ylide 1 could attack the 
aldehyde on its re or si faces. Initially, the preferred si face attack should 
proceed through intermediates I and II, after rotation of the C-C bond. 
This pathway should lead to the cis epoxide not detected due to the high 
barrier for ring closure being this step the rate determing step. Taking into 
account the reversibility of the betaine formation, as demonstrated by 
Aggarwal in crossover experiments, makes this pathway non-productive 
instead reverting back to the starting aldehyde and ylide. Then, the attack 
on the re face should led us to intermediates I’ and II’ being the ring 
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Hence, with the development of this new methodology of 
asymmetric epoxidation,56 natural products of biological interest, such as 
the case of bengamides (11),62 the cyclodepsipeptides globomycin (12) and 
SF-1902 A5 (13),63 or the sphingoid-type bases such as clavaminol H (14), 
phytosphingosine (15), sphinganine (16) or sphingosine (17) have been 
synthesized (Figure 1.5).64
From this point, the next step and main goal of this thesis was the 
use of this emerging approach to the synthesis of new scaffolds and their 













































Sphinganine (16): R = CH3(CH2)14-
Sphingosine (17): R = (E)-C13H27CH=CH-
Globomycin (12) R = CH3, n = 3 
SF-1902 A5 (13) R = CH3, n = 5




1.5. Aims and Outline of This Thesis
The remainder of this thesis will be the result of my efforts in the 
field of asymmetric total synthesis. The aim of every total synthesis 
discussed in this thesis is to develop an efficient route to the final product 
in relation to the introduction of stereogenic elements. The study 
objectives include the preparation and characterization of natural 
products and analogues with biological activity as antibiotic and/or 
antitumor agents. The biological background as well as the synthetic 
history of each target compounds will be introduced prior to discussion of 
the actual synthesis.
Chapter 2 provides a comprehensive review of the current 
research status of bengamides and includes a brief introduction to the 
structure, classification and precedents together with their eminent role as 
antitumor agents. As main objective, the major part of this chapter 
summarizes the strategies and experimental approaches to a new class of 
bengamide analogues containing either one or two epoxides throughout 
the polyketide chain, that might mimic the mode of action of fumagillin. 
With the purpose of better understanding the mechanism of action 
exhibited by bengamides, azido derivative in position C4 will be also 
described. Finally, the biological evaluation of some of the analogues 
synthesized will be discussed.
Chapter 3 describes the synthesis of gummiferol, a cytotoxic 
metabolite with antitumor activity that possesses two consecutive oxirane 
rings conjugated to a triacetylene moiety, by means of the use of chiral 
sulfur ylides. The isolation and characterization is described across this 
chapter as well as the synthesis of the natural product and analogues 
reported to date. In this way, the second objective will be to develop an 
alternative to the previous synthesis of gummiferol by generating the 
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epoxides in a stereoselective fashion by means of the chiral sulfur ylide 
methodology.
In Chapter 4, depudecin, a new microbial metabolite with 
promising antiangiogenic activity is presented together with its biological 
synthesis. Hence, our ultimate goal will be to stablish an efficient and 
straightforward route toward its total synthesis.
A further chapter (Chapter 5) has been included, displaying 
additional synthetic projects carried out during this thesis. Hence, 
contributions to the synthesis of the natural products globomycin, 
epibestatin and celebeside A, as well as the protease inhibitor 
AcArgValArgArgCMK, are described by using the solid phase synthesis 
methodology.
Finally, a summary of the outcome of this work, a general 
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In 1986, Crews et al. described how "The methanol extract of an 
undescribed Fiji sponge contains the novel seven-membered ring heterocycles, bengamide A 
and bengamide B, which are cyclized by a ɣ-hydroxylysine. [...] These compounds are 
biotoxic to eukaryotic cells, nematodes, and bacteria".1 Within the huge variety of 
natural products with potential biological applications,2,3 those containing 
an α-amino-ε-caprolactam moiety have attracted great interest in the 
pharmaceutical industry,4 which is currently the case of  bengamides.
2.1. Structure and Classification of Bengamides
Bengamides5 (Table 2.1) comprise a family of natural products 
isolated from marine sponge of the Jaspidae family, discovered in 1986 by 
Crews and co-workers, with a wide range of biological activities as 
__________________________________________
Bengamides, isolated from marine sponges, have proved to be a 
prolific family of natural products by virtue of their 
unprecedented molecular architectures and impressive biological 
profiles, including antitumor, antibiotic and anthelmintic 
properties. Such antitumor activity is related to the inhibition 
of methionine aminopeptidase enzymes involved in the cell 
cycle of  endothelial cells and angiogenesis.
______________________________________________
antitumoral, antibiotic and anthelminthic.6,7 Some new members of the 
bengamides family (bengamides E, E' and F'), have been recently 
identified and isolated from Myxococcus virescens bacteria and reported by 
Crews et al.8
Harvesting bengamide-producing sponges or finding a 
bengamide-producing organism that could be growth in culture have been 
completely unsuccessful so far,9 stirring up great interest in total synthesis 
that could provide suitable amounts of these compounds. In this way, 
numerous syntheses of bengamides have been reported, all of them 
utilizing an amide coupling reaction between a protected polyhydroxylated 
side-chain intermediate and a cyclolysine intermediate, and employing 
different starting materials, such as L- and D- glucose,10,11 L-
quebrachitol12 or D-tartaric acid,13 among others.14
2.2. Bengamides as Inhibitors of MetAP
Within all the members of the bengamides family, bengamides A 
(18)  and B (19) are the most potent, with IC50 values against larynx 
epithelial carinoma of 0.001 and 0.0024 µM, respectively, followed by 
bengamide E (11), with an IC50 value of 3.3 µM.15 Whereas in vivo studies 
demonstrated cytotoxicity profile against MDA-MB-435 human 
mammary carcinoma,16 in vitro anti tumour activity of bengamide B (19) 
disclosed a unique profile in the NCI 60 cell line panel compared to 
standard anti tumor agents, revealing arrest at both G1 and G2/M phases 
of the cell cycle by FACS (Fluoresecence-activated cell sorter), which 
suggests that the cytotoxicity exhibited by the bengamides was due to 
inhibition of  a novel target.6
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Bengamide R1 R2 R3 R4
A (18) H OCO(CH2)12CH3 H HB (19) CH3
G (20) H OCO(CH2)11CH3 H HH (21) CH3
I (22) H OCO(CH2)13CH3 H HJ (23) CH3
L (24) H OCO(CH2)11CH(CH3)2 H HM (25) CH3
N (26) H OCO(CH2)10CH(CH3)2 H HO (27) CH3
Y (28) H OH H H








H HD (31) CH3
TYPE II
Bengamide R1 R2 R3 R4
E (11) H H H H
F (32) CH3 H H H
E’ (33) H H H CH3
F’ (34) CH3 H H CH3
P (35) H H C(=O)(CH)12CH3 H
Q (36) CH3 H C(=O)(CH)12CH3 H
R (37) H H C(=O)(CH)14CH3 H
Proteomic studies carried out by Towbin et al. allowed to establish 
MetAPs, enzymes related to the protein biosynthesis, as the molecular 
targets for bengamides5 inhibiting the tumor growth both in vitro and in 






Methionine aminopeptidase enzymes represent a unique class of 
metal dependent amino peptidases that remove unblocked N-terminal 
initiator methionine on either peptides or proteins,18 both in a co-
translational or post-translational mode,19 suggesting a role in regulating 
processes rather than general protein degradation.18 The removal of the 
N-terminal methionine by MetAPs is a critical step in the maturation of 
many proteins and is essential for further amino terminal modifications.20 
Therefore, its inhibition has acquired a special importance since it has 
been demonstrated that MetAP2 is involved in the development of a 
certain number of  tumours.21
2.3.1. Comparison between MetAP Type I and II
There are two isoforms of methionine aminopeptidases, type I 
(MetAP1) and II (MetAP2),22,23 differing from one another by particular 
differential sequences. Thus, the type II enzymes present an α-helical 
domain of 60 residues inserted in a surface loop of the C-terminal half of 
the molecule.24 The proximity of this domain to the active site suggests 
that it is the key for the differentiation in specifity of the two classes. Also, 
the modifications due to the presence of N-terminal extensions further 
differentiate the enzymes.18 Moreover, type I is further divided into types 
Ia, Ic (prokaryotes) and Ib (only in eukaryotes) (Figure 2.1).25,26 The 
eukaryotic MetAPs are differentiated from their prokaryotic counterparts 
by an additional N-terminal extension.24 The eukaryotic MetAP2 has two 
putative zinc finger motifs at the extreme N-terminus and a highly charged 
N-terminus with alternating polyacidic and polybasic stretches in a 
similarly sized segment. Although the catalytic domains of both MetAPs 
possess very similar structures, all the residues that form the methionine-
binding pocket are different, but the shape of the pocket is conserved. 
Furthermore, MetAP2 also contains an inserted region contacting the 
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catalytic domain in some of the same area covered by the connector of 
the type I.25 These data support the proposal that MetAP types I and II 
may present a common functional role.
From the biomedical point of view, MetAP2 has attracted much 
more attention that MetAP1 due to the discovery of MetAP2 and not 
MetAP1 as the biological target of some of the anti-antiogenic 
compounds, such as the aforementioned fumagillin (38) and ovalicin (39)27 
(Figure 2.2), together with their synthetic analogues and other synthetic 
molecules.28 One reason is the smaller active site pocket of the type I 
enzyme, which limits accessibility. A second reason is that inhibitor 
binding to HsMetAP1 requires ~120º rotation of His210 and disruption of 
hydrogen bonding to Tyr195.25 In HsMetAP2, a histidine (His339) 
undergoes a related conformational change, but there is no loss of 
hydrogen bonding.27 Taking into account that methionine amino 
peptidases have been identified as antitumor target for these anti-
angiogenic agents, it would be interesting to investigate the role of these 
enzymes in angiogenesis. However, despite numerous studies stressing the 
role of aminopeptidases in the formation of new blood vessels, it is still 
unclear what role MetAP2 plays in regulating angiogenesis.29




The overall relationship between the structures of type I and type 
II human MetAP is illustrated in Figure 2.3.25 The catalytic domains, 
with only 27% sequence identity, however, have very similar structures. All 
the metal-binding residues in the active site are conserved, whereas almost 
all of the residues that form the methionine-binding pocket are different. 

















Figure 2.2. Fungal metabolites inhibitors of  angiogenesis
Figure 2.3. Stereo diagram showing the relationship of tHsMetAP1 (green) and 
HsMetAP2 (cyan) structures. The catalytic  domains are very similar. The connector 
region of tHsMetAP2 (red) and the insert domain (blue) of HsMetAP2 are located in 
similar regions of  the surface of  the catalytic domains25
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In the presence of excess Co+2, a third cobalt ion binds in the 
active site region. This fact explains why excess of metal ions can be 
inhibitory.25 Also, the N-terminal region of the protein contains three 
distinct Pro-x-x-Pro motifs, supporting the prior sugggestion that this 
region of  the protein may participate in binding to the ribosome.
The recently reported structure of M. tuberculosis MetAP provided 
the first example of a MetAP with a structured extension at the amino-
terminus. Within this extension, there is a sequence element Pro-X-X-Pro 
motif that is arranged on the surface of the protein in such a way that it 
seems poised to bind an SH3 protein domain. This led to the suggestion 
that the PxxP motif of M. tuberculosis MetAP might be the target site for 
mediating MetAP binding to ribosome.30
2.3.2. Structure of the Complex MetAP2-Bengamide
In order to shed light to the mechanism of inhibition of 
methionine aminopeptidases (MetAP) by bengamides, HsMetAP2 was co-
crystallized together with the synthetic inhibitor LAF153 (40), a non-
acylated derivative from LAF389 (41), that also inhibits HsMetAP2 both in 
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This enzyme-substrate complex structure proved the mode of 
interaction of these bioactive compounds at the active site of the 
methionine aminopeptidases (Figure 2.5-A). Hence, the X-ray structure 
revealed a critical dinuclear metal center placed as a deep invagination in 
the surface of the enzyme.18 On the other hand, the hydrophobic pocket 
P1, in the innermost portion of the active-site, interacted with the 
terminal alkyl group of the olefin, while pocket P2, formed at the solvent-
exposed surface, hold the caprolactam ring. The coordination of the 
cobalt ions with the hydroxyl groups at C3, C4, and C5 occurred in a 
similar way to that observed for peptidic inhibitors of aminopeptidases 
(Figure 2.5-B). 31
Once the mechanism of interaction was known, considerable 
variations of the structure of bengamides have been made and numerous 
analogues owning better bioactivity profile synthesized, such LAF-389 
(41)32 and its synthetic analogues (42) and (43),33 which exhibited an 
increased antitumor activity compared to bengamide A (IC50 = 0.001 ± 
0.0006 μM) and stressed the influence of the alkyl group at P1 and the 
caprolactam moiety in the biological activity (Figure 2.6).
Figure 2.5. (A) Structure of human MetAP2 in complex with the bengamide 
analogue LAF153 (B) Mechanism of  action of  bengamides with MetAPs
























Angiogenesis, the formation of new blood vessels from pre-existing 
microvasculature takes place during physiologic and reparative processes.34 
Neovascularization is critical for the growth of tumours and is a dominant 
feature in a variety of angiogenic diseases such as diabetic retinopathy, 
haemangiomas, arthritis and psoriasis.35 Frequently described as one of 
the hallmarks of cancer, because of its role in tumour growth, invasion 
and metastasis,36 the discovery of fumagillin, a fungal metabolite isolated 
from a species of Aspergillus sp. that can potentially suppress tumour 
growth, supported the development of new angiogenesis inhibitors.28,37 
Different types of anti-angiogenic agents have been shown to affect 
angiogenesis, and some of these agents are now in clinical trials in patients 
with cancer or AIDS.38
2.4.1. Angiogenesis Process
In their book Angiogenesis, A. Rodríguez-Quesada and M. A. 
Medina pointed out that "the growth of new blood vessels from the existing 
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of the steps involved in angiogenesis may be a potential target for pharmacological 
intervention of  angiogenesis-dependent diseases”.39
The angiogenesis process is divided into four steps, each of which 
can be considered as a pharmacological target (Figure 2.7).36
The first step covers an activating proangiogenic signal that elicits 
the switching on of the angiogenic phenotype of resting endothelial cells. 
During the second step, those activated cells cause the degradation of the 
basal membrane, extracellular matrix remodeling, proliferation and 
migration. Finally, morphogenesis contributes to the alignment of 
endothelial cells by forming a new micro vessel that is stabilized by the 
recruitment of  pericytes and smooth muscle cells.
2.4.2. Angiogenesis and Fumagillin
Fumagillin (38), isolated during routine culturing of capillary 
endothelial cells contaminated by the fungus Aspergillus fumigatus was one of 
the first reported inhibitors of  the endothelial cell proliferation.28
Despite fumagillin inhibits endothelial cell proliferation in vitro and 
tumour-induced angiogenesis in vivo, its prolonged administration was 
1 2 3
54
Figure 2.7. Scheme of  the steps of  the angiogenic process39
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limited because it caused severe weight loss. This result has led to develop 
new derivatives displaying more potent activity and without the usual toxic 
side-effects.28 One of this fumagillin analogues, TNP-470 (44) (also known 
as AGM-1470) (TAP Pharmaceuticals Inc., Deerfield, IL, EUA), exhibits 
an IC50 value 50-fold more active than the fumagillin parent and a 
reasonably better selectivity (Figure 2.8).
The molecular mechanism of the inhibition of angiogenesis by 
AGM-1470 (44) is specifically related to the type II methionine 
aminopeptidase. It also inhibits the activation of the cyclin-dependent 
kinases and the phosphorylation of the retinoblastoma gene product.40 
This compound is currently undergoing in phase II clinical trials for a 
variety of cancers, including Kaposi’s sarcoma, prostate cancer, cervical 
carcinoma, glioblastoma, pancreatic cancer and renal cancer.41
2.4.2.1. Structure of HsMetAP2 Complexed with Fumagillin
The relationship between the antiproliferative activity of various 
fumagillin analogues with their ability to inhibit MetAP2 activity in vitro 
suggests that MetAP2 is the physiologically relevant target of fumagillin-
based therapeutic agent.40 This proposal is supported by a recent report 
that human endothelial cells are specially sensitive to fumagillin and that 
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The X-ray analysis of the complex MetAP2-fumagillin showed a 
covalent bond between an imidazole nitrogen atom of His231 and the 
carbon of the spirocyclic epoxide (Figure 2.9).27,40 This covalent bond 
formation is responsible for fumagillin’s irreversible inhibition.27
Although not predicted, the formation of this C-N bond is 
analogous to the alkylation of a catalytic histidine by α-chloroketone-type 
inhibitors of  serine proteases.42
The residue of His231 does not move considerably upon bond 
formation; its nucleophilic imidazole nitrogen is perfectly positioned to 
bind with the methylene of the epoxide (Figure 2.10-A). The oxygen, 
liberated from the breaking of the epoxide is coordinated with cobalt (3.28 
Å), and it occupies the approximate position of the cobalt-associated water 
molecule in the uncomplexed structure.27 A molecule of water, equidistant 
from both cobalts, forms a hydrogen bond with this fumagillin oxygen 
(Figure 2.10-A). The only residue that moves significantly upon 
fumagillin complexation is His330, which rotates its side chain to avoid 
close contacts with fumagillin (Figure 2.10-B).27
Figure 2.9. Overall structure of  the complex HsMetAP2 and fumagillin27
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The epoxide-bearing side chain of fumagillin occupies the 
completely covered pocket near the active site (Figure 2.10-B).27 It has 
hydrophobic contacts with His231 at the mouth of the pocket, Tyr444, 
Ile338, His339, and Phe219. A well-defined water molecule forms hydrogen 
bonds with the side chain epoxide and the methoxyl group at C5 (Figure 
2.10-A).27 The long unsaturated side chain protrudes from the binding 
pocket and makes two hydrophobic contacts with Leu328 and Leu447, and 
both residues are conserved in the MetAP2 family. Leu447 lies near the end 
of the insertion that defines the MetAP2 family and the constriction 
formed by the Leu447-Leu328 pair provides a structural basis for the 
MetAP2 family’s requirement for a substrate with a small side chain at 
P2.43 The terminal carboxyl of the side chain makes a hydrogen bond 
with Asp376.27
A B
Figure 2.10. (A) LIGPLOT of fumagillin in the binding pocket (B) Fumagillin in 




2.4.2.2.  Differences between  Bengamides and Fumagillin  and 
Ovalicin
Bengamides differ from the known MetAPs inhibitors, fumagillin 
and ovalicin in several aspects. Inhibition by fumagillin and ovalicin is 
achieved at the molecular level by the presence of two epoxide groups and 
the subsequent covalent binding to His231 located in the active site of 
MetAP2 as mentioned before (Figure 2.11).27,44 Additionally, both 
compounds are selective inhibitors of endothelial cell proliferation, 
whereas bengamides inhibit all the tested cells (endothelial and epithelial). 
As depicted in Figure 2.11, the highly specific affinity of the bengamides 
towards methionine aminopeptidases is the result of multiple interactions 
that include hydrophobic and polar interactions of the terminal alkyl 
group of the olefin and the caprolactam moiety with the P1 pocket and 
the solvent-exposed P2 region, respectively, together with a coordination of 
the cobalt ions, present at the active site, with the hydroxyls at the C-3, 




































Figure 2.11. Interaction of  bengamides and fumagillin with MetAP2
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2.5. Synthesis of Bengamide Analogues
The intriguing biological activity exhibited by bengamides as 
promising new anticancer compounds led to our research group to 
delineate a synthetic strategy for bengamides and analogues, based on the 
above mentioned novel asymmetric epoxidation methodology.45,46
This synthetic strategy, consisted of three key steps detailed below, 
provided ready access to a set of analogues by modifications at C-2 and 
olefinic positions, as well as by modification of the lactam residue (Figure 
2.12)  by means of (1) an epoxide opening for the introduction of the 
methyl group at the C-2 position, (2) an olefin cross metathesis, as a means 
for the introduction of the isopropyl substituent of the olefin, and (3) an 
amide coupling for the incorporation of  the ε-caprolactam residue.
Interestingly, this strategy was envisioned as a diversity-oriented 
synthetic approach, capable of delivering a wide array of analogues, 
allowing the incorporation of structural modifications at positions essential 
in the interaction of the molecules with the active site of methionine 
amino peptidases.47 In this way, the synthesis of new derivatives of 
bengamides has allowed to deepen in the extensive structure-activity 
relationship study, as in the case of the potent cyclopentyl analogue, 
recently described and that possess  a three- to fourfold more potent IC50 
than its natural counterpart bengamide E against different tumour cell 
















synthesized symplified analogues containing an open amide instead of a 
caprolactam ring, exhibiting potent cytotoxicity and better aqueous 
solubility compared with natural bengamides.48
2.5.1. New Analogues of Bengamides
The first objective of this thesis is the total synthesis of new 
analogues of bengamides containing oxirane rings through the polyketide 
chain, that could simulate the carbon skeleton of fumagillin and mimic its 
interaction with His231, by means of a covalent interaction between the 
nitrogen atom in the imidazol ring and one of the epoxide carbons. The 
consequent biological evaluation of each of the synthesized analogues will 
provide new results about the structure/activity relationship which could 































































Figure 2.13. Epoxy bengamides as new potential fumagilllin-like inhibitors
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Taking advantadge of this approach, we found also interesting to 
extend this methodology to the synthesis of amino derivatives of 
bengamides. The propitious interaction between amine groups and Co+2 
cations present at the active site might involve a significant increase in the 
biological activity of these new analogues. In this way, the initial steps 
towards the synthesis of 4-amino derivatives have been established 
(Figure 2.14).
2.5.2. Retrosynthesis
The synthesis of the 2,3:4,5-diepoxi (45) and 4,5-epoxi (46) 
derivatives of bengamides has been established from readily available 
starting material such as isobutyraldehyde (49), that easily provides the 
isopropyl group at the terminal olefinic position of bengamides (Scheme 






















With the aim of extending the number of analogues, propargyl 
alcohol (54) was also considered as starting material, since it allows the 
introduction of a TMS- group at the terminal olefinic position, an isosteric 
group of the isopropyl one (Scheme 2.2).49 Additionally, these silyl 
derivatives could be easily transformed into new functional groups by 
taking advantage of the vinyl silanes reactivity.50,51 For the introduction of 
the stereogenic centers at the main skeleton of bengamides, the chiral 
sulfur ylides protocol was employed resulting in the appropriate setting-up 
of  the mono- and di-epoxi groups.52,53 
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Finally, for the synthesis of the amino derivative (55), a strategy 
involving the azido opening of the corresponding α,β-unsaturated ɣ,ẟ-
epoxy ester has been planned, as depicted in Scheme 2.3. Thus, starting 
from epoxy amide 58, by conversion into the corresponding α,β-
unsaturated ester 57 and subsequent oxirane ring opening, syn azido 
alcohol 56 can be synthesized, from which 4-amino bengamide E (55) 
would be accomplished.










































2.5.3. Synthesis of Epoxy  Bengamide Analogues Derived 
from Isobutyraldehyde
The preparation of the main fragment of bengamides (58) started 
with the formation of the allylic alcohol 60 via reduction of the 
corresponding α,β-unsaturated ester 59 (75% isolated yield), which was 
synthesized from isobutyraldehyde by a Wittig reaction with 
(carbethoxymethylene)triphenylphosphorane (87%). Subsequent oxidation 
into the α,β-unsaturated aldehyde by means of MnO2, followed by 
reaction with the sulfonium salt 4 under basic conditions afforded 
epoxyamide 58, which was obtained as a single diastereoisomer (in 58% 
yield over 2 steps) after purification by flash column chromatography 
(Scheme 2.4). From this key intermediate both mono- and di-epoxi 
analogues can be synthesized as described below.
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Reagents and conditions:  (a) Ph3PCHCO2Et, DCM, 25ºC, 87%. (b) DIBAL-
H, -78ºC, 30 min, 75%. (c) MnO2, DCM, 25ºC, 12 h. (d) 4, 3.0 M NaOH, 
tBuOH, 25ºC, 16 h, 58% (over 2 steps).
Once the first oxirane ring was installed in a stereoselective 
fashion, the construction of a second oxirane group was undertaken via 
direct reduction of 58 to the epoxy aldehyde by the action of sodium 
bis(2-methoxyethoxy)aluminum hydride (Red-Al)54 followed by a second 
reaction with sulfonium salt 4, according to a two-phase protocol,55 due to 
the presence of the first oxirane ring contiguous to the carbonyl group, to 
obtain diepoxy amide 48 in an excellent 85% overall yield from 58 
(Scheme 2.5).
Reduction of 48 with Super-H yielded the expected diepoxy 
alcohol 47 which was considered a key product for the consecution of 
both coveted epoxy analogues of  bengamide E (Scheme 2.5).
In a first set, diepoxy alcohol 47 was oxidized to the 
corresponding diepoxy acid by the action of TEMPO/BAIB conditions 
and coupled with amino lactam 62 in the presence of BOP and DIPEA, 
to furnish the diepoxy bengamide E analogue 45. On the other hand, 47 
was treated with methanol in the presence of B(OMe)3 and DBU to yield 
the corresponding 2-methoxyl derivative 61 in both chemo- and 
regioselective manners. Selective oxidation of the primary alcohol and 
coupling of the resulting acid with amino lactam 62 were carried out 








(49) (59) (60) (58)




without problems to obtain the desired 5,6-epoxy bengamide E 46 
(Scheme 2.5).
Reagents and conditions: (a) Red-Al, THF, 0ºC, 45 min. (b) 4, 5.0 M NaOH, 
CH2Cl2-H2O, 25ºC, 85% (over 2 steps). (c) Super-H, THF, 0ºC, 30 min, 70%. (d) 
B(OMe)3, DBU, MeOH, reflux, 12 h.(e) TEMPO/BAIB, CH3CN-H2O, 25ºC, 16 
h. (f) 62, BOP, DIPEA, DMF, 25ºC, 16 h, 55% for 45 (from 47),  47% for 46 
(from 47).
2.5.4. Synthesis of Epoxy  Bengamide Analogues Derived 
from  Propargyl Alcohol
Given the positive results obtained in the synthesis of the epoxy 
and diepoxy bengamide analogues, we deemed it of interest to extend this 
chemistry to the trimethyl silyl derivatives 50 and 51 because the presence 
of this trimethylsilyl moiety can serve as an isostere for the isopropyl group 
found in the natural bengamides, as well as a handle to expand the 
synthetic possibilities for further structural modifications at the terminal 
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olefinic position in virtue of the activity of vinylsilanes.50,51 The main 
fragment of these TMS-derivatives was accomplished from propargyl 
alcohol in a four-steps sequence involving introduction of the silyl ether, 
reduction to the corresponding allylic alcohol under Red-Al conditions56 
and subsequent oxidation and coupling with the sulfur ylide derived from 
L-Met (1). In this way, the epoxy amide 64 was obtained in a gratifying 
75% overall yield (Scheme 2.6).
Reagents and conditions: (a) EtMgBr, TMSCl,  0ºC. (b) Red-Al, THF, 0ºC, 45 
min. (c) MnO2, DCM, 16 h. (d) 4, 5.0 M NaOH, tBuOH, 25ºC, 75% (overall 
yield).
The key epoxy amide 64 was then converted into the 
corresponding diepoxy amide via direct reduction to the epoxy aldehyde 
by the action of sodium bis(2-methoxyethoxy)aluminum hydride (Red-
Al)54 followed by a second reaction with sulfonium salt 4, according to the 
two-phase method,55 proceeding in a 84% yield over 2 steps (Scheme 
2.7).
Reduction of 53 with Super-H to yield the diepoxy alcohol 52 
and subsequent reactions sequence as proceeded above rendered both 
coveted epoxy analogues of  bengamide E (Scheme 2.7).
Scheme 2.6. Synthesis of  the epoxyamide 64











Reagents and conditions: (a) Red-Al, THF, 0ºC, 45 min. (b) 4, 5.0 M NaOH, 
CH2Cl2-H2O, 25ºC, 84% (over 2 steps). (c) Super-H, THF, 0ºC, 30 min, 55%. (d) 
B(OMe)3, DBU, MeOH, reflux, 12 h. (e) TEMPO/BAIB, CH3CN-H2O, 25ºC, 16 
h. (f) 62, BOP, DIPEA, DMF, 25ºC, 16 h, 30% for 50 (from 52),  26% for 51 
(from 52).
Thus, proceeding in a similar manner as for analogues 45 and 46, 
epoxy and diepoxy bengamide analogues 50 and 51 were obtained, in 
similar, or even better yields compared with the isopropyl series.
2.5.5. Synthesis of Amino Derivatives of Bengamide E
The synthesis of the amino derivative 55 started from the 
previously described epoxy amide 58, which was subjected to reduction 
and Wittig-Martin reaction to yield the ɣ,ẟ-epoxy α,β-unsaturated ester 
(57) in 82% yield over 2 steps (Scheme 2.8).
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Reagents and conditions:  (a) Red-Al, THF, 0ºC, 45 min. (b) 
Bu3P=CHCO2Et, CH2Cl2, 12 h, 82% (over 2 steps).
With the unsaturated-epoxy system in hand, the next step was the 
palladium-mediated oxirane ring opening, that should proceed with 
double inversion of configuration as described by Miyashita et al. to 
render the syn-azido alcohol 56 in 82% yield (Scheme 2.9).57
Reagents and conditions:  (a) TMSN3, Pd[PPh3]4,  25ºC, 5 h, then citric acid 
10% in MeOH, 82%.
Syn-azido alcohol 56 was then protected as the silyl ether by 
reaction with TBSOTf and 2,6-lutidine and treated with DIBAL-H at 
-78ºC to afford the allylic alcohol 67 in 85% yield over 2 steps. With the 
azido allylic alcohol in hand, we proceeded with the epoxidation of the 
double bond. To this aim, 67 was subjected to a Sharpless asymmetric 












































epoxidation by treatment with TBHP in the presence of D-(-)-DET. 
However, the resulting epoxy alcohol 68 was obtained in a discouraging 
10% yield. Further attemps to improve the yield of this epoxidation were 
unsuccessfull. Nevertheless, we were able to bring enought amount of 
azido epoxy alcohol to continue the delineated synthetic sequence. Thus, 
azido derivative 68 was treated with methanol in the presence of B(OMe)3 
and DBU to yield the corresponding 2-methoxyl derivative 69 in both 
chemo- and regioselective manners. Selective oxidation and coupling of 
the crude carboxylic acid with amino lactam 62 were carried out in the 
same manner as described before, to obtain the amide 70 in 86% over 3 
steps. Deprotection of the silyl ether under TBAF conditions yielded the 
desired 4-azido-bengamide derivative 71 in 55% yield (Scheme 2.10). 
Although the reduction of the azide into the amine has not been tested 
yet, the azido derivative 71 represents a valuable precursor of the amino 
analogue of bengamide E and we feel confident this new derivative will be 
soon obtained.
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Reagents and conditions: (a) TBSOTf, 2,6-lutidine, CH2Cl2, 25ºC, quant. (b) 
DIBAL-H, -78ºC, 45 min, 82%. (c) SAE, D-(-)-DET, 10%. (d) B(OMe)3, DBU, 
MeOH, reflux,  16 h.  (e) TEMPO/BAIB, CH3CN-H2O, 25ºC, 16 h. (f) 62, BOP, 
DIPEA, DMF, 25ºC, 16 h, 86% (over 3 steps). (g) TBAF, THF, 0ºC, 40 min, 55%. 
h. Ph3P, THF-H2O (2:1), 25ºC, 16 h.
2.6. Biological Evaluation of Bengamide E 
Analogues
Having prepared the analogues of bengamide E, 45-46 and 
50-51, our next goal in this research was to evaluate their antitumor 
properties to determine the influence of the described structural 
modifications against the anti proliferative potency. The determination of 

































































the cytotoxic properties of all these compounds was performed by 
measuring their IC50 values against a panel of different tumour cell lines 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) dye reduction assay. This cytotoxicity was examined in four 
different cancer cell lines, namely, HL 60 (human promyelocytic 
leukemia), MDA-MB-231 (human breast carcinoma), HT1080 (human 
fibrosarcoma), and HT29 (human colon adenocarcinoma), and in a 
primary culture of non transformed bovine aorta endothelial (BAE) cells. 
Bengamide E and fumagillin were used as controls to compare the activity 
of the new synthesized analogues. The results of this investigation are 
summarized in Table 2.2.
According to these results, bengamide E analogues tested 
displayed a well-defined cytotoxicity in tumour cells as well as in 
endothelial cells. This is in agreement with previous observations 
indicating that inhibition of MetAP2 by bengamides does not result in 
selective inhibition of endothelial cell proliferation.7 Dose-response curves 
obtained with bengamide E and its analogues showed a sharp decrease in 
cell survival at concentrations that are around the IC50.
In contrast, fumagillin showed a biphasic effect on the growth of 
proliferating endothelial cells, indicating that fumagillin antiproliferative 
activity is not endothelial specific, what is in agreement with previously 
reported data.58
Fumagillin (38), the fungal metabolite that potently inhibits 
angiogenesis by blocking endothelial cell proliferation and has advanced 
into clinical trials for multiple cancers, showed a biphasic effect on the 
growth of proliferating endothelial cells. At owed concentrations there is a 
first decrease in cell number, probably due to a cytostatic effect, and after a 
plateau covering several orders of concentration, a second cytotoxic effect 
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is observed. These biphasic dose-response curves, typical of fumagillin and 
its derivatives, were obtained with the tumor cell lines studies, indicating 
that fumagillin anti proliferative activity is not endothelial specific, which is 
in agreement with previously reported data.58
Dose-dependent effect on the in vitro growth of tumor and 
endothelial cells of bengamide E (11), fumagillin (38) and compounds 
(45), (46) and (50) is shown in Table 2.3.
Table 2.2. In vitro antitumoral activity (µM) of bengamide E (11), fumagillin (38) 
and synthetic analogues (45), (46) and (50) against different tumor cell lines and 
BAEC
Cell Lines
Compound MDAMB231 HT29 HT1080 HL60 BAE
Bengamide E (9) 1.6±0.54 0.95±0.16 0.29±0.03 0.68±0.10 0.28±0.03
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Cells were incubated for 72 h in the presence of each compound, and the ratios of viable cells 
were determined by MTT assay. The drug concentration required to inhibit cell growth by 50% 
(IC50) was determined from semilogarithmic dose-response plots, and results represent the means 
± SDs of  three independent experiments.
These biological evaluations revealed that the epoxy and diepoxy 
bengamide analogues 45-47 and 50-51 were completely inactive in the 
cytotoxic studies, indicating that the replacement of the 1,2-hydroxyl 
systems by an oxirane ring produced a complete lack of interaction with 
the active site of the enzymes, not resulting in a fumagillin-like interaction 




2.7. Summary and Concluding Remarks
In this chapter, the implementation of the novel asymmetric 
epoxidation methodology, based on the use of a new class of chiral 
sulfonium salts in the synthesis of epoxy and diepoxy bengamides 
derivatives has proved to be useful and efficient. The synthetic value of 
this protocol has been demonstrated by its application in the concise total 
synthesis of analogues 45-46 and 50-51 in good yield (12% for 45, over 9 
steps; 11% for 46, over 10 steps; 10% for 50 over 9 steps and 9% for 51 
over 10 steps)  and with high selectivity (ee> 98%). In theory, 50 and 51 
can also be utilized in future cross-coupling reactions to access bengamides 
of  any desired alkyl substitution at the terminal olefinic position.
Additionally, cytotoxic studies have been carried out over 
compounds 45-46 and 50, revealing that replacement of the hydroxyl 
groups by an oxirane ring throughout the polyketide chain of bengamides 
results in a total lack of  antiproliferative activity.
Finally, the first steps towards new amino bengamide derivatives, 
considered promising new bengamide analogues, have been undertaken 
with the synthesis of the precursor 71, containing the azido group at 
position C4.




2.8.1. General  Procedures for  the Synthesis of Epoxy  and 
Diepoxy Amides
2.8.1.1. Synthesis of Epoxy Amides
To a solution of sulfonium salt (4 or 6) (1.1 equiv) in tBuOH (~ 
0.08 M) was added a 3.0 M aqueous NaOH solution (1.1 equiv). After 10 
min at 25ºC, a solution of the corresponding aldehyde (1.0 equiv), in 
tBuOH (~ 0.1 M) was added, and the crude reaction mixture was 
vigorously stirred overnight at 25ºC. After this time, both phases were 
separated, and the aqueous layer was extracted twice with EtOAc. 
Combined organic extracts were then washed with H2O and brine, dried 
over anhydrous MgSO4, filtered, and concentrated under vacuum. Flash 
column chromatography (silica gel, EtOAc 20-30% in hexanes) afforded 
the corresponding epoxy amide.
2.8.1.2. Synthesis of Diepoxy Amides
To a solution of the corresponding epoxy amide (1.0 equiv) in dry 
THF (0.08 M) was added dropwise Red-Al 70% w/v in toluene (2.2 equiv) 
at 0ºC. After 1 h at 0ºC, the reaction mixture was quenched by addition of 
a saturated aqueous NH4Cl solution. After separation of both layers, the 
aqueous phase was extracted with EtOAc, the organic extracts were 
washed with brine and dried over MgSO4, and the solvent was evaporated 
under reduced pressure. The resulting crude epoxy aldehyde was used for 
the next step without further purification.
To obtain the corresponding diepoxy amide, a 5.0 M aqueous 
NaOH solution (1.0 equiv) was added to a solution of sulfonium salt (4  or 
6) (1.1 equiv) and the crude aldehyde in CH2Cl2-H2O (1:1) (~ 0.4 M). The 




both phases were separated, and the aqueous layer was extracted twice 
with EtOAc. Combined organic extracts were then washed with H2O and 
brine, dried over anhydrous MgSO4, filtered, and concentrated. 
Purification of the crude product by flash column chromatography (silica 
gel, 20-30% EtOAc in hexanes) provided corresponding diepoxy amide.
2.8.2. Epoxy Bengamides Derived from Isobutyraldehyde
2.8.2.1. Synthesis of the Ester 59 from Isobutyraldehyde (49)
Isobutyraldehyde (49) (2.0 g, 28.0 mmol, 1.0 equiv) was dissolved 
in CH2Cl2 (140 mL) and over this solution was added Ph3P=CHCO2Et 
(19.5 g, 55.4 mmol 2.0 equiv). After 30 minutes the reaction was complete 
and the solvent was removed under reduced pressure. Flash column 
chromatography (silica gel, 10% EtOAc in hexanes) of the crude product 
furnished α,β-insaturated ester 59 (3.6 g, 90% yield) as a white solid and 
whose data matched with those reported in the literature.59
Rf = 0.78 [Silica gel, 40% EtOAc in hexanes]. 1H RMN (400 MHz, 
CDCl3), δ (ppm): 6.88 (dd, J = 15.7, 6.6 Hz, 1H, CHCH=CH), 5.71 (dd, 
J = 15.7, 1.5 Hz, 1H, CHCH=CH), 4.06 (q, J = 7.1 Hz, 2H, 
COOCH2CH3), 2.48-2.32 (m, 1H, (CH3)3CH), 1.20 (t, J = 6.4 Hz, 3H, 
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2.8.2.2. Reduction of Ester 59 to Allylic Alcohol 60
At -78ºC, DIBAL-H 1.0 M in toluene (25 mL, 25.0 mmol, 2.5 
equiv) was added over a solution of ester 59 (1.4 g, 9.9 mmol, 1.0 equiv) in 
CH2Cl2 (50 mL). After 30 minutes, the reaction was complete and it was 
allowed to warm at 0ºC. At this temperature, the mixture was diluted with 
EtOAc and a saturated aqueous Na+/K+ tartrate solution. After 2 hours of 
vigorous stirring, the aqueous phase was extracted twice with EtOAc and 
the organic layer washed with water and brine, then dried over anhydrous 
MgSO4. and filtered. The solvent was then removed carefully under 
reduced pressured at low temperature. Flash column chromatography 
(silica gel, 30% de EtOAc in hexanes) rendered allylic alcohol 60 (840 mg, 
85% yield) as a colourless oil.
Rf = 0.23 [Silica gel, 40% EtOAc in hexanes]. 1H NMR (400 MHz, 
CDCl3), δ (ppm): 5.70-5.63 (m, 1H, CH=CHCH2), 5.58 (dtd, J = 15.4, 
5.5, 0.8 Hz, 1H, CHCH=CH), 4.08 (d, J = 5.5 Hz, 2H, CH=CHCH2), 
2.34-2.25 (m, 1H, (CH3)2CH), 1.92 (bs, 1H, OH), 1.01 (d, J = 6.8 Hz, 6H, 
CH3). 13C NMR (100 MHz, CDCl3), δ (ppm): 138.75, 128.67, 62.96, 
31.36, 20.37.
2.8.2.3. Synthesis of the Epoxy Amide 58
To a solution of allylic alcohol (60) (102 mg, 1.0 mmol, 1.0 equiv) 







b. 4, NaOH, tBuOH











stirring for 12 hours at 25ºC, the crude mixture was filtered through 
Celite, and the resulting clear solution was concentrated under reduced 
pressure at 20ºC to obtain the corresponding α,β-unsaturated aldehyde, 
which was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (350 mg, 
1.12 mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 0.34 mL, 1.02 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of epoxy amides to yield epoxy amide 58 (184 mg, 58% over 
two steps) as a yellow oil.
Rf = 0.18 [Silica gel, 30% EtOAc in hexanes]. [α]25D = +15.9 (c 0.4, 
CH2Cl2) . 1H NMR(400 MHz, CDCl3), δ  (ppm): 6.02 (dd, J = 15.6, 6.5 
Hz, 1H, CH=CHCH(O)), 5.13 (ddd, J = 15.7, 8.0, 1.4 Hz, 1H, 
CHCH=CH), 4.27 (ddd, J = 8.5, 4.8, 3.2 Hz, 1H, NHCH), 4.01 (ddd, J = 
9.1, 5.3, 1.4 Hz, 1H, OCH2CH), 3.88 (d, J = 9.3 Hz, 1H, OCH2CH), 
3.54-3.49 (m, 2H, =CHCH(O) and COCH(O)), 2.59-2.51 (m, 1H, 
CH3SCH2), 2.46-2.37 (m, 1H, CH3SCH2), 2.37-2.28 (m, 1H, (CH3)2CH), 
2.07 (s, 3H, CH3S), 2.05-1.97 (m, 1H, SCH2CH2), 1.80-1.72 (m, 1H, 
SCH2CH2), 1.63 (s, 3H, CH3C), 1.53 (s, 3H, CH3C), 0.99 (d, J = 6.8 Hz, 
3H, CH3CH), 0.98 (d, J = 6.7 Hz, 3H, CH3CH). 13C NMR (100 MHz, 
CDCl3), δ (ppm): 163.57, 146.05, 122.52, 95.91, 67.03, 58.53, 55.83, 
55.48, 34.27, 30.95, 30.81, 26.29, 23.02, 21.80, 21.77, 15.84. HRMS 
(ESI-TOF) m/e 314.1790 calcd for C16H27NO3S [M + H]+, found 
314.1784.
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2.8.2.4. Synthesis of the Diepoxy Amide 48
To a solution of epoxy amide 58 (320 mg, 1.02 mmol, 1.0 equiv) 
in dry THF (20 mL) was added dropwise Red-Al (0.7 mL, 2.24 mmol, 2.2 
equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was quenched by 
addition of a saturated aqueous NH4Cl solution. After separation of both 
layers, the aqueous phase was extracted with EtOAc, the organic extracts 
were washed with brine and dried over MgSO4, and the solvent was 
evaporated under reduced pressure. The resulting crude epoxy aldehyde 
was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (350 mg, 
1.12 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.20 mL, 1.02 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 48 (310 mg, 85% 
over two steps) as a yellow oil.
Rf = 0.37 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +35.1 (c  0.7, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 6.00-5.92 (m, 1H, 
(CH3)2CHCH=), 5 .09 (ddd, J = 15.6, 8 .3 , 1 .4 Hz, 1H, 
(CH3)2CHCH=CH), 4.31 (ddd, J = 8.5, 4.8, 3.3 Hz, 1H, NCH), 4.00 
(ddd, J = 9.2, 5.2, 1.4 Hz, 1H, OCH2CH), 3.90 (dd, J = 9.2, 0.6 Hz, 1H, 
OCH2CH), 3.58 (d, J = 2.0 Hz, 1H, COCH(O)), 3.36 (dd, J = 8.3, 1.7 
Hz, 1H, COCH(O)CH), 3.34 (dd, J = 3.6, 1.9 Hz, 1H, =CHCH(O)), 3.01 
(dd, J = 3.5, 2.1 Hz, 1H, =CHCH(O)CH), 2.57 (ddd, J = 13.0, 7.7, 5.1 
Hz, 1H, CH3SCH2), 2.47 (ddd, J = 13.2, 8.4, 7.2 Hz, 1H, CH3SCH2), 
2.37-2.27 (m, 1H, (CH3)3CH), 2.11 (s, 3H, CH3S), 2.09-2.01 (m, 1H, 
SCH2CH2), 1.86-1.76 (m, 1H, SCH2CH2), 1.63 (s, 3H, CH3C), 1.52 (s, 
a. RedAl
b. 4, NaOH, tBuOH















3H, CH3C), 0.99 (d, J = 6.8 Hz, 6H, (CH3)2CH). 13C NMR (100 MHz, 
CDCl3), δ (ppm): 162.96, 145.36, 122.84, 95.94, 67.05, 56.54, 56.43, 
55.98, 55.55, 51.20, 34.45, 30.90, 30.71, 26.22, 22.96, 21.86, 21.83, 
15.85. HRMS (ESI-TOF) m/e 356.1896 calcd for C18H29NO4S [M + H]+, 
found 356.1872.
2.8.2.5. Synthesis of the Diepoxy Alcohol 47
Diepoxy amide 48 (100 mg, 0.28 mmol, 1.0 equiv) in THF (6 mL) 
was reduced by treatment with Super-H 1.0 M in THF (0.7 mL, 0.7 
mmol, 2.5 equiv) at 0ºC. After 1 h at this temperature, the reaction 
mixture was diluted with Et2O and washed with a saturated aqueous 
NH4Cl solution. The aqueous phase was separated, extracted with Et2O 
twice and the combined organic phase washed with water and brine, dried 
over anhydrous MgSO4 and concentrated under reduced pressure. 
Purification by flash column chromatography (silica gel, 30% EtOAc in 
hexanes) provided diepoxy alcohol 47 (36 mg, 70%) as a pale yellow oil.
Rf = 0.26 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +27.2 (c  0.9, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 5.95 (ddd, J = 15.6, 6.5, 
3.3 Hz, 1H, (CH3)2CHCH=), 5.10 (ddd, J = 15.6, 8.3, 1.3 Hz, 1H, 
(CH3)2CHCH=CH), 4.01-3.93 (m, 1H, CH2OH), 3.75-3.65 (m, 1H, 
CH2OH), 3.33 (dd, J = 8.2, 2.0 Hz, 1H, =CHCH(O)), 3.20-3.16 (m, 1H, 
=CHCH(O)CH), 3.09-2.97 (m, 1H, (O)CHCH2), 2.91 (dd, J = 4.6, 2.1 
Hz, 1H, CH(O)CHCH2), 2.40-2.27 (m, 1H, (CH3)2CH), 1.00 (d, J = 6.8 
Hz, 6H, (CH3)2CH). 13C NMR (100 MHz, CDCl3), δ (ppm): 145.06, 
123.17, 60.57, 57.87, 56.26, 55.72, 53.53, 30.90, 21.88, 21.86. HRMS 
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2.8.2.6. Synthesis of the Diepoxy Amide 45
Diepoxy alcohol 47 ( 50 mg, 0.27 mmol, 1.0 equiv) was dissolved 
in a 1:1 mixture of CH3CN/H2O (8 mL) and the resulting solution was 
treated with BAIB (535 mg, 1.6 mmol, 6.0 equiv), followed by TEMPO 
(40 mg, 0.22 mmol, 0.8 equiv) at 25ºC. After 5 h, the crude mixture was 
diluted with EtOAc, quenched by the addition of a saturated aqueous 
Na2S2O3 solution and, after separation of both layers, the aqueous phase 
was then extracted with EtOAc. The organic solution was washed again 
with a saturated aqueous Na2S2O3 solution, then dried over anhydrous 
MgSO4 and the solvent was evaporated under reduced pressure. The 
crude acid was dissolved in DMF (3 mL) and treated with DIPEA (0.1 mL, 
0.5 mmol, 2.0 equiv), amino lactam 62 (67 mg, 0.41 mmil, 1.5 equiv) and 
BOP (150 mg, 0.32 mmol, 1.2 equiv) at 25ºC. After being stirred at this 
temperature overnight, the crude mixture was diluted with Et2O and 
washed with a saturated aqueous NH4Cl solution. The aqueous phase was 
extracted with Et2O and the combined organic phases were washed with 
brine, dried over anhydrous MgSO4 and the solvent was evaporated under 
vacuum. Purification of the obtained crude product by flash column 
chromatography (silica gel, 80% EtOAc in hexanes) provided diepoxy 
amide 45 (3 mg, 55% over 2 steps) as a white amorphous solid.
Rf = 0.43 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +49.4 (c  0.4, 
DMSO) . 1H NMR (400 MHz, CDCl3), δ (ppm): 7.46 (d, J = 5.5 Hz, 1H, 
CONHCH), 6.10 (t, J = 6.0 Hz, 1H, CONHCH2), 5.95 (dd, J = 15.6, 6.6 
Hz, 1H, (CH3)2CHCH=CH), 5.09 (ddd, J = 15.6, 8.2, 1.4 Hz, 1H, 
(CH3)3CHCH=CH), 4.50 (ddd, J = 11.4, 6.0, 1.4 Hz, 1H, CHNHCO), 
3.45 (d, J = 2.1 Hz, 1H, (O)CHCONH), 3.35 (dd, J = 8.2, 1.8 Hz, 1H, 
a. TEMPO/BAIB
b. 62, DIPEA, BOP














=CHCH(O)), 3.30-3.24 (m, 2H, CONHCH2,), 3.05 (dd, J = 4.5, 2.1 Hz, 
1H, CH(O)CHCO), 2.90 (dd, J = 4.5, 2.1 Hz, 1H, =CHCH(O)CH), 
2.38-2.28 (m, 1H, (CH3)2CH), 2.04-1.96 (m, 2H, CH2), 1.90-1.79 (m, 2H, 
CH2), 1.50-1.36 (m, 2H, NHCHCH2), 1.00 (d, J = 6.8 Hz, 6H, 
(CH3)2CH). 13C NMR (100 MHz, CDCl3), δ (ppm): 174.62, 166.83, 
145.43, 122.65, 57.19, 56.99, 56.40, 52.67, 51.73, 42.15, 31.38, 30.92, 
28.87, 27.86, 21.83. HRMS (ESI-TOF) m/e 309.1814 calcd for 
C16H24N2O4 [M + H]+, found 309.1802.
2.8.2.7. Synthesis of the Epoxy Amide 46
Epoxy alcohol 47 (15 mg, 0.08 mmol, 1.0 equiv) was dissolved in a 
1:1 mixture of MeOH/B(OMe)3 (3 mL) and the resulting solution was 
treated with DBU (10 µL, 0.08 µmol 1.0 equiv) and heated at 65ºC for 12 
hours. After this time, the reaction mixture was allowed to reach room 
temperature, cooled to 0ºC, and then treated with a saturated aqueous 
NaHCO3 solution. After stirring for 30 min at 0ºC, EtOAc was added and 
both phases were separated. The aqueous phase was extracted with 
EtOAc and the combined organic extracts were washed with water and 
brine, then dried over anhydrous MgSO4 and the solvent was evaporated 
under reduced pressure. The resulting crude product was used in the next 
step without further purification.
The crude of the diol ( 0.08 mmol, 1.0 equiv) was dissolved in a 
1:1 mixture of CH3CN/H2O (4 mL) and the resulting solution was treated 
with BAIB (160 mg, 0.49 µmol, 6.0 equiv)  followed by TEMPO (10 mg, 
0.065 mmol, 0.8 equiv) at 25ºC. After 5 h, the crude mixture was diluted 










a. B(OMe)3, MeOH, DBU
b. TEMPO/BAIB
c. 62, DIPEA, BOP
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solution and, after separation of both layers, the aqueous phase was then 
extracted with EtOAc. The organic solution was washed again with a 
saturated aqueous Na2S2O3 solution, then dried over anhydrous MgSO4 
and the solvent was evaporated under reduced pressure. The crude acid 
(0.08 mmol, 1.0 equiv) was dissolved in DMF (5 mL) and treated with 
DIPEA (30 µL, 0.16 mmol, 2.0 equiv), amino lactam 62 (20 mg, 0.12 
µmol, 1.5 equiv) and BOP (44 mg, 0.096 mmol, 1.2 equiv) at 25ºC. After 
being stirred at this temperature overnight, the crude mixture was diluted 
with Et2O and washed with a saturated aqueous NH4Cl solution. The 
aqueous phase was extracted with Et2O and the combined organic phases 
were washed with brine, dried over anhydrous MgSO4 and the solvent was 
evaporated under vacuum. Purification of the obtained crude product by 
flash column chromatography (silica gel, 80% EtOAc in hexanes) provided 
amide 46 (13 mg, 47% over 3 steps) as a colourless oil.
Rf = 0.21 [Silica-gel, EtOAc]. [α]25D = +111.0 (c 0.1, CH2Cl2) . 1H NMR 
(400 MHz, CDCl3), δ (ppm): 7.78 (d, J = 12.3 Hz, 1H, CONHCH), 
5.94-5.87 (m, 1H, CONHCH2), 5.84 (ddd, J = 15.5, 6.5, 1.0 Hz, 1H, 
(CH3)2CHCH=CH) , 5 .36 (ddd , J = 15 .5 , 7 .1 , 1 .4 , 1H, 
(CH3)3CHCH=CH), 4.59-4.50 (m, 2H, CHNHCO and CHOH), 
4.05-4.02 (m, 1H, OH), 3.86 (s, 3H, CHOCH3), 3.40-3.19 (m, 4H, 
CONHCH2,=CHCH(O) and CH3OCH), 2.39-2.30 (m, 1H, (CH3)2CH), 
2.09-1.95 (m, 2H, CH2), 1.91-1.19 (m 2H, CH2), 1.67-1.56 (m, 2H, 
NHCHCH2), 1.02 (d, J = 6.8, 6H (CH3)2CH). 13C NMR (100 MHz, 
CDCl3), δ (ppm): 175.6, 175.2, 143.4, 122.4, 82.9, 57.8, 57.0, 53.4, 52.1, 
51.6, 42.1, 31.4, 30.2, 28.9, 27.9, 22.1, 22.0. HRMS (ESI-TOF) m/e 




2.8.3. Epoxy Bengamides Derived from Propargyl Alcohol
2.8.3.1. Synthesis of Allylic Alcohol 63
A solution of propargyl alcohol 54 (1.0 g, 18.3 mmol, 1.0 equiv) in 
THF (20 mL) was added dropwise over a solution of EtMgBr (40% in 2-
methyltetrahydrofurane) (18 mL, 55.0 mmol, 3.0 equiv) in THF (100 mL) 
at 0ºC. Once the addition was completed, the reaction mixture was 
allowed to warm to room temperature  and stirred for 3 hours. After this 
time, TMSCl (5.4 mL, 42.2 mmol, 2.3 equiv) was added dropwise and 
carefully keeping temperature under 25ºC. The reaction was stirred 
overnight and then quenched by the dropwise addition of 3.6 M H2SO4 
(27 mL, 97.2 mmol, 5.3 equiv) at 0ºC. The organic layer was separated 
and the aqueous phase was extracted with Et2O. All the organic extracts 
were combined, dried over MgSO4 and concentrated in vacuo. The 
residual yellow liquid was used in the next step without further 
purification.56
In a round flask was dissolved Red-Al (sodium bis 
(methoxyethoxy)aluminum hydride in 60% w/v in toluene (10 mL, 29.3 
mmol, 1.6 equiv) in anhydrous Et2O (40 mL). The solution was cooled to 
0ºC and treated dropwise with a solution of the crude above obtained 
(18.3 mmol, 1.0 equiv) in Et2O (34 mL). Ten minutes after complete 
addition the ice bath was removed, and the reaction was complete within 
1 hour. The reaction was quenched by the dropwise addition of 3.6 M 
H2SO4 (37 mL, 132.0 mmol, 7.2 equiv). The organic layer was separated 
and the aqueous layer was extracted with Et2O. All the organic extracts 
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residual colourless oil, whose data correspond to those described in 
literature,56 was used in the next step without further purification.
1H NMR (400 MHz, CDCl3), δ  (ppm): 6.18 (dt, J = 18.8, 4.4 Hz, 1H, 
SiCH=CH ), 5.92 (dt, J = 18.8, 1.7 Hz, 1H, SiCH=CH), 4.18 (dd, J = 
4.4, 1.7 Hz, 2H, CH2OH), 2.10 (sa, 1H, OH), 0.08 (s, 9H, (CH3)3Si). 13C 
NMR (100 MHz, CDCl3), δ (ppm): 145.08, 129.05, 64.99, -1.39.
2.8.3.2. Synthesis of Epoxy Amide 64
Allylic alcohol (64) (880 mg, 6.7 mmol, 1.0 equiv) was dissolved in 
CH2Cl2 (40 mL) and over this solution was added MnO2 85% (9.4 g, 107.0 
mmol, 16.0 equiv). After 12 hours the reaction was completed and the 
mixture was filtered off thought a pad of celite. The solvent was then 
removed at low temperature under vacuum, and the resulting crude 
aldehyde was then used immediately in the next step without further 
purification.
The crude aldehyde was reacted with sulfonium salt 4 (1.9 g, 6.1 
mmol,  1.0 equiv) and NaOH (3.0 M aqueous solution, 1.8 mL, 5.6 mmol, 
1.0 equiv) according to the general procedure described above for the 
synthesis of epoxy amides to yield epoxy amide 64 (1.2 g, 75% over 4 
steps) as a yellow oil.
Rf = 0.44 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +25.1 (c  0.3, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.30-6.24 (m, 1H, 
SiCH=CH), 5.72-5.65 (m, 1H, SiCH=CH), 4.25 (ddd, J = 10.2, 4.9, 3.2 
Hz, 1H, NCH), 3.98 (ddd, J = 9.1, 5.2, 1.4 Hz, 1H, OCH2CH), 3.85 (d, J 
a. MnO2












= 9.2 Hz, 1H, OCH2CH), 3.53-3.48 (m, 2H, =CHCH(O) y COCH(O)), 
2.52 (ddd, J = 13.2, 7.0, 5.1 Hz, 1H, CH3SCH2), 2.38 (ddd, J = 13.4, 8.9, 
6.7 Hz, 1H, CH3SCH2), 2.02 (s, 3H, SCH3), 2.01-1.94 (m, 1H, 
SCH2CH2), 1.75-1.69 (m, 1H, SCH2CH2), 1.59 (s, 3H, C(CH3)3), 1.49 (s, 
3H, C(CH3)3), 0.03 (s, 9H, (CH3)3Si). 13C NMR (100 MHz, CDCl3), δ 
(ppm): 166.07, 140.44, 138.61, 95.76, 68.69, 66.96, 59.49, 55.81, 55.74, 
30.68, 26.20, 22.91, 15.74, -1.64. HRMS (ESI-TOF) m/e 344.1716 calcd 
for C16H29NO3SSi [M + H]+, found 344.1709.
2.8.3.3. Synthesis of the diepoxy amide 53
Epoxy amide 64 (110 mg, 0.32 mmol, 1.0 equiv) in dry THF (5 
mL) was treated dropwise with Red-Al 60% w/v in toluene (0.22 mL, 0.70 
mmol, 2.2 equiv) at 0ºC. After 1 hour at this temperature, the reaction 
mixture was diluted with a saturated aqueous NH4Cl solution. The 
aqueous phase was then separated, extracted twiced with EtOAc and the 
combined organic phase washed with H2O and brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The 
resulting crude aldehyde was used in the next step without further 
purification.
The crude aldehyde was reacted with sulfonium salt 4 (111 mg, 
0.35 mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 0.06 mL, 0.32 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 53 (102 mg, 84% 
over two steps) as a yellow oil.
a. RedAl
b. 4, NaOH, tBuOH
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Rf = 0.19 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +31.4 (c  0.1, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.23 (dd, J = 18.7, 0.5 
Hz, 1H, SiCH=CH), 5.67 (dd, J = 18.7, 7.6 Hz, 1H, SiCH=CH), 
4.34-4.28 (m, 1H, NCH), 4.00 (ddd, J = 9.1, 5.2, 1.2 Hz, 1H, OCH2CH), 
3.89 (d, J = 9.2 Hz, 1H, OCH2CH), 3.58 (d, J = 1.9 Hz, 1H, COCH(O)), 
3.40-3.36 (m, 1H, COCH(O)CH), 3.35 (dd, J = 3.6, 2.0 Hz, 1H, 
=CHCH(O)), 3.03 (dd, J = 3.6, 2.0 Hz, 1H, =CHCH(O)CH), 2.58 (ddd, J 
= 13.0, 7.5, 5.1 Hz, 1H, SCH2CH2), 2.46 (ddd, J = 13.3, 8.4, 7.2 Hz, 1H, 
SCH2CH2), 2.10 (s, 3H, CH3S), 2.08-2.02 (m, 1H, SCH2CH2), 1.85-1.76 
(m, 1H, SCH2CH2), 1.63 (s, 3H, CH3(C)), 1.52 (s, 3H, CH3(C)), 0.06 (s, 
9H, (CH3)3Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 162.87, 140.85, 
137.86, 95.94, 67.04, 57.56, 56.68, 55.96, 55.46, 51.20, 34.43, 30.71, 
26.22, 22.94, 15.87, -1.58. HRMS (ESI-TOF) m/e 386.1821 calcd for 
C18H31NO4SSi [M + H]+, found 386.1820.
2.8.3.4. Synthesis of the Diepoxy Alcohol 52
Epoxy amide 53 (50 mg, 0.13 mmol, 1.0 equiv) in THF (4 mL) 
was treated with Super-H 1.0 M in THF (0.33 mL, 0.33 mmol, 2.5 equiv) 
at 0ºC. After 1 h at this temperature, the reaction mixture was diluted with 
Et2O and washed with a saturated aqueous NH4Cl solution. The aqueous 
phase was separated, extracted with Et2O twice and the combined organic 
phase washed with water and brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. Purification by flash column 
chromatography (silica gel, 40% EtOAc in hexanes) provided epoxy 


















Rf = 0.22 [Silica gel, 60% EtOAc in hexanes]. [α]25D = +16.4 (c  0.2, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.23 (d, J = 18.7, 1H, 
SiCH=CH), 5.69 (dd, J = 18.7, 7.6 Hz, 1H, SiCH=CH), 4.00-3.94 (m, 
1H, CH2OH), 3.75-3.67 (m, 1H, CH2OH), 3.38-3.33 (m, 1H, 
=CHCH(O)), 3.19 (dd, J = 5.7, 2.3 Hz, 1H, =CHCH(O)CH), 3.08 (dd, J 
= 4.7, 2.2 Hz, 1H, (O)CHCH2), 2.93 (dd, J = 4.7, 2.1 Hz, 1H, 
CH(O)CHCH2), 0.08 (s, 9H, (CH3)3Si). 13C NMR (100 MHz, CDCl3): δ 
(ppm) 141.17, 137.51, 60.41, 57.99, 57.45, 55.74, 53.43, -1.58. HRMS 
(ESI-TOF) m/e 215.110 calcd for C10H18O3Si [M + H]+, found 215.1112.
2.8.3.5. Synthesis of the Diepoxy Amide 50
Diepoxy alcohol 52 (40 mg, 0.2 mmol, 1.0 equiv) was dissolved in 
a 1:1 mixture of CH3CN/H2O (8 mL) and the resulting solution was 
treated with BAIB (370 mg, 1.12 mmil, 6.0 equiv)   followed by TEMPO 
(24 mg, 0.15 mmol, 0.8 equiv) at 25ºC. After 5 h, the crude mixture was 
diluted with EtOAc, quenched by the addition of a saturated aqueous 
Na2S2O3 solution and, after separation of both layers, the aqueous phase 
was then extracted with EtOAc. The organic solution was washed again 
with saturated aqueous Na2S2O3 solution then dried over anhydrous 
MgSO4 and the solvent evaporated under reduced pressure.
The crude acid was dissolved in DMF (4 mL) and treated with 
DIPEA (0.06 mL, 0.4 mmol, 2.0 equiv), amino lactam 62 (46 mg, 0.27 
mmol, 1.5 equiv) and BOP (100 mg, 0.22 mmol, 1.2 equiv) at 25ºC. After 
being stirred at this temperature overnight, the crude mixture was diluted 
with Et2O and washed with a saturated aqueous NH4Cl solution. The 
aqueous phase was extracted with Et2O and the combined organic phases 
a. TEMPO/BAIB
b. 62, DIPEA, BOP
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were washed with brine, dried over anhydrous MgSO4 and the solvent was 
evaporated under vacuum. Purification of the obtained crude product by 
flash column chromatography (silica gel, 80% EtOAc in hexanes) provided 
diepoxy amide 50 (20 mg, 30% over 2 steps) as a colourless oil.
Rf = 0.33 [Silica gel, EtOAc]. [α]25D = +33.1 (c 0.4, CH2Cl2). 1H RMN 
(400 MHz, CDCl3), δ (ppm): 7.46 (d, J = 5.9 Hz, 1H, NHCHCO), 6.23 
(dd, J = 18.7, 0.6 Hz, 1H, SiCH=CH), 6.17 (t, J = 7.2 Hz, 1H, 
CONHCH2), 5.67 (dd, J = 18.7, 7.5 Hz, 1H, SiCH=CH), 4.50 (ddd, J = 
11.4, 5.8, 1.3 Hz, 1H, NHCHCO), 3.46 (d, J = 2.1 Hz, 1H, COCH(O)), 
3.37 (ddd, J = 7.5, 2.0, 0.5 Hz, 1H, =CHCH(O)), 3.30-3.23 (m, 2H, 
CONHCH2), 3.06 (dd, J = 4.5, 2.0 Hz, 1H, COCH(O)CH), 2.93 (dd, J = 
4.5, 2.0 Hz, 1H, =CHCH(O)CH), 2.07-1.95 (m, 2H, CH2), 1.91-1.78 (m, 
2H, CH2), 1.70-1.55 (m, 2H, NHCHCH2), 0.08 (s, 9H, (CH3)3Si). 13C 
NMR (100 MHz, CDCl3), δ (ppm) 174.6, 162.54, 140.61, 137.95, 57.52, 
57.28, 56.83, 52.67, 51.73, 42.10, 31.42, 28.84, 27.85, -1.62. HRMS (ESI-
TOF) m/e 339.1740 calcd for C16H26N2O4Si [M + H]+, found 339.1725.
2.8.3.6. Synthesis of the Epoxy Amide 51
Diepoxy alcohol 52 (50 mg, 0.21 mmol, 1.0 equiv) was dissolved 
in a 1:1 mixture of MeOH/B(OMe)3 (5 mL) and the resulting solution 
was treated with DBU (33 µL, 0.26 mmol 1.0 equiv) and heated at 65ºC 
for 12 hours. After this time, the reaction mixture was allowed to reach 
room temperature, cooled to 0ºC, and then treated with a saturated 
aqueous NaHCO3 solution. After stirring for 30 min at 0ºC, EtOAc was 
added and both phases were separated. The aqueous phase was extracted 











a. B(OMe)3, MeOH, DBU
b. TEMPO/BAIB
c. 62, DIPEA, BOP









and brine, then dried over anhydrous MgSO4 and the solvent was 
evaporated under reduced pressure. The resulting crude product was used 
in the next step without further purification.
The crude of the corresponding epoxy diol (0.21 mmol, 1.0 equiv) 
was dissolved in 1:1 mixture of CH3CN/H2O (8 mL) and the resulting 
solution was treated with BAIB (415 mg, 1.26 µmol, 6.0 equiv) followed by 
TEMPO (27 mg, 0.17 mmol, 0.8 equiv) at 25ºC. After 5 h, the crude 
mixture was diluted with EtOAc , quenched by the addition of a saturated 
aqueous Na2S2O3 solution, and, after separation of both layers, the 
aqueous phase was then extracted with EtOAc. The organic solution was 
washed with saturated aqueous Na2S2O3 solution, then dried over 
anhydrous MgSO4 and the solvent was evaporated under reduced 
pressure.
The crude acid (0.21 mmol, 1.0 equiv) was dissolved in DMF (5 
mL) and treated with DIPEA (0.1 mL, 0.42 mmol, 2.0 equiv), amino 
lactam 62 (52 mg, 0.32 mmol, 1.5 equiv) and BOP (114 mg, 0.25 mmol, 
1.2 equiv) at 25ºC. After being stirred at this temperature overnight, the 
crude mixture was diluted with Et2O and washed with a saturated 
aqueous NH4Cl solution. The aqueous phase was extracted with Et2O and 
the combined organic phases were washed with brine, dried over 
anhydrous MgSO4 and the solvent was evaporated under vacuum. 
Purification of the obtained crude product by flash column 
chromatography (silica gel, 80% EtOAc in hexanes) provided epoxy amide 
51 (20 mg, 26% over 3 steps) as a colourless oil.
Rf = 0.21 [Silica gel, EtOAc]. [α]25D = +11.0 (c 0.1, CH2Cl2). 1H NMR 
(400 MHz, CDCl3), δ (ppm): 7.74 (d, J = 7.1 Hz, 1H, NHCHCO), 6.10 
(dd, J = 18.8, 1.2 Hz, 1H, SiCH=CH), 6.00 (dd, J = 18.7, 4.9 Hz, 1H, 
SiCH=CH), 5.96-5.88 (m, 1H, CONHCH2), 4.55 (ddd, J = 11.3, 6.6, 1.6 
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Hz, 1H, NHCHCO), 4.10 (dd, J = 4.9, 1.2 Hz, 1H, CHOH ), 3.42 (s, 3H, 
OCH3), 3.37-3.19 (m, 4H, CONHCH2, =CHCH(O) y CH3OCH), 
2.24-2.18 (m, 1H, CH(O)CHCHOH), 2.04-1.95 (m, 2H, CH2), 1.91-1.74 
(m, 2H, CH2), 1.55-1.35 (m, 2H, NHCHCH2), 0.08 (s, 9H, (CH3)3Si). 13C 
NMR (100 MHz, CDCl3), δ (ppm): 175.18, 169.74, 140.22, 133.81, 84.47, 
77.20, 57.71, 51.56, 42.18, 31.60, 29.69, 28.98, 27.98, 14.10, -1.39. 
HRMS (ESI-TOF) m/e 371.2002 calcd for C17H30N2O5Si [M + H]+, 
found 371.1986.
2.8.4. Amino Bengamide Derivative
2.8.4.1. Synthesis of the Epoxy α,β-unsaturated Ester 57
Epoxy amide 58 (170 mg, 0.5 mmol, 1.0 equiv) in dry THF (10 
mL) was treated dropwise with Red-Al 60% w/v in toluene (0.4 mL, 1.1 
mmol, 2.2 equiv) at 0ºC. After 1 hour at this temperature, the reaction 
mixture was diluted with a saturated aqueous NH4Cl solution. The 
aqueous phase was then separated, extracted twice with EtOAc and the 
combined organic phase washed with H2O and brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The 
resulting crude aldehyde was used in the next without further purification.
A solution of tributyl(ethoxycarbonylmethylene)phosphonium 
bromide (230 mg, 0.6 mmol, 1.5 equiv) in CH2Cl2 (10 mL) was washed 
twice with a 1.0 M NaOH aqueous solution, dried over anhydrous 
MgSO4, and diluted with toluene (10 mL). After CH2Cl2 was removed, the 
resulting solution was then added to a stirred solution of the 
















toluene (10 mL) at 95ºC. After 30 min, the solvent was evaporated and the 
residue was purified by flash column chromatography (silica gel, 20% 
EtOAc in hexanes) to provide the corresponding α,β-unsaturated ester 57 
(85 mg, 82% over 2 steps) as a pale yellow oil.
Rf = 0.7 [Silica gel, 30% EtOAc in hexanes]. [α]25D = +20.6 (c 0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.71 (dd, J = 15.7, 6.9 
Hz, 1H, CH(O)CHCH=), 6.12 (dd, J = 15.7, 0.7 Hz, 1H, CH=CHCO), 
5.94 (dd, J = 15.6, 6.5 Hz, 1H, (CH3)2CHCH=), 5.15 (ddd, J = 15.6, 8.0, 
1.4 Hz, 1H, (CH3)2CHCH=CH), 4.20 (q, J = 7.1 Hz, 2H, OCH2CH3), 
3.35 (ddd, J = 6.9, 1.9, 0.7 Hz, 1H, CH=CHCH(O)CH), 3.27 (dd, J = 
8.0, 1.9 Hz, 1H, CH=CHCH(O)), 2.34 (dqd, J = 13.5, 6.7, 1.3 Hz, 1H, 
(CH3)2CH), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.01 (d, J = 6.8 Hz, 3H, 
(CH3)2CH), 0.99 (d, J = 6.8 Hz, 3H, (CH3)2CH). 13C NMR (100 MHz, 
CDCl3), δ (ppm): 165.65, 144.91, 144.07, 123.59, 123.09, 61.44, 60.57, 
58.07, 30.91, 21.86, 14.20. HRMS (H-ESI) m/e 211.13287 calcd for 
C12H18O3 [M + H]+, found 211.13275.
2.8.4.2. Synthesis of the Azido Alcohol 56
Epoxy unsaturated ester 57 (105 mg, 0.5 mmol, 1.0 equiv) was 
dissolved in THF (5 mL) and over this solution was added TMSN3 (0.13 
mL, 1.0 mmol, 2.0 equiv) and Pd[PPh3]4 (30 mg, 0.02 mmol, 0.05 equiv) 
at rt. After 5 hours, the mixture was treated at 0ºC with a 10% citric acid 
solution in MeOH and was stirred at the same temperature for 1 hour 
more. Solid NaHCO3 was then added and the mixture stirred for 1 min 
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purified by flash column chromatography (silica gel, 10% EtOAc in 
hexanes) to yield syn-azido alcohol 56 (103 mg, 82%) as a pale yellow oil.
Rf = 0.34 [Silica-gel, 40% EtOAc in hexanes]. [α]25D = -12.0 (c 1.0, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.81 (dd, J = 15.6, 6.7 
Hz, 1H, CH(OH)CHN3CH=), 6.08 (dd, J = 15.6, 1.3 Hz, 1H 
CH=CHCO), 5.76 (ddd, J = 15.5, 6.7, 1.0 Hz, 1H, (CH3)2CHCH=), 5.40 
(ddd, J = 15.5, 6.9, 1.4 Hz, 1H, (CH3)2CHCH=CH), 4.22 (q, J = 7.1 Hz, 
2H, OCH2CH3), 4.09 (t, J = 7.4 Hz, 1H, CH=CHCHOH), 4.02 (td, J = 
6.5, 1.3 Hz, 1H,CH=CHCH(OH)CHN3), 2.32 (dqd, J = 13.4, 6.7, 1.3 
Hz, 1H, (CH3)2CH), 1.30 (t, J = 7.1 Hz, 3H,  OCH2CH3),1.00 (d, J = 6.8 
Hz, 3H, (CH3)2CH), 0.99 (d, J = 6.8 Hz, 3H, (CH3)2CH). 13C NMR (100 
MHz, CDCl3), δ (ppm): 165.49, 142.94, 141.21, 124.90, 124.51, 74.68, 
67.39, 60.77, 30.87, 22.02, 22.00, 14.18. HRMS (H-ESI) m/e 276.13186 
calcd for C12H19N3O3 [M + H]+, found 276.13168.
2.8.4.3. Synthesis of the Silyl Ether 66
To a solution of azido alcohol 66 (20 mg, 0.07 mmol, 1.0 equiv) in 
CH2Cl2 (5 mL) was added at 0ºC 2,6-lutidine (0.02 mL, 0.09 mmol, 1.2 
equiv)  and TBSOTf (0.02 mL, 0.16 mmol, 2.0 equiv). After 1 hour at this 
temperature, the mixture was quenched with MeOH, diluted with Et2O 
and washed with a saturated aqueous NH4Cl solution. The aqueous phase 
was extracted with Et2O and the combined organic layers were washed 
with brine, dried over MgSO4 and the solvent was evaporated under 
reduced pressure. The crude product was subjected to purification by flash 
column chromatography (silica gel, 15% EtOAc in hexanes) to yield 66 















Rf = 0.80 [Silica gel, 20% EtOAc in hexanes]. [α]25D = + 29.0 (c 0.2, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.81 (dd, J = 15.7, 6.7 
Hz, 1H, CHCH=CHCO), 6.08 (dd, J = 15.6, 1.3 Hz, 1H, 
CHCH=CHCO), 5.64 (dd, J = 15.5, 6.8 Hz, 1H, (CH3)2CHCH=), 5.37 
(ddd, J = 15.5, 7.4, 1.3 Hz, 1H, (CH3)2CHCH=CH), 4.21 (q, J = 7.1 Hz, 
2H, OCH2CH3), 4.09 (ddd, J = 6.8 Hz, 1H, CH=CHCHO), 3.86 (td, J = 
6.1, 1.5 Hz, 1H, CH=CHCHCHN3), 2.31 (dqd, J = 13.5, 6.7, 1.4 Hz, 
1H, (CH3)2CH), 1.29 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.99 (dd, J = 6.8, 
2.5 Hz, 3H, (CH3)2CH), 0.98 (dd, J = 6.8, 2.5 Hz, 3H, (CH3)2CH) 0.87 (s, 
9H, OSiCH(CH3)3), 0.09 (s, 3H, OSiCH(CH3)2), 0.04 (s, 3H, 
OSiCH(CH3)2). 13C NMR (100 MHz, CDCl3), δ  (ppm): 165.72, 142.29, 
141.81, 125.89, 123.86, 76.79, 67.34, 60.56, 30.83, 25.76, 22.04, 18.13, 
14.19, -2.95, -4.17, -4.88. HRMS (H-ESI) m/e 390.21834 calcd for 
C18H33N3O3Si [M + Na]+, found 390.21799.
2.8.4.4. Synthesis of the Allylic Alcohol 67 
A solution of 66 (80 mg, 0.22 mmol, 1.0 equiv) in CH2Cl2 (5 mL) 
was cooled at -78ºC and then treated with DIBAL-H 1.0 M solution in 
toluene (0.54 mL, 0.54 mmol, 2.5 equiv) After 20 min, the reaction was 
quenched by adding of EtOAc at -78ºC and the mixture was allowed to 
reach rt and treated with a saturated aqueous Na+/K+ tartrate solution. 
The resulting mixture was vigorously stirred until a clear separation of 
both organic and aqueous phases. The aqueous phase was then separated, 
the organic extract washed with water and brine, dried over MgSO4 and 
the solvent evaporated under reduced pressure. The crude of the alcohol 
was then purified by flash column chromatography (silica gel, 15% EtOAc 
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Rf = 0.71 [Silica gel, 40% EtOAc in hexanes]. [α]25D =  +5.0 (c 0.5, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 5.91 (dtd, J = 15.5, 5.2, 
1.0 Hz, 1H CH=CHCO), 5.68 (ddt, J = 15.5, 7.3, 1.6 Hz, 1H 
CH(OH)CHN3CH=), 5.60 (ddd, J = 15.5, 6.7, 0.9 Hz, 1H 
(CH3)2CHCH=) , 5 .38 (ddd, J = 15 .5 , 7 .3 , 1 .3 Hz, 1H 
(CH3)2CHCH=CH), 4.22 – 4.15 (m, 2H, CH2OH), 4.03 (t, J = 6.3 Hz,
1H, CH=CHCHOSi)), 3.71 (t, J = 6.6 Hz, 1H CH=CHCH(OH)CHN3), 
2.30 (dqd, J = 13.4, 6.7, 1.1 Hz, 1H (CH3)2CH)), 0.99 (d, J = 6.7 Hz, 3H 
(CH3)2CH), 0.98 (d, J = 6.7 Hz, 3H (CH3)2CH), 0.90 (s, 9H, 
OSiCH(CH3)3), 0.08 (s, 3H, OSiCH(CH3)2), 0.04 (s, 3H, OSiCH(CH3). 
13C NMR (100 MHz, CDCl3), δ (ppm) 140.94, 133.66, 126.47, 126.27, 
76.81, 68.32, 62.88, 30.80, 25.80, 22.15, 22.08, 18.18, -4.13, -4.81.
2.8.4.5. Synthesis of the Epoxy Alcohol 68
To a solution of titanium tetraisopropoxide (0.02 mL, 0.08 mmol, 
0.35 equiv) in CH2Cl2 (5 mL) was added D(-)-DET (0.01 mL, 0.08 mmol, 
0.35 equiv) at -20ºC. After 15 min at this temperature, a solution of allylic 
alcohol 67 (70 mg, 0.22 mmol, 1.0 equiv) in CH2Cl2 (3 mL) was added 
dropwise, followed by the addition, after additional 30 min, of TBHP 5.5 
M in decane (0.06 mL, 0.34 mmol, 1.6 equiv)  at the same temperature. 
After 8 h at this temperature, the reaction mixture was quenched with 
Me2S (0.07 mL, 0.98 mmol, 4.6 equiv) at 0ºC filtered and the solvent was 
evaporated under reduced pressure. The crude product was purified by 
flash column chromatography (silica gel, 20% EtOAc in hexanes) to 
















Rf = 0.63 [Silica-gel, 40% EtOAc in hexanes]. [α]25D = +29.5 (c 0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 5.70 (ddd, J  = 15.5, 6.6, 
0.9 Hz, 1H (CH3)2CHCH=), 5.41 (ddd, J = 15.6, 7.6, 1.4 Hz, 1H, 
(CH3)2CHCH=CH), 4.21 - 4.13 (m, 1H, CH=CHCHO), 3.94 (d, J = 12.6 
Hz, 1H, CHN3CH(O)CH), 3.62 (d, J = 13.4 Hz, 1H, CHN3CH(O)CH), 
3.15 -3.11 (m, 1H, =CHCHOCHN3), 3.1 -3.09 (m, 2H, CH(O)CHCH2), 
2.39 - 2.25 (m, 1H, (CH3)2CH), 1.68 (bs, 1H, OH), 1.01 (d, J = 6.7, 3H, 
(CH3)2CH), 0.97 (d, J = 6.7, 3H, (CH3)2CH), 0.90 (s, 9H, (CH3)3CSi), 0.10 
(s, 3H, (CH3)2Si, 0.06 (s, 3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ 
(ppm): 141.60, 125.92, 75.36, 67.84, 60.56, 56.99, 54.61, 30.76, 25.76, 
22.07, 21.92, 18.08, -4.11, -4.87.
2.8.4.6. Synthesis of the Amide 70
Epoxy alcohol 68 (10 mg, 30 µmol, 1.0 equiv) was dissolved in a 
1:1 mixture of MeOH/B(OMe)3 (2 mL) and the resulting solution was 
treated with DBU (5 µL, 30 µmol, 1.0 equiv) and heated at 70ºC for 12 
hours. After this time, the reaction mixture was allowed to reach room 
temperature, cooled to 0ºC, and then treated with a saturated aqueous 
NaHCO3 solution. After stirring for 30 min at 0ºC, EtOAc was added and 
both phases were separated. The aqueous phase was extracted with 
EtOAc and the combined organic extracts were washed with water and 
brine, then dried over anhydrous MgSO4 and the solvent was evaporated 
under reduced pressure. The resulting crude product was used in the next 




c. 62, DIPEA, BOP
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The crude of the corresponding diol was dissolved in 1:1 mixture 
of CH3CN/H2O (4 mL) and the resulting solution was treated with BAIB 
(55 mg, 168 µmol, 6.0 equiv)   followed by TEMPO (4 mg, 30 µmol, 0.8 
equiv) at 25ºC. After 5 h, the crude mixture was diluted with EtOAc, 
quenched by the addition of a saturated aqueous Na2S2O3 solution and, 
after separation of both layers, the aqueous phase was then extracted with 
EtOAc. The organic solution was washed again with a saturated aqueous 
Na2S2O3 solution, then dried over anhydrous MgSO4 and the solvent was 
evaporated under reduced pressure.
The crude acid was dissolved in DMF (4 mL) and treated with 
DIPEA (10 µL, 56 µmol, 2.0 equiv), amino lactam 62 (7 mg, 42 µmol, 1.5 
equiv) and BOP (15 mg, 34 µmol, 1.2 equiv) at 25ºC. After being stirred at 
this temperature overnight, the crude mixture was diluted with Et2O and 
washed with a saturated aqueous NH4Cl solution. The aqueous phase was 
extracted with Et2O and the combined organic phases were washed with 
brine, dried over anhydrous MgSO4 and the solvent was evaporated under 
vacuum. Purification of the obtained crude product by flash column 
chromatography (silica gel, 60% EtOAc in hexanes) provided amide 70 
(12 mg, 86% over 3 steps) as a colourless oil.
Rf = 0.33 [Silica-gel, 80% EtOAc in hexanes]. [α]25D = + 18.4 (c 0.3, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 7.93 (d, J = 6.2 Hz, 1H, 
CONHCH), 6.09 (t, J = 6.7 Hz, 1H, CONHCH2), 5.72 (ddd, J = 15.5, 
6.5, 0.8 Hz, 1H, (CH3)2CHCH=CH), 5.34 (ddd, J = 15.6, 7.7, 1.4 Hz, 
1H, (CH3)3CHCH=CH), 4.54 (ddd, J = 11.3, 6.2, 1.8 Hz, 1H, 
CHNHCO), 4.44 - 4.36 (m, 1H, CH=CHCHO), 3.76 - 3.73 (m, 1H, 
CHOH), 3.54 (s, 3H, CHOCH3), 3.38 (dd, J = 8.4, 1.6 Hz, 1H, 
CH=CHCHOCHN3), 3.34 - 3.19 (m, 3H, CONHCH2 and CH3OCH), 
2.37 - 2.23 (m, 1H, (CH3)2CH), 2.15 - 1.98 (m, 2H, CH2), 1.92 - 1.75 (m, 




(CH3)2CH), 0.97 (d, J = 6.8, 3H, (CH3)2CH), 0.92 (s, 9H, (CH3)3CSi), 0.13 
(s, 3H, (CH3)2Si), 0.06 (s, 3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ 
(ppm): 174.78, 171.79, 141.62, 126.39, 80.76, 77.20, 75.05, 71.24, 67.68, 
59.95, 51.95, 42.16, 31.23, 30.70, 28.89, 27.95, 25.82, 25.75, 22.13, 
21.77, 18.08.
2.8.4.7. Synthesis of the Azido Analogue of Bengamide E 71
Silyl ether 70 (15 mg, 0.03 mmol, 1.0 equiv) was dissolved in THF 
(2 mL) and over this solution was added 1.0 M TBAF in THF (0.04 mL, 
0.04 mmol, 1.2 equiv) at rt. After 30 min, the reaction crude was diluted 
with EtOAc and a saturated aqueous NH4Cl solution. The aqueous phase 
was then extracted with EtOAc and the organic extracts washed with 
H2O, brine and dried over MgSO4. The solvent was removed under 
vaccuum and the crude product was purified by flash column 
chromatography (silica gel, EtOAc) to afford azido analogue of bengamide 
E 71 (6 mg, 50%) as a colourless oil.
Rf= 0.23 [Silica gel, EtOAc]. [α]25D = +20.6 (c 0.2, CH2Cl2). 1H RMN 
(400 MHz, CDCl3), δ (ppm): 7.94 (d, J = 6.3 Hz, 1H, CONHCH), 6.01 (t, 
J = 6.6 Hz, 1H, CONHCH2), 5.85 (ddd, J = 15.5, 6.5, 1.2 Hz, 1H, 
(CH3)2CHCH=CH), 5.51 (ddd, J = 15.5, 6.5, 1.4 Hz, 1H, 
(CH3)3CHCH=CH), 4.60 – 4.47 (m, 2H, CHNHCO and =CHCHOH), 
4.29 (d, J = 2.6 Hz, 1H, OH), 3.92 (dt, J = 7.9, 2.8 Hz, 1H, 
CHOHCHN3CHOH), 3.84 (d, J = 7.9 Hz, 1H, CHOCH3), 3.55 (s, 3H, 
CHOCH3), 3.41 (dd, J = 5.0, 3.0 Hz, 1H, =CHCHOHCHN3), 3.37 – 3.23 
(m, 2H, CH2), 2.95 (d, J = 2.9 Hz, 1H, OH), 2.42 – 2.28 (m, 1H, 
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1.39 (m, 2H, NHCHCH2), 1.02 (d, J = 6.7, 3H, (CH3)2CH), 1.02 (d, J = 
6.7 Hz, 3H, (CH3)2CH). 13C RMN (100 MHz, CDCl3), δ (ppm): 174.63, 
171.61, 141.37, 125.49, 80.26, 74.26, 73.73, 65.18, 59.99, 52.05, 42.17, 
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Adenia gummifera  (Passifloraceae) is a species that grows in various 
regions of Africa. The juice from the leaves of this plant is used in 
Tanzania to treat colic, while the crushed leaves are applied externally in 
the treatment of broken bones.1 The roots are employed as a diuretic, to 
treat filariasis, and against infertility,2 although these are just a few 
examples of the many medicinal uses traditionally related to A. gummifera.3 
Despite the fact that polyacetylenes are in general known to be labile, the 
concomitant presence of high unsaturation and epoxide functionalities 
might well confer the observed cytotoxic activity.
__________________________________________
The structure of Gummiferol, isolated from the leaves of 
Adenia gummifera contains apart from a conjugated 
triacetylene moiety two oxirane rings, exhibiting significant 
activity against the KB human cell line and a broad cytotoxic 
spectrum against other human cancer cell lines.
______________________________________________
Conjugated acetylene moieties are common structural units found 
on an extensive number of natural products, many of which display an 
impressive biological activity as antibacterial (72),4 antiparisitic (73)5 and 
insecticidal agents (74).6 This class of polyacetylenes shows in addition an 
inhibitory effect on HIV-1 integrase7 and cytotoxicity against a wide range 
of  cell lines.8, 9-11
3.2. Biological Context
In 1995, Wall et al. isolated from the leaves of Adenia gummifera by 
treatment with a 50% MeOH/CHCl3 an organic portion that exhibited 
an ED50 value of 1.1 µg/mL in the human epidermoid carcinoma (KB) 
cell line assay.12 Subsequent purification by flash column chromatography 
rendered (-)-gummiferol, whose structure was still unknown.
3.2.1. Cytotoxicity Tests
Although a diverse array of polyacetylenes has been isolated 
mainly from species of the Compositae and Umbelliferae families and to a 
lesser extent from plants of other families,13 the polyacetylene diepoxide 















structural variant is a C14-monoepoxy acetylene compound previously 
isolated from Panax quinqufolium (Araliaceae) as a cytotoxic constituent.14
The concomitant presence of high unsaturation and epoxide 
functionalities might well confer the observed cytotoxic activity, shown in 
Table 3.1.12
Table 3.1. Cytotoxicity of  gummiferol
Cell line ED50 (µg/mL) Cell line ED50 (µg/mL)
BC1......................... 0.2 P-388....................... 0.03
HT........................... 0.1 A-431....................... 0.5
Lul........................... 0.9 LNCaP..................... 0.2
Mel2........................ 1.3 ZR-75-1................... 0.2
Col2........................ 0.6 U-373...................... 0.05
KB.......................... 0.3 KB-V(-VLB)............ 0.4
KB-V(+VLB).......... 0.3
Particular striking is its significant activity against various cell lines 
including strong activity against P388 (mouse leukaemia) and U373 
(human glioblastoma). This antitumoral profile renders gummiferol as an 
interesting synthesis and biomedical endeavour.
3.3. Structure and Synthesis of Gummiferol
Until today, only Takamura and co-workers have reported a total 
synthesis of gummiferol that let to establish its absolute configuration 
(Scheme 3.1).15 Prior to that, Wall et al. described the structure of the 
natural product on the basis of its spectra,12 although the stereochemistry 
of the two oxirane rings remained unknown until Takamura's publication. 
The unambiguous stereochemical elucidation of (-)-gummiferol (75) was 




The main core of gummiferol was assembled by connection of 
chiral building block 76 and the dicetylene moiety 77 via  a Cadiot-
Chodkiewicz coupling.17
For the preparation of enantiopure fragment 76, dienol 78 was 
selected as starting material,18 which was subjected to a first Sharpless 
asymmetric epoxidation with a significant recovery of starting material. 
Epoxy alcohol 79 was then converted into the allylic alcohol 81 by a 3-
step sequence involving Parikh-Doering oxidation,10 Horner-Wadsworth-
Emmons reaction19 and DIBAL-H reduction. A second Sharpless 
epoxidation delivered the desired diepoxy alcohol 82 in a 80% yield 
(Scheme 3.2).
















Reagents and conditions: (a) SAE, (+)-DIPT, 42% (71% brsm). (b) SO3·Pyr, 
Et3N, DMSO, CH2Cl2,  0ºC to rt.  (c) (EtO)2P(O)CH2CO2Et, DIPEA, LiCl, 
CH3CN, 0ºC to rt,  80% (over 2 steps). (d) DIBAL-H, CH2Cl2,  -78ºC, 80% (2 
cycles). (e) SAE, (+)-DIPT, 80%.
Conversion of the diepoxy alcohol 82 into the bromo derivative 
76 commenced with a Parikh-Doering oxidation,10 followed by one-
carbon homologation with CBr4/Ph3P/Et3N20 and subsequent treatment 
with TBAF to afford the bromoacetylenic alcohol 76 (Scheme 3.3).21
The assembly of the diacetylene unit and the bromoacetylenic 
alcohol 76 proceeded via a Cadiot-Chodkiewicz reaction,17 after which the 
synthesis of gummiferol was completed by acetylation and deprotection of 
the remaining hydroxyl moiety by treatment with buffered HF-pyridine to 
give 75 in a 83% overall yield (Scheme 3.3).


























Reagents and conditions:  (a) SO3·Pyr, Et3N, DMSO, CH2Cl2, 0ºC to rt. 
(b)CBr4, Ph3P, Et3N, CH2Cl2, -78ºC. (c) TBAF, THF, 0ºC to rt, 70% (over 3 steps). 
(d) 77, CuCl, NH2OH·HCl,  Et3N, MeOH, -78ºC. (e) Ac2O, Pyr, DMAP, CH2Cl2, 
0ºC, 56% (over 2 steps). (f) HF·Pyr, THF, 0ºC, quant.
This methodology described by Takamura was extended to the 
synthesis of the enantiomer ent-(75) and the two possible diastereoisomers 
of  (-)-gummiferol, diepoxides (85) and ent-(85).



























More recently, in 2013, the same authors improved the procedure 
above described and applied it to the synthesis of both enantiomers of 
(75)  and ent-(75) (Figures 3.2).22 Furthermore, they prepared a series of 
gummiferol analogues that allowed a detailed structure-activity 
relationship study (Figure 3.3).
The growth-inhibitory activity of all these synthetic products 
against HL60 and HeLa S3 cells allowed to determine that the 
stereochemistry of the diepoxide unit has little effect on the cytotoxic 
activity and how crucial was the presence of the triacetylene moiety for 


































Table 3.2. Growth-inhibitory activity (µM) of (-)-gummiferol and its synthetic 
isomers
Compound HL60 HeLa S3 Compound HL60 HeLa S3
(75) 1.22 6.76 (86) >100 >100
ent-(75) 1.23 6.68 (87) 12.3 31.6
(85) 1.62 8.61 (88) 4.63 22.4
ent-(85) 3.61 19.1 (89) 4.75 17.4
An important aspect of the synthesis of the (-)-gummiferol, as 
described above, is that it constitutes a general method for the preparation 
of any desired diastereoisomer. However there is still room for 
improvement, for instance in the yields of the first Sharpless epoxidation, 
that still remain in 42% (71% based on recovered starting material).
3.4. Synthesis of Gummiferol
The first total synthesis of Gummiferol offers new opportunities 
both in the biological and medical fields. However, even though the 
synthesis previously described constitutes a general method capable of 
producing a range of (non-natural) gummiferol isomers, alternative (more 
efficient) approaches remain a continuing area of  research.
Considering the promising biological profile displayed by 
gummiferol and with the aim of offering an alternative to the only 
synthesis reported, a more efficient synthetic strategy has been postulated 
based on the use of chiral sulfur ylides,23 that opens up access to all the 
diastereoisomers of gummiferol by reducing the number of steps and 
offers an unexplored option to the Sharpless asymmetric epoxidation for 
these particular systems.
3.4.1. Retrosynthetic Analysis of Gummiferol
The retrosynthetic strategy for the synthesis of gummiferol is 




in the natural product provided diepoxy alkyne 94 and some ot the 
diacetylenes 90-92 as suitable building blocks. Both key fragments would 
be assembled via a Cadiot-Chodkiewicz coupling.17
3.4.2. Synthesis of the Diacetylene Fragment
According to the above retrosynthetic analysis, synthesis of 
gummiferol commenced with the preparation of alkynes 90-92. This 
synthetic task was accomplished from the commercial dialkyne 93, 
following the procedure described by V. Fiandenese et al. for the synthesis 
of the alcohol 97.24 The subsequent deprotection of the terminal alkyne 
and iodation under basic conditions provided compound 91,25 that did not 
required any further purification (Scheme 3.5). Subsequent protection 



























(90) X = H; R = H
(91) X = I; R = H
(92) X = I ; R = TBS






into the corresponding silyl ether by action of TBSOTf and 2,6-lutidine 
provided iodide 92 in 68% overall yield. 
Reagents and conditions: (a) MeLi-LiBr, Et2O, 0ºC, 8 h. (b) (CH2O)n, Et2O, 
0ºC, 8 h. (c) K2CO3, MeOH, 25ºC,12 h. (d) TBSOTf, 2,6-lutidine, CH2Cl2, 0ºC 
to rt, 3 h. (e) KOH, I2, H2O-MeOH, 0ºC to rt. (f) TBSOTf, 2,6-lutidine, CH2Cl2, 
0ºC to rt, 3 h, 68% overall yield.
3.4.3. Synthesis of the Diepoxy Alkyne
3.4.3.1. First Approach to the Synthesis of the Diepoxy Alkyne 94
We first envisioned the synthesis of the diepoxy alkyne 94 from 
readily available isopropyliden-D-glyceraldehyde (IDG) (99) as depicted in 
Scheme 3.6. This suitable starting material would provide an 
stereochemical induction over the introduction of  the first oxirane ring.
However, our initial efforts were made in vain since all the 
conditions tested for the synthesis of the diepoxy amide, by reduction of 





































the known epoxy amides 100-102 and subsequent reaction with the 
corresponding non-chiral sulfur ylide, provided complex crude mixtures 
and very low yields. In light of these discouraging results, we turned our 
attention to an alternative strategy (Scheme 3.7).
Reagents and conditions:  (a) Me2S=CHCOR (with R = NMe2, NEt2, 
Indoline), 5.0 M NaOH, CH2Cl2- H2O, 25ºC, 8 to 12 h. (b) Red-Al, THF, 0ºC,  1 
h. (c) Me2S=CHCOR (with R = NMe2, NEt2,  Indoline), 5.0 M NaOH, CH2Cl2- 
H2O, 25ºC, 8 to 12 h.
3.4.3.2.  Second Approach to the Synthesis of the Diepoxy  Alkyne 
94
In a second attemp towards our synthetic target, we planned the 
synthesis of the building block 94 from alcohol 96 in a strategy that 
combined the Sharpless asymmetric epoxidation (SAE) together with the 
use of our chiral sulfur ylides, as depicted in Scheme 3.8. This new 
starting material would provide (-)-gummiferol (75) as well as its non-
natural enantiomer, (+)-gummiferol, ent-(75).
From the epoxy alcohols ent-106 and 106, the epoxy amides 
ent-107 and 107 were obtained by Parikh-Doering oxidation,10 followed 
by treatment with the sulfur ylides derived from L- and D- methionine (1) 
and (2), respectively. Thus, epoxy amides ent-107 and 107 were obtained 
in 60 and 57% yields respectively from the correspoding epoxy alcohols 
ent-106 and 106. Subsequent conversion into the corresponding allylic 















(100) R = NMe2
(101) R = NEt2
(102) R = Indoline
(103) R = NMe2
(104) R = NEt2




alcohols and protection with Ac2O/Pyr furnished the diepoxy alkenes 
ent-110 and 110, 73 and 30% overall yields respectively (Scheme 3.8).
Reagents and conditions: (a) PCC, NaOAc, CH2Cl2, 25ºC, 16 h.  (b) DIBAL-
H, CH2Cl2, -78ºC,  45 min (c) SAE, 73% for ent-106, 65% for 106 (over 2 steps). 
(d) SO3·Pyr, CH2Cl2, DMSO, 0ºC to rt. (e) 4 or 6, 5.0 M NaOH, CH2Cl2-H2O, 
57% for ent-107,  60% for 107 (over 2 steps). (f) Red-Al, THF, 0ºC, 45 min. (g) 
Ph3PCHCO2Et, CH2Cl2, 25ºC, 57% for ent-108, 60% for 108 (over 2 steps). (h) 
DIBAL-H, CH2Cl2, -78ºC, 45 min, 76% for ent-109, 36% for 109.  (i) Ac2O/Pyr, 
25ºC, 12 h, 73% for ent-110,  30% for 110. (j) TBAF (k) SO3·Pyr, CH2Cl2, DMSO, 
0ºC to rt or Swern oxidation or TEMPO/BAIB, CH3CN-H2O, 25ºC, 16 h or 
PCC, NaOAc, CH2Cl2, 25ºC, 16 h. (l) OB-reagent, K2CO3.
































ent-(109) R = OH
ent-(110) R = OAc
(108)
a-c
d, e d, e








(109) R = OH








As depicted in Scheme 3.8, chiral sulfur ylides methodology 
enabled us to synthesize each of the epoxides ent-110 and 110 in a good 
overall yield (slightly better for ent- isomer) and in a stereospecific fashion. 
reducing the number steps with regard to Takamura’s synthesis. 
Nevertheless, we found several inconveniences during the insertion of the 
alkyne via Ohira-Bestmann reaction. Thus, despite deprotection of silyl 
ethers ent-110 and 110 proceeded in a very good yield, subsequent 
oxidations to the aldehyde by treatment with either SO3·Pyr, Swern 
conditions, TEMPO/BAIB or PCC, followed by reaction with the O-B 
reagent resulted in the not obtention of the desired alkynes and although 
several oxidation conditions were tested to obtain the corresponding 
aldehyde, we were not able to isolate alkynes ent-94 and 94. The failure of 
this key step forced us to consider a new approach and we finally decided 
to establish to this aim a new and shorter strategy.
Starting again from alcohol 96a, which was converted into the 
corresponding aldehyde by action of PCC and subsequent reaction with 
salts 4 and 6 in basic media, epoxy amides ent-111 and 111 were obtained 
in a 40% yield over 2 steps, according to the one-phase procedure. 
Consequent reduction by action of Red-Al, followed by treatment with 
chiral sulfonium salts once again, supplied diepoxy amides ent-113 and 




Reagents and conditions: (a) PCC, NaOAc, CH2Cl2,  25ºC, 16 h. (b) 4 or 6, 
3.0 M NaOH, tBuOH, 25ºC, 12 h, 40% for ent-111, 40% for 111, 40% for 
ent-112,  40% for ent-112 (over 2 steps). (c) Red-Al, THF, 0ºC, 45 min to 1 h. (d) 4 
or 6, 5.0 M NaOH, CH2Cl2, rt, 95% for ent-113,  61% for 113, 95% for ent-114, 
70% for 114 (over 2 steps).
We decided also to assume a last modification and we changed the 
TBS- group by the TBDPS- one which not only increases the molecular 
weight of the compounds but also allows to easily monitor the reaction by 
UV, and to our delight, better yields were obtained in all the cases in the 
reactions performed with TBDPS- groups.
From these compounds ent-113, 113 and ent-114 and 114, 
diepoxy alkynes were synthesized through succesive reduction under Red-
Al and Ohira-Bestmann coupling reactions. Thus, alkynes ent-94 and 94 
were obtained in a 12% and 44% yields (over 2 steps), respectively. In 
terms of yield, it should be mentioned the differences in results between 
both enantiomeric series, which might be explained because of the lability 
of the aldehydes, despite the coupling reaction was set up inmediately 
(Schemes 3.10-A and 3.10-B).
















ent-111: R = TBS
ent-112: R = TBDPS
111: R = TBS












c, d c, d
ent-113: R = TBS
ent-114: R = TBDPS
113: R = TBS
114: R = TBDPS
(96a) R = OTBS




Albeit all our best efforts were made to couple diepoxy alkenes 
ent-94 and 94 with alkynes 90-92 we were not able to obtain gummiferol 
by this methodology, even though different conditions were tested (Table 
3.3).
With these discouraging results in hand, we finally resolved to 
reproduce the conditions reported by Takamura and finally, the coupling 
between alcohols ent-116 and 116 and alkyne 77 was accomplished in the 
presence of Cu (I) and EtNH2. In this way, precursor of (+) -gummiferol 
was obtained in a 55% overall yield (Scheme 3.10-A). In the case of (-)-
gummiferol, the same scheme is being accomplished to afford precursor 
84 (Scheme 3.10-B).
Reagents and conditions: (a) Red-Al,  THF, 0ºC, 45 min. (b) Ohira-Bestmann 
reagent, K2CO3, MeOH, 25ºC, 16 h. (c) TBAF, THF, 25ºC, 12 h. d) Ac2O/Pyr, 
25ºC, 2h, 30% (over 2 steps). (e) Red-Al, THF, 0ºC, 45 min. (f) CBr4,  Ph3P, Et3N, 
25ºC, min, 40% (over 2 steps). (g) TBAF, THF, 0ºC,  1 h.  (h) 77, CuI, EtNH2, .(i) 
Ac2O/Pyr, DMAP, 51% (over 3 steps).
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Reagents and conditions: (a) Red-Al,  THF, 0ºC, 45 min. (b) Ohira-Bestmann 
reagent, K2CO3, MeOH, 25ºC, 16 h, 44%. (c) TBAF, THF, 25ºC, 12 h (d) 
Ac2O,/Pyr, 25ºC, 2 h,  25% (over 2 steps). (e) Red-Al, THF, 0ºC, 45 min. (f) CBr4, 
Ph3P, Et3N, 25ºC, min, 40%. (g) TBAF, THF, 0ºC, 1 h. (h) 77, CuI, EtNH2. (i) 
Ac2O/Pyr, DMAP.





1 X = H Y = H R = H
2 X = H Y = I R = H
3 X = H Y = I R = OTBS
4 X = Br Y = H R = OTBS
Reagents and Conditions: (1) Cu(OAc)2, Piperidine, CH2Cl2, 25ºC, 10-20 h. 
(2) (Ph3P)PdCl2, CuI, DIPA,THF, 2 h. (3) X, CuCl, NH2OH, 0ºC to -78ºC, 
EtNH2, MeOH or CuI, Piperidine, 25ºC, 1 h. (4) CuCl, NH2OH, 0ºC to -78ºC, 
EtNH2, MeOH, 3 h. 







113: R = TBS




















115 R  = OTBS




The final deprotection of both precursors ent-84 and 84 was 
tested in different standard desilylation protocols (TBAF, HF·Pyr). In both 
cases, we could not detect any trace of gummiferol, and we suspect that 
the products were decomposed. Nevertheless, we keep working on this 
final step and several conditions are being tried. (Scheme 3.11).






















3.5. Summary and Concluding Remarks
In this chapter, new approaches towards the synthesis of natural 
and non-natural gummiferol were described. In particular, the 
development of an alternative route to construct the diepoxy alkyne was 
discussed. It was shown, that the application of our chiral sulfur ylides 
methodology is a feasible and efficient alternative to asymmetric catalysis 
for the synthesis of  the chiral part of  the chain.
Compound ent-84 was prepared from alcohol 96b in 10 steps and 
8% overall yield and with complete stereo control. In comparison, 
Takamura and co-workers synthesized a similar building block in 11 steps 
and 8% overall yield. In their case, the stereoselective introduction of the 
epoxide moieties was accomplished with moderate diastereoselectivity and 
modest yields using a Sharpless asymmetric epoxidation reaction.
From readily available starting material, this new route is in 
principle suitable for the synthesis of all the diastereoisomers of 
gummiferol together with other analogues that could be synthesized by 
taking advantage of  the chiral sulfur ylide methodology.  
Unfortunately, although several attemps have being made, 
deprotection of precursos ent-84 and 84 is currently obstructed by the lack 





3.6.1. General Procedures for the Synthesis of Epoxy  and 
Diepoxy Amides
3.6.1.1. Synthesis of Epoxy Amides
To a solution of sulfonium salt (4 or 6) (1.1 equiv) in tBuOH (~ 
0.08 M) was added a 3.0 M aqueous NaOH solution (1.1 equiv). After 10 
min at 25ºC, a solution of the corresponding aldehyde (1.0 equiv), in 
tBuOH (~ 0.1 M) was added, and the crude reaction mixture was 
vigorously stirred overnight at 25ºC. After this time, both phases were 
separated, and the aqueous layer was extracted twice with EtOAc. 
Combined organic extracts were then washed with H2O and brine, dried 
over anhydrous MgSO4, filtered, and concentrated under vacuum. Flash 
column chromatography (silica gel, EtOAc 30-50% in hexanes) afforded 
the corresponding epoxy amide.
3.6.1.2. Synthesis of Diepoxy Amides
To a solution of the corresponding epoxy amide (1.0 equiv) in dry 
THF (0.08 M) was added dropwise Red-Al 70% w/v in toluene (2.2 equiv) 
at 0ºC. After 1 h at 0ºC, the reaction mixture was quenched by addition of 
a saturated aqueous NH4Cl solution. After separation of both layers, the 
aqueous phase was extracted with EtOAc, the organic extracts were 
washed with brine and dried over MgSO4, and the solvent was evaporated 
under reduced pressure. The resulting crude epoxy aldehyde was used for 
the next step without further purification.
To obtain the corresponding diepoxy amide, a 5.0 M aqueous 
NaOH solution (1.0 equiv) was added to a solution of sulfonium salt (4  or 
6) (1.1 equiv) and the crude aldehyde in CH2Cl2-H2O (1:1) (~ 0.4 M). The 




both phases were separated, and the aqueous layer was extracted twice 
with EtOAc. Combined organic extracts were then washed with H2O and 
brine, dried over anhydrous MgSO4, filtered, and concentrated. 
Purification of the crude product by flash column chromatography (silica 
gel, 30-50% EtOAc in hexanes) provided corresponding diepoxy amide.
3.6.2. Synthesis of (+)-Gummiferol
3.6.2.1. Synthesis of the Diepoxy Amide ent-107
Epoxy alcohol ent-106 (320 mg, 1.47 mmol 1.0 equiv) was 
dissolved in a CH2Cl2/DMSO (1:1) mixture (6 mL) and cooled at 0ºC. At 
this temperature, Et3N (0.6 mL, 4.4 mmol, 3.0 equiv) was added followed 
by SO3·Pyr (420 mg, 2.6 mmol, 1.8 equiv). The mixture was allowed to 
reach rt and after 5 hours was quenched by addition of buffer pH = 7 and 
diluted with Et2O. The aqueous phase was extracted with Et2O and the 
combined organic extracts were washed with water and brine, then dried 
over anhydrous MgSO4 and the solvent removed under reduced pressure. 
The resulting crude of the aldehyde was used in the next step without 
further purification.
The crude aldehyde was reacted with sulfonium salt 4 (350 mg, 
1.12 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.27 mL, 1.36 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide ent-107 (460 mg, 




















Rf = 0.20 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 26.7 (c 0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 4.34-4.28 (m, 1H, 
CONCH), 4.02 (ddd, J = 9.2, 5.2, 1.4 Hz, 1H, OCH2CH), 3.93-3.88 (m, 
2H, OCH2CH and SiOCH2), 3.74 (dd, J = 12.3, 3.6 Hz, 1H, 
CH2CH(O)CH), 3.58 (d, J = 2.0 Hz, 1H, CH(O)CHCO), 3.37 (dd, J = 
3.3, 2.0 Hz, 1H, CH(O)CHCO), 3.16-3.11 (m, 2H, CH2CH(O)CH and 
SiOCH2), 2.59 (ddd, J = 13.0, 7.7, 5.1 Hz, 1H, SCH2CH2), 2.52-2.43 (m, 
1H, SCH2CH2), 2.13 (s, 3H, CH3S), 2.10 -2.05 (m, 1H, SCH2CH2), 1.84 
(d, J = 5.4 Hz, 1H, SCH2CH2), 1.65 (s, 3H, (CH3)2C), 1.53 (s, 3H, 
(CH3)2C), 0.88 (s, 9H, (CH3)3CSi), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 3H, 
(CH3)2Si). 13C NMR (100 MHz, CDCl3), δ  (ppm): 162.94, 95.86, 67.01, 
61.57, 56.29, 55.95, 55.50, 51.69, 51.23, 34.40, 30.61, 26.17, 25.78, 
25.65, 18.27, 15.70, -5.42, -5.44.
3.6.2.2. Synthesis of the ɣ,ẟ-Diepoxy α,β-Unsaturated Ester 
ent-108
Diepoxiamide ent-107 (230 mg, 0.53 mmol, 1.0 equiv) in dry THF 
(8 mL) was treated dropwise with Red-Al 60% w/v in toluene (0.33 mL, 
1.17 mmol, 2.2 equiv) at 0ºC. After 1 hour at this temperature, the 
reaction mixture was diluted with a saturated aqueous NH4Cl solution. 
The aqueous phase was then separated, extracted twiced with EtOAc and 
the combined organic phase washed with H2O and brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The 





















The crude aldehyde was dissolved in CH2Cl2 (10 mL) and over 
this solution was added the phophorous ylide Ph3P=CHCO2Et (280 mg, 
0.8 mmol 1.5 equiv). After 30 minutes the reaction is complete and the 
solvent was removed under reduced pressure. Flash column 
chromatography (silica gel, 20% EtOAc in hexanes) afforded the α,β-
unsaturated diepoxy ester ent-108 (100 mg, 57% over 2 steps) as a pale 
yellow oil.
Rf = 0.58 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 8.1 (c  0.4, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.63 (dd, J = 15.7, 7.2 
Hz, 1H, CH=CHCO), 6.14 (dd, J = 15.7, 0.7 Hz, 1H, CH=CHCO), 4.18 
(q, J = 6.8 Hz, 2H, CH2CH3), 3.86 (dd, J = 12.3, 2.8 Hz, 1H, SiOCH2), 
3.72 (dd, J = 12.3, 3.9 Hz, 1H, SiOCH2), 3.45 (ddd, J = 7.2, 1.9, 0.7 Hz, 
1H, CH(O)CHCH=), 3.10-3.07 (m, 1H, CH2CH(O)), 3.03 (dd, J = 4.0, 
2.1 Hz, 1H, CH2CH(O)CH), 2.99 (dd, J = 4.0, 1.9 Hz, 1H, 
CH(O)CHCH=), 1.26 (t, J = 7.1 Hz, 3H, CH2CH3), 0.86 (s, 9H, 
(CH3)3CSi), 0.04 (s, 3H, (CH3)2Si), 0.05 (s, 3H, (CH3)2Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 165.39, 143.03, 124.68, 61.81, 60.66, 58.49, 
56.22, 53.76, 52.60, 25.81, 18.30, 14.17, -5.38, -5.40.
3.6.2.3. Synthesis of the Allylic Alcohol ent-109
At -78ºC, DIBAL-H 1.0 M in toluene (1.15 mL, 1.15 mmol, 2.5 
equiv) was added over a solution of ester ent-108 (151 mg, 0.46 mmol, 1.0 
equiv) in CH2Cl2 (10 mL). After 30 minutes, the reaction was complete 
and it was allowed to warm at 0ºC. At this temperature, the mixture was 
diluted with EtOAc and a saturated aqueous Na+/K+ tartrate solution. 
















with EtOAc and the organic layer washed with water and brine, then 
dried over anhydrous MgSO4. and filtered. The solvent was then removed 
carefully under reduced pressured at low temperature. Purification by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) rendered the 
allylic alcohol ent-109 (100 mg, 76% yield) as a pale yellow oil.
Rf = 0.40 [Silica gel, 30% EtOAc in hexanes]. [α]25D = +14.4 (c  0.5, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.10 (dtd, J = 15.6, 5.1, 
0.6 Hz, 1H, CH=CHCH2), 5.47 (ddt, J = 15.6, 7.9, 1.7 Hz, 1H, 
CH=CHCH2), 4.17 (dd, J = 5.2, 1.7 Hz, 2H, =CHCH2OH), 3.87 (dd, J 
= 12.2, 2.8 Hz, 1H, SiOCH2), 3.73 (dd, J = 12.2, 4.0 Hz, 1H, SiOCH2), 
3.39 (ddd, J = 7.9, 2.1, 0.6 Hz, 1H, (O)CHCH=), 3.09 (ddd, J = 4.1, 2.8, 
2.3 Hz, 1H, CH2CH(O)CH), 2.99 (dd, J = 4.4, 2.2 Hz, 1H, 
CH2CH(O)CH), 2.92 (dd, J = 4.3, 2.1 Hz, 1H, CH(O)CHCH=), 1.74 (bs, 
1H, OH), 0.88 (s, 9H, (CH3)3CSi)), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 3H, 
(CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 135.40, 127.12, 62.50, 
62.04, 58.00, 56.06, 55.29, 53.26, 25.84, 18.33, -5.37, -5.36.
3.6.2.4. Synthesis of Acetyl Derivative ent-110
Over a solution of the allylic alcohol ent-109 (32 mg, 0.1 mmol, 
1.0 equiv) in pyridine (3 mL) was added Ac2O (0.4 mL, 4.5 mmol, 40 
equiv) at rt. After 12 h at the same temperature, the solvent was removed 
under vacuum and the crude product was purified by flash column 
chromatography (silica gel, 10 % EtOAc in hexanes) to furnish acetate 
ent-110 (27 mg, 73% yield) as a pale yellow oil.
Rf = 0.91 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 10.2 (c 0.3, 














0.6 Hz, 1H, CH=CHCH2), 5.50 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H, 
CH=CHCH2), 4.58 (dd, J = 5.8, 1.5 Hz, 2H, =CHCH2OAc), 3.89-3.85 
(ddd, J = 12.2, 2.8, 0.4, 1H, SiOCH2), 3.73 (dd, J = 12.2, 4.0 Hz, 1H, 
SiOCH2), 3.37 (ddd, J = 7.8, 2.1, 0.6 Hz, 1H, CH(O)CHCH=), 3.09 
(ddd, J = 4.0, 2.8, 2.2 Hz, 1H, CH2CH(O)CH), 2.99 (dd, J = 4.3, 2.2 Hz, 
1H, CH2CH(O)CH), 2.93 (dd, J = 4.3, 2.1 Hz, 1H, CH(O)CHCH=), 2.07 
(s, 3H, OCOCH3), 0.88 (s, 9H, (CH3)3CSi)), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 
3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 170.58, 130.20, 
129.84, 63.62, 61.98, 57.97, 56.07, 54.93, 53.10, 25.84, 20.85, 18.33, 
-5.35, -5.37.
3.6.2.5. Synthesis of the Epoxy Amide ent-111
Over a suspension of PCC (1.9 g, 8.9 mmol, 1.5 equiv) in CH2Cl2 
(20 mL) was added NaOAc anhydrous (1.9 g, 23.7 mmol, 4.0 equiv) 
followed by cis-allylic alcohol 96a (1.1 mL, 5.93 mmol, 1.0 equiv) dissolved 
in CH2Cl2 (10 mL). The reaction mixture was stirred at rt for 6 h and the 
resulting crude was filtered off through a pad of SiO2 and washed with 
Et2O. The solvent was then removed under vacuum and the crude 
aldehyde was used in the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (1.2 g, 3.93 
mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 1.2 mL, 3.57 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of epoxy amides to yield epoxy amide ent-111 (600 mg, 40% 














Rf = 0.37 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +42.6 (c  0.1, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.08 (dtd, J = 15.4, 4.2, 
0.6 Hz, 1H, CH2CH=CH), 5.47 (ddt, J = 15.4, 8.1, 1.9 Hz, 1H, 
CH2CH=CH), 4.26 (ddd, J = 10.2, 4.9, 3.2 Hz, 1H, CONCH), 4.15 (dt, J 
= 3.8, 1.8 Hz, 2H, SiOCH2), 3.98 (ddd, J = 9.1, 5.2, 1.3 Hz, 1H, 
OCH2CH), 3.85 (dd, J = 9.2, 0.8 Hz, 1H, OCH2CH), 3.56 (dd, J = 8.1, 
1.7 Hz, 1H, =CHCH(O)CH), 3.50 (d, J = 1.9 Hz, 1H, CH(O)CHCO), 
2.51 (ddd, J = 13.3, 7.0, 5.0 Hz, 1H, SCH2CH2), 2.39 (ddd, J = 13.4, 8.9, 
6.7 Hz, 1H, SCH2CH2), 2.04 (s, 3H, CH3S), 2.02-1.96 (m, 1H, 
SCH2CH2), 1.77-1.70 (m, 1H, SCH2CH2), 1.60 (s, 3H, (CH3)2C), 1.50 (s, 
3H, (CH3)2C), 0.86 (s, 9H, (CH3)3CSi), 0.02 (s, 6H, (CH3)2Si). 13C NMR 
(100 MHz, CDCl3), δ (ppm): 163.39, 137.11, 124.44, 95.83, 66.99, 62.48, 
57.78, 55.83, 55.38, 34.25, 30.75, 26.25, 25.85, 22.96, 18.29, 15.77, -5.39, 
-5.41. HRMS (H-ESI) m/e 416.22853 calcd for C20H37NO4SSi [M + H]+, 
found 416.22855.
3.6.2.6. Synthesis of the Diepoxy Amide ent-113
To a solution of epoxy amide ent-111 (100 mg, 0.24 mmol, 1.0 
equiv) in dry THF (6 mL) was added dropwise Red-Al 60% w/v (0.15 mL, 
0.53 mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
























The crude aldehyde was reacted with sulfonium salt 4 (85 mg, 
0.26 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.04 mL, 0.24 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide ent-113 (36 mg, 
95% over two steps) as a yellow oil.
Rf = 0.26 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +51.9 (c  1.0, 
CH2Cl2). 1H RMN (400 MHz, CDCl3), δ (ppm): 6.04 (dtd, J = 15.4, 4.3, 
0.7 Hz, 1H, CH2CH=CH), 5.44 (ddt, J = 15.4, 8.0, 1.9 Hz, 1H, 
CH2CH=CH), 4.33-4.26 (m, 1H, CONCH), 4.17 (dd, J = 4.2, 1.8 Hz, 
2H, SiOCH2), 4.02- 3.97 (m, 1H, OCH2CH), 3.89 (d, J = 9.2 Hz, 1H, 
OCH2CH), 3.57 (d, J = 1.9 Hz, 1H, CH(O)CHCO), 3.42 (dd, J = 7.9, 1.7 
Hz, 1H, =CHCH(O)CH), 3.35 (dd, J = 3.3, 1.9 Hz, 1H, CH(O)CHCO), 
3.02 (dd, J = 3.3, 2.1 Hz, 1H, =CHCH(O)CH), 2.57 (ddd, J = 13.0, 7.7, 
5.1 Hz, 1H, SCH2CH2), 2.47 (dt, J = 13.3, 7.9 Hz, 1H, SCH2CH2), 2.11 
(s, 3H, CH3S), 2.08-2.01 (m, 1H, SCH2CH2), 1.86-1.75 (m, 1H, 
SCH2CH2), 1.63 (s, 3H, (CH3)2C), 1.51 (s, 3H, (CH3)2C), 0.88 (s, 9H, 
(CH3)3CSi), 0.04 (s, 6H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 
162.92, 136.24, 125.09, 95.94, 67.05, 62.64, 56.56, 55.99, 55.67, 55.40, 
51.24, 34.46, 30.69, 26.21, 25.89, 22.95, 18.36, 15.83, -5.32, -5.34. 
HRMS (H-ESI) m/e 458.23910 calcd for C22H39NO5SSi [M + H]+, found 
458.23907.
3.6.2.7. Synthesis of the Alkyne ent-115
To a solution of epoxy amide ent-113 (170 mg, 0.38 mmol, 1.0 
equiv) in dry THF (10 mL) was added dropwise Red-Al 60% w/v (0.20 





















was quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
To a solution of crude of aldehyde in dry MeOH (10 mL) was 
added K2CO3 (100 mg, 0.7 mmol, 2.0 equiv) at rt followed by a solution of 
the Ohira-Bestmann reagent [(dimethyl(diazomethyl)phosphonate, 
CH3COC(N2)PO(OMe)2)] (140 mg, 0.7 mmol, 2.0 equiv) in MeOH (5 
mL). The progress of the reaction was monitored by TLC. After the 
reaction was complete, it was then diluted with H2O and Et2O. The 
aqueous phase was extracted with Et2O, dried over MgSO4 and the 
solvent removed under pressure. Flash column chromatography (silica gel, 
10% EtOAc en hexanes) rendered the alkyne ent-115 as a pale yellow oil 
(12 mg , 12 % over 2 steps).
Rf = 0.54 [Silica gel, 20% EtOAc in hexanes]. [α]25D = +66.0 (c  0.25, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm) 6.05 (dtd, J = 15.4, 4.3, 
0.5 Hz, 1H, CH2CH=CH), 5.45 (ddt, J = 15.4, 8.0, 1.9 Hz, 1H, 
CH2CH=CH), 4.19 (dd, J = 4.3, 1.9 Hz, 2H, SiOCH2), 3.41-3.37 (ddd, J 
= 8.0, 2.1, 0.6 Hz, 1H, =CHCH(O)CH), 3.36 (dd, J  = 1.7 Hz, 1H, 
CH(O)CHCCH), 3.26 (dd, J = 3.5, 2.1 Hz, 1H, CH(O)CHCCH), 2.97 
(dd, J = 3.5, 2.1 Hz, 1H, =CHCH(O)CH), 2.34 (d, J = 1.7 Hz, 1H, 
CCH), 0.90 (s, 9H, (CH3)3CSi), 0.07 (s, 6H, (CH3)2Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 136.23, 125.14, 79.32, 72.41, 62.65, 57.24, 56.61, 
55.49, 42.59, 25.90, 18.38, -5.31, -5.33. HRMS (H-ESI) m/e 281.15675 




3.6.2.8. Synthesis of the Diepoxy Alkyne ent-94
Alkyne ent-115 (15 mg, 0.05 mmol, 1.0 equiv) was dissolved in 
THF (5 mL) and over this solution was added 1.0 M TBAF in THF (0.08 
mL, 0.08 mmol, 1.5 equiv) at rt. After 45 min, the reaction mixture was 
diluted with Et2O and a saturated solution of NH4Cl. The aqueous phase 
was then extracted with EtOAc and the organic extract washed with H2O, 
brine and dried over MgSO4. The solvent was removed under vacuum 
and the crude alcohol was used in the next step without further 
purification.
Over a solution of the allylic alcohol in pyridine (2 mL) was added 
Ac2O (0.2 mL, 2.0 mmol, 40 equiv) at rt. After 12 h at the same 
temperature, the solvent was removed under vacuum and the crude 
product was purified by flash column chromatography (silica gel, 10 % 
EtOAc in hexanes) to furnish alkyne ent-94 (3 mg, 30% yield over 2 steps) 
as a pale yellow oil.
Rf = 0.54 [Silica gel, 20% EtOAc in hexanes]. [α]25D = +50.7 (c  0.1, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.04 (dtd, J = 15.6, 5.8, 
0.6 Hz, 1H, CH2CH=CH), 5.50 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H, 
CH2CH=CH), 4.59 (dd, J = 5.7, 1.5 Hz, 2H, OCH2), 3.39 (dd, J = 7.9, 
1.9 Hz, 1H, CH=CHCH(O)CH), 3.37-3.35 (m, 1H, CH(O)CHC), 3.27 
(dd, J = 3.4, 2.1 Hz, 1H, CH(O)CHC), 2.99 (dd, J = 3.4, 2.0 Hz, 1H, 
=CHCH(O)CH), 2.34 (d, J = 1.7 Hz, 1H, CCH), 2.08 (s, 3H, CH3CO). 
13C NMR (100 MHz, CDCl3), δ (ppm): 170.53, 130.34, 129.59, 79.18, 


















3.6.2.9. Synthesis of the Diepoxy Amide ent-112
Over a suspension of PCC (3.2 g, 14.8 mmol, 1.5 equiv) in 
CH2Cl2 (20 mL) was added NaOAc anhydrous (3.2 g, 39.5 mmol, 4.0 
equiv) followed by cis-allylic alcohol 96b (2.0 mL, 9.9 mmol, 1.0 equiv) 
dissolved in CH2Cl2 (10 mL). The reaction mixture was stirred at rt for 6 h 
and the resulting crude was filtered off through a pad of SiO2 and washed 
with Et2O. The solvent was then removed under vacuum and the crude 
aldehyde was used in the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (3.4 g, 10.9 
mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 3.3 mL, 9.9 mmol, 
1.0 equiv) according to the general procedure described above for the 
synthesis of epoxy amides to yield epoxy amide ent-112 (2.1 g, 40% over 
two steps) as a pale yellow oil.
Rf = 0.55 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +23.0 (c  0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 7.68 – 7.64 (m, 4H, CH 
aromatic), 7.43 – 7.36 (m, 6H, CH aromatic), 6.12 (dt, J = 15.4, 4.0 Hz, 
1H, CH2CH=CH), 5.65 (ddt, J = 15.4, 8.1, 2.0 Hz, 1H, CH2CH=CH), 
4.32 (ddd, J = 8.3, 4.7, 3.2 Hz, 1H, CONCH), 4.23 (dt, J = 3.7, 1.7 Hz, 
2H, SiOCH2), 4.03 (ddd, J = 9.1, 5.2, 1.3 Hz, 1H, OCH2CH), 3.90 (d, J 
= 9.1 Hz, 1H, OCH2CH), 3.64 (dd, J = 8.1, 1.6 Hz, 1H, 
=CHCH(O)CH), 3.57 (d, J = 1.9 Hz, 1H, CH(O)CHCO), 2.57 (ddd, J = 
13.2, 6.9, 5.1 Hz, 1H, SCH2CH2), 2.43 (ddd, J = 13.4, 9.0, 6.6 Hz, 1H, 
SCH2CH2), 2.11 – 2.05 (m, 1H, SCH2CH2), 2.04 (s, 3H, CH3S), 1.84 – 
1.76 (m, 1H, SCH2CH2 ), 1.66 (s, 3H, (CH3)2C), 1.56 (s, 3H, (CH3)2C), 















136.74, 135.48, 133.32, 129.81, 127.77, 124.52, 95.94, 67.07, 63.29, 
60.37, 57.90, 55.87, 55.55, 34.33, 30.84, 26.83, 26.32, 23.05, 19.26, 
15.83.
3.6.2.10. Synthesis of the Diepoxy Amide ent-114
To a solution of epoxy amide ent-111 (166 mg, 0.31 mmol, 1.0 
equiv) in dry THF (10 mL) was added dropwise Red-Al 60% w/v (0.2 mL, 
0.62 mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (110 mg, m 
0.34 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.01 mL, 0.31 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide ent-114 (170 mg, 
95% over two steps) as a pale yellow oil.
Rf = 0.45 [Silica gel, 40% EtOAc in hexanes]. [α]25D = +35.1 (c  0.4, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 7.71 – 7.67 (m, 4H, CH 
aromatic), 7.47 – 7.40 (m, 6H, CH aromatic), 6.08 (dt, J = 15.4, 4.2 Hz, 
1H, CH2CH=CH), 5.59 (ddt, J = 15.4, 8.0, 1.9 Hz, 1H, CH2CH=CH), 
4.36 (ddd, J = 9.9, 4.8, 3.6 Hz, 1H, CONCH), 4.25 (dd, J = 4.1, 1.9 Hz, 
2H, SiOCH2), 4.06 (ddd, J = 9.1, 5.2, 1.3 Hz, 1H, OCH2CH), 3.95 (d, J 
























(dd, J = 7.9, 2.0 Hz, 1H, =CHCH(O)CH), 3.43 (dd, J = 3.3, 1.9 Hz, 1H, 
CH(O)CHCO), 3.08 (dd, J = 3.4, 2.1 Hz, 1H, =CHCH(O)CH), 2.63 
(ddd, J = 13.0, 7.7, 5.1 Hz, 1H, SCH2CH2), 2.52 (ddd, J = 13.2, 8.2, 7.3 
Hz, 1H, SCH2CH2), 2.15 (s, 3H, CH3S), 2.14 – 2.09 (m, 1H, SCH2CH2), 
1.92 – 1.82 (m, 1H, SCH2CH2), 1.69 (s, 3H, (CH3)2C), 1.58 (s, 3H, 
(CH3)2C), 1.09 (s, 9H, (CH3)3CSi). 13C NMR (100 MHz, CDCl3), δ (ppm): 
162.94, 135.79, 135.50, 133.39, 129.77, 127.74, 125.15, 95.98, 67.08, 
63.39, 56.61, 56.01, 55.74, 55.40, 51.31, 34.49, 30.74, 26.82, 26.24, 
22.98, 19.24, 15.86. HRMS (H-ESI) m/e 582.27040 calcd for 
C32H43NO5SSi [M + H]+, found 582.27057.
3.6.2.11. Synthesis of the Dibromo Alkene ent-116
To a solution of epoxy amide ent-114 (80 mg, 0.14 mmol, 1.0 
equiv) in dry THF (5 mL) was added dropwise Red-Al 60% w/v (0.08 mL, 
0.27 mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
To a solution of CBr4 (130 mg, 0.37 mmol, 2.7 equiv) in CH2Cl2 
(5 mL) was added Ph3P (195 mg, 0.74 mmol, 5.3 equiv) at 0ºC. The 
mixture was stirred at the same temperature for 15 min, and Et3N (0.1 mL 
0.7 mmol, 5.3 equiv) was added to the resulting mixture at 0ºC. After the 
mixture was stirred at the same temperature for 5 min, the aldehyde 






















mixture was stirred at the same temperature for 2 h. The reaction was 
quenched with a saturated aqueous NaHCO3 and the mixture was diluted 
with EtOAc, washed with H2O and brine, and then dried over Na2SO4. 
Concentration and purification by flash column chromatography (silica 
gel, 10% EtOAc in hexanes) gave the corresponding dibromo alkene 
ent-116 (32 mg, 40% over 2 steps) as a pale yellow oil.
Rf = 0.75 [Silica gel, 10% EtOAc in hexanes]. [α]25D = +26.6 (c  0.8, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 7.69 - 7.63 (m, 2H, CH 
aromatic), 7.46 - 7.33 (m, 8H, CH aromatic), 6.16 (dd, J = 7.8, 0.7 Hz, 
1H, CH=CHBr2), 6.08 - 5.99 (m, 1H, CH2CH=), 5.60 - 5.51 (m, 1H, 
CH2CH=CH), 4.23 (dd, J = 4.2, 2.0 Hz, 2H, CH2CH=), 3.64 (ddd, J = 
7.8, 2.0, 0.7 Hz, 1H,(O)CHCH=CHBr2), 3.41 (dd, J = 7.9, 2.2 Hz, 1H, 
CH=CHCH(O)CH), 3.07 (ddd, J = 3.9, 2.0, 0.7 Hz, 1H, 
CH(O)CHCH=CHBr2), 2.98 (ddd, J = 3.9, 2.1, 0.7 Hz, 1H, 
CH=CHCH(O)CH), 1.06 (s, 9H, (CH3)3CSi). 13C NMR (100 MHz, 
CDCl3), δ (ppm): 135.62, 135.50, 134.46, 133.41, 133.28, 129.76, 127.72, 
125.23, 63.39, 57.17, 56.66, 55.61, 54.98, 26.82, 19.25.
3.6.2.12. Synthesis of the Precursor of Gummiferol ent-84
To a solution of the dibromo alkene ent-116 (51 mg, 0.09 mmol, 
1.0 equiv) in THF (5 mL) was added TBAF (1.0 M solution in THF, 0.4 
mL, 0.36 mmol, 4.0 equiv) at 0ºC. The mixture was stirred at room 
temperature for 1 h and the solvent was then removed under vacuum. 
Corresponding bromo alkyne was obtained as a colourless amorphous 




















To a 70% aqueous solution of EtNH2 (2.25 mL) in MeOH (3 mL) 
was added CuCl (4 mg, 45.0 µmol, 0.5 equiv) at room temperature that 
resulted in the formation of a blue solution. To the resulting mixture was 
added NH2OH·HCl (19 mg, 270.0 µmol, 3.0 equiv) at the same 
temperature to discharge the blue color. To the resulting mixture was 
added diacetylene 77 (19 mg, 99.0 µmol, 1.1 equiv) in MeOH (1.0 mL) at 
room temperature, and the mixture was stirred at the same temperature 
for 20 min that resulted in the formation of a yellow suspension. To the 
resulting mixture was added bromo acetylene above obtained in MeOH 
(1.0 mL) at -78ºC, and the mixture was stirred at the same temperature for 
20 min. The mixture was diluted with Et2O, washed with H2O and brine, 
dried over Na2SO4 and the solvent removed under vacuum. The resulting 
trialkyne was used in the next step without any further purification.
To a solution of the obtained trialkyne in CH2Cl2 (4 mL) were 
added pyridine (0.05 mL, 0.63 mmol, 7.0 equiv), Ac2O (0.04 mL, 0.45 
mmol, 5.0 equiv) and 4-DMAP (4 mg, 0.03 mmol, 0.3 equiv) at 0ºC. The 
mixture was stirred at the same temperature for 20 min. The mixture was 
then diluted with Et2O, washed with H2O and brine, and then dried over 
MgSO4. Concentration and purification by flash column chromatography 
(silica gel, 30% EtOAc in hexanes) gave acetate ent-84 (20 mg, 51% yield 
over 3 steps) as a yellow oil.
Rf = 0.7 [Silica gel, 60% EtOAc in hexanes]. [α]25D = +11.2 (c 0.5, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.04 (ddd, J = 15.2, 6.1, 
5.5 Hz, 1H, AcOCH2CH=), 5.49 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H, 
AcOCH2CH=CH), 4.59 (dd, J = 5.7, 1.5 Hz, 2H, AcOCH2), 4.39 (s, 2H, 
CH2OTBS), 3.44 (d, J = 2.0 Hz, 1H, CH(O)CHC), 3.38 (dd, J = 8.1, 1.8 
Hz, 1H, =CHCH(O)), 3.33 (dd, J = 3.2, 2.0 Hz, 1H, CH(O)CHC), 3.01 
(dd, J = 3.2, 2.0 Hz, 1H,=CHCH(O)CH), 2.08 (s, 3H, CH3CO), 0.90 (s, 




(ppm): 170.54, 130.50, 129.43, 77.80, 73.63, 69.49, 69.14, 63.48, 63.14, 
62.01, 57.48, 56.24, 55.07, 52.11, 43.05, 25.72, 20.83, 18.25, -5.22. 
HRMS (H-ESI) m/e 359.31559 calcd for C22H28O5Si [M - CH3CO+ H]+, 
found 359.31555.
3.6.3. Synthesis of (-)-Gummiferol
3.6.3.1. Synthesis of the Diepoxy Amide 107
Epoxy alcohol 106 (340 mg, 1.56 mmol 1.0 equiv) was dissolved 
in a CH2Cl2/DMSO (1:1) mixture (6 mL) and cooled at 0ºC. At this 
temperature, Et3N (0.7 mL, 4.7 mmol, 3.0 equiv) was added followed by 
SO3·Pyr (450 mg, 2.8 mmol, 1.8 equiv). The mixture was allowed to reach 
rt and 5 hours later was quenched by addition of buffer pH = 7 and 
diluted with Et2O. The aqueous phase was extracted with Et2O and the 
combined organic extracts were washed with water and brine, then dried 
over anhydrous MgSO4 and the solvent removed under reduced pressure. 
The resulting crude of the aldehyde was used in the next step without 
further purification.
The crude aldehyde was reacted with sulfonium salt 6 (530 mg, 
1.7 mmol 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.31 mL, 1.53 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 107 (426 mg, 65% 
over 2 steps) as a pale yellow oil.
Rf = 0.2 [Silica gel, 40% EtOAc in hexanes]. [α]25D = - 19.2 (c 0.4, 




















3.5 Hz, 1H, CONCH), 3.97 (ddd, J = 9.1, 5.2, 1.3 Hz, 1H, OCH2CH), 
3.89-3.86 (m, 1H, OCH2CH), 3.85 (d, J = 2.0 Hz, 1H, SiOCH2), 3.69 
(dd, J = 12.3, 3.7 Hz, 1H, CH2CH(O)CH), 3.54 (d, J = 2.0 Hz, 1H, 
CH(O)CHCO), 3.30 (dd, J = 3.4, 2.0 Hz, 1H, CH(O)CHCO), 3.11 – 3.06 
(m, 2H, SiOCH2 and CH2CH(O)CH), 2.59-2.50 (m, 1H, SCH2CH2), 
2.48-2.39 (m, 1H, SCH2CH2), 2.08 (s, 3H, CH3S), 2.05-2.00 (m, 1H, 
SCH2CH2), 1.83-1.73 (m, 1H, SCH2CH2), 1.59 (s, 3H, CH3C), 1.48 (s, 
3H, CH3C), 0.84 (s, 9H, (CH3)3CSi), 0.02 (s, 3H, (CH3)2Si), 0.00 (s, 3H, 
(CH3)2Si). 13C NMR (100 MHz, CDCl3), δ  (ppm): 162.92, 95.87, 67.03, 
61.59, 56.29, 55.96, 55.50, 51.73, 51.25, 34.42, 30.64, 26.19, 25.80, 
22.93, 18.28, 15.73, -5.39, -5.41.
3.6.3.2. Synthesis of the ɣ,ẟ-Diepoxy α,β-Unsaturated Ester 108
Diepoxy amide 107 (213 mg, 0.5 mmol, 1.0 equiv) in dry THF (8 
mL) was treated dropwise with Red-Al 60% w/v in toluene (0.31 mL, 1.08 
mmol, 2.2 equiv) at 0ºC. After 1 hour at this temperature, the reaction 
mixture was diluted with a saturated aqueous NH4Cl solution. The 
aqueous phase was then separated, extracted twiced with EtOAc and the 
combined organic phase washed with H2O and brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The 
resulting crude aldehyde was used in the next step without further 
purification.
The crude aldehyde was dissolved in CH2Cl2 (10 mL) and over 
this solution was added the phophorous ylide Ph3P=CHCO2Et (260 mg, 
0.75 mmol 1.5 equiv). After 30 minutes the reaction is over and the solvent 




















(silica gel, 20% EtOAc in hexanes) gave the α,β-unsaturated diepoxy ester 
108 (100 mg, 60% yield over 2 steps) as a pale yellow oil.
Rf = 0.64 [Silica gel, 40% EtOAc in hexanes]. [α]25D = - 12.4 (c 0.7, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.64 (dd, J = 15.7, 7.2 
Hz, 1H, CH=CHCO), 6.15 (dd, J = 15.7, 0.7 Hz, 1H, CH=CHCO), 4.19 
(q, J = 7.1 Hz, 2H, CH2CH3), 3.87 (dd, J = 12.3, 2.8 Hz, 1H, SiOCH2), 
3.74 (dd, J = 12.3, 3.9 Hz, 1H, SiOCH2), 3.47 (ddd, J = 7.2, 2.0, 0.7 Hz, 
1H, CH(O)CHCH=), 3.10 (ddd, J = 3.9, 2.7, 2.1 Hz, 1H, CH2CH(O)), 
3.04 (dd, J = 4.0, 2.1 Hz, 1H, CH2CH(O)CH), 3.01 (dd, J = 4.0, 2.0 Hz, 
1H, CH(O)CHCH=), 1.28 (t, J = 7.1 Hz, 3H, CH2CH3), 0.88 (s, 9H, 
(CH3)3CSi), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 3H, (CH3)2Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 165.41, 143.02, 124.71, 61.82, 60.69, 58.50, 
56.24, 53.77, 52.62, 25.82, 18.32, 14.18, -5.37, -5.39.
3.6.3.3. Synthesis of the Allylic Alcohol 109
At -78ºC, DIBAL-H 1.0 M in toluene (0.53 mL, 0.53 mmol, 2.5 
equiv) was added over a solution of ester 108 (70 mg, 0.21 mmol, 1.0 
equiv) in CH2Cl2 (10 mL). After 30 minutes, the reaction was complete 
and it was allowed to warm at 0ºC. At this temperature, the mixture was 
diluted with EtOAc and a saturated aqueous Na+/K+ tartrate solution. 
After 2 hours of vigorous stirring, the aqueous phase was extracted twice 
with EtOAc and the organic layer washed with water and brine, then 
dried over anhydrous MgSO4. and filtered. The solvent was then removed 
carefully under reduced pressured at low temperature. Purification by flash 
column chromatography (silica gel, 20% EtOAc in hexanes) rendered the 
















Rf = 0.35 [Silica-gel, 30% EtOAc in hexanes]. [α]25D = - 20.2 (c  0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.11 (dt, J = 15.6, 5.1 
Hz, 1H, CH=CHCH2), 5.49 (ddt, J = 15.6, 7.9, 1.7 Hz, 1H, 
CH=CHCH2), 4.19 (d, J = 3.9 Hz, 2H, =CHCH2OH), 3.88 (dd, J = 
12.2, 2.8 Hz, 1H, SiOCH2), 3.74 (dd, J = 12.2, 4.0 Hz, 1H, SiOCH2), 
3.40 (dd, J = 7.9, 2.1 Hz, 1H, (O)CHCH=), 3.09 (ddd, J = 4.0, 2.8, 2.1 
Hz, 1H, CH2CH(O)CH), 3.00 (dd, J = 4.3, 2.1 Hz, 1H, CH2CH(O)CH), 
2.93 (dd, J = 4.3, 2.1 Hz, 1H, CH(O)CHCH=), 1.61 (bs, 1H, OH), 0.89 
(s, 9H, (CH3)3CSi)), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 3H, (CH3)2Si). 13C 
NMR (100 MHz, CDCl3), δ (ppm): 135.29, 127.24, 62.57, 62.05, 58.00, 
56.05, 55.25, 53.25, 25.84, 18.34, -5.35, -5.36.
3.6.3.4. Synthesis of the Acetyl Derivative 110
Over a solution of the allylic alcohol 109 (43 mg, 0.15 mmol, 1. 
equiv) in pyridine (4 mL) was added Ac2O (0.6 mL, 6.0 mmol, 40 equiv) at 
rt. After 12 h at the same temperature, the solvent was removed under 
vacuum and the crude product was purified by flash column 
chromatography (silica gel, 10 % EtOAc en hexanes) to furnish acetate 
110 (15 mg, 30% yield) as a pale yellow oil.
Rf = 0.91 [Silica gel, 40% EtOAc in hexanes]. [α]25D = -15.3 (c 0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.03 (dtd, J = 15.6, 5.8, 
0.6 Hz, 1H, CH=CHCH2), 5.51 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H, 
CH=CHCH2), 4.58 (dd, J = 5.8, 1.5 Hz, 2H, =CHCH2OH), 3.92 - 3.83 
(m, 1H, SiOCH2), 3.74 (dd, J = 12.2, 4.0 Hz, 1H, SiOCH2), 3.38 (dd, J = 
8.0, 1.9 Hz, 1H, CH(O)CHCH=), 3.09 (ddd, J = 4.0, 2.8, 2.1 Hz, 1H, 
CH2CH(O)CH), 2.99 (dd, J = 4.3, 2.1 Hz, 1H, CH2CH(O)CH), 2.93 (dd, 














9H, (CH3)3CSi)), 0.07 (s, 3H, (CH3)2Si), 0.06 (s, 3H, (CH3)2Si). 13C NMR 
(100 MHz, CDCl3), δ (ppm): 130.19, 129.83, 63.61, 61.98, 57.97, 56.07, 
54.93, 53.10, 30.91, 25.84, 20,93 18.33, -5.36. -5.37.
3.6.3.5. Synthesis of the Epoxy Amide 111
Over a suspension of PCC (1.6 g, 7.4 mmol, 1.5 equiv) in CH2Cl2 
(20 mL) was added NaOAc anhydrous (1.6 g, 19.8 mmol, 4.0 equiv) 
followed by cis-alcohol 96a dissolved in CH2Cl2 (1.0 g, 4.94 mmol, 1.0 
equiv). The reaction mixture was stirred at rt for 6 h and the resulting 
crude was filtered off through a pad of SiO2 and washed with Et2O. The 
solvent was then removed under vacuum and the crude aldehyde was used 
in the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 6 (1.3 g, 4.0 
mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 1.2 mL, 3.6 mmol, 
1.0 equiv) according to the general procedure described above for the 
synthesis of epoxy amides to yield epoxy amide 111 (800 mg, 40% over 
two steps) as a pale yellow oil.
Rf = 0.43 [Silica gel, 40% EtOAc in hexanes]. [α]25D = -11.1 (c 0.8, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.09 (ddd, J = 15.4, 4.4, 
4.0 Hz, 1H, CH2CH=CH), 5.48 (ddt, J = 15.4, 8.1, 2.0 Hz, 1H, 
CH2CH=CH), 4.27 (ddd, J = 10.2, 4.9, 3.1 Hz, 1H, CONCH), 4.17 (dt, J 
= 3.7, 1.7 Hz, 2H, SiOCH2), 3.99 (ddd, J = 9.1, 5.2, 1.4 Hz, 1H, 
OCH2CH), 3.89 – 3.84 (m, 1H, OCH2CH), 3.58 (dd, J = 8.1, 1.7 Hz, 1H, 
=CHCH(O)CH), 3.51 (d, J = 1.9 Hz, 1H, CH(O)CHCO), 2.53 (ddd, J = 














SCH2CH2), 2.05 (s, 3H, CH3S), 2.03-1.96 (m, 1H, SCH2CH2), 1.78-1.71 
(m, 1H, SCH2CH2), 1.61 (s, 3H, CH3C), 1.51 (s, 3H, CH3C), 0.87 (s, 9H, 
(CH3)3CSi), 0.03 (s, 6H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 
163.42, 137.15, 124.45, 95.89, 67.01, 62.51, 57.82, 55.85, 55.44, 34.27, 
30.79, 26.27, 25.88, 22.99, 18.32, 15.81, -5.37, -5.38.
3.6.3.6. Synthesis of the Diepoxy amide 113
To a solution of epoxy amide 111 (112 mg, 0.27 mmol, 1.0 equiv) 
in dry THF (6 mL) was added dropwise Red-Al 60% w/v (0.15 mL, 0.54 
mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 6 (100 mg, 
0.30 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.06 mL, 0.30 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 113 (76 mg, 61% 
over two steps) as a pale yellow oil.
Rf = 0.26 [Silica gel, 40% EtOAc in hexanes]. [α]25D = -21.4 (c 1.0, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.04 (dt, J = 15.4, 4.3 
Hz, 1H, CH2CH=CH), 5.50-5.40 (m, 1H, CH2CH=CH), 4.34-4.27 (m, 
1H, CONCH), 4.18 (dd, J = 4.2, 1.9 Hz, 2H, SiOCH2), 4.01 (dd, J = 8.7, 
























1.9 Hz, 1H, CH(O)CHCO, 3.43 (dd, J = 8.0, 1.9 Hz, 1H, 
=CHCH(O)CH), 3.36 (dd, J = 3.3, 1.9 Hz, 1H, CH(O)CHCO), 3.05-3.02 
(m, 1H, =CHCH(O)CH), 2.58 (ddd, J = 12.9, 7.7, 5.2 Hz, 1H, 
SCH2CH2), 2.52 – 2.41 (m, 1H, SCH2CH2), 2.11 (s, 3H, CH3S), 2.05 
(ddd, J = 20.8, 9.3, 5.1 Hz, 1H, SCH2CH2), 1.81 - 1.70 (m, 1H, 
SCH2CH2), 1.63 (s, 3H, (CH3)2C), 1.52 (s, 3H, (CH3)2C), 0.89 (s, 9H, 
(CH3)3CSi), 0.05 (s, 6H, (CH3)2Si.
3.6.3.7. Synthesis of the Alkyne 115
To a solution of epoxy amide 113 (76 mg, 0.17 mmol, 1.0 equiv) 
in dry THF (5 mL) was added dropwise Red-Al 60% w/v (0.1 mL, 0.37 
mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
The crude of the aldehyde was dissolved in dry MeOH (5 mL) 
and over this solution was added K2CO3 (50 mg, 0.33 mmol, 2.0 equiv) at 
rt followed by a solution of the Ohira-Bestmann reagent 
[(dimethyl(diazomethyl)phosphonate, CH3COC(N2)PO(OMe)2)] (70 mg, 
0.33 mmol, 2.0 equiv) in MeOH (2 mL). The progress of the reaction was 
monitored by TLC. After completion, the reaction crude was diluted with 
H2O and Et2O. The aqueous phase was extracted with Et2O, dried over 





















flash column chromatography (silica gel, 20% EtOAc en hexanes) 
rendered the alkyne 115 (20 mg, 44 % over 2 steps) as a pale yellow oil.
Rf = 0.8 [Silica-gel, 40% EtOAc in hexanes]. [α]25D = -38.0 (c 0.2, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.05 (dtd, J = 15.4, 4.3, 
0.6 Hz, 1H, CH2CH=CH), 5.45 (ddt, J = 15.4, 8.0, 1.9 Hz, 1H, 
CH2CH=CH), 4.20 (dd, J = 4.2, 1.8 Hz, 2H, SiOCH2), 3.40 (dd, J = 8.0, 
1.6 Hz, 1H, =CHCH(O)CH), 3.36 (dt, J = 3.3, 1.6 Hz, 1H, 
CH(O)CHCCH), 3.26 (dd, J = 3.5, 2.1 Hz, 1H, CH(O)CHCCH), 2.97 
(dd, J = 3.5, 2.1 Hz, 1H, =CHCH(O)CH), 2.34 (d, J = 1.7 Hz, 1H, 
CCH), 0.91 (s, 9H, (CH3)3CSi), 0.07 (s, 6H, (CH3)2Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 136.24, 125.14, 79.29, 72.30, 62.66, 57.25, 56.61, 
55.52, 42.59, 25.90, 18.20, -5.31, -5.33.
3.6.3.8. Synthesis of the Diepoxy Alkyne 94
Alkyne 115 (20 mg, 0.07 mmol, 1.0 equiv) was dissolved in THF 
(5 mL) and over this solution was added 1.0 M TBAF in THF (0.11 mL, 
0.11 mmol, 1.5 equiv) at rt. After 45 min, the reaction mixture was diluted 
with Et2O and NH4Cl. The aqueous phase was then extracted with 
EtOAc and the organic extract washed with H2O, brine and dried over 
MgSO4. The solvent was removed under vacuum and the crude alcohol 
was used in the next step without further purification.
Over a solution of the allylic alcohol in pyridine (2 mL) was added 
Ac2O (0.2 mL, 2.0 mmol, 40 equiv) at rt. After 12 h at the same 
temperature, the solvent was removed under vacuum and the crude 


















EtOAc in hexanes) to furnish acetate 94 (4 mg, 25% yield over 2 steps) as 
a pale yellow oil.
Rf = 0.52 [Silica gel, 20% EtOAc in hexanes]. [α]25D = - 45.3 (c 0.5, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 6.04 (dtd, J = 15.6, 5.8, 
0.7 Hz, 1H, CH2CH=CH), 5.59 - 5.42 (m, CH2CH=CH), 4.61 (dd, J = 
5.8, 1.6 Hz, 2H, OCH2), 3.42 - 3.33 (m, 2H, CH=CHCH(O)CH and 
CH(O)CHC), 3.27 (dd, J = 3.4, 2.0 Hz, 1H, CH(O)CHC), 2.99 (dd, J = 
3.4, 2.0 Hz, 1H, =CHCH(O)CH), 2.34 (d, J = 1.7 Hz, 1H, CCH), 2.13 - 
2.03 (s, 3H, CH3CO).
3.6.3.9. Synthesis of the Diepoxy Amide 112
Over a suspension of PCC (1.6 g, 7.4 mmol, 1.5 equiv) in CH2Cl2 
(20 mL) was added NaOAc anhydrous (1.6 g, 20.0 mmol, 4.0 equiv) 
followed by cis-allylic alcohol 96b (0.9 mL, 5.0 mmol, 1.0 equiv) dissolved 
in CH2Cl2 (10 mL). The reaction mixture was stirred at rt for 6 h and the 
resulting crude was filtered off through a pad of SiO2 and washed with 
Et2O. The solvent was then removed under vacuum and the crude 
aldehyde was used in the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 6 (1.7 g, 5.4 
mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 1.7 mL, 5.0 mmol, 
1.0 equiv) according to the general procedure described above for the 
synthesis of epoxy amides to yield epoxy amide 112 (1.0 g, 40% over two 















Rf = 0.6 [Silica gel, 40% EtOAc in hexanes]. [α]25D = -9.4 (c 1.0, CH2Cl2). 
1H NMR (400 MHz, CDCl3), δ (ppm): 7.67 – 7.64 (m, 4H, CH aromatic), 
7.44 – 7.36 (m, 6H, CH aromatic), 6.12 (dt, J = 15.4, 4.0 Hz, 1H, 
CH2CH=CH), 5.65 (ddt, J = 15.4, 8.1, 1.9 Hz, 1H, CH2CH=CH), 4.31 
(dt, J = 8.2, 5.0 Hz, 1H, CONCH), 4.23 (dt, J = 3.6, 1.7 Hz, 2H, 
SiOCH2), 4.03 (ddd, J = 9.1, 5.2, 1.3 Hz, 1H, OCH2CH), 3.90 (d, J = 9.2 
Hz, 1H, OCH2CH) 3.63 (dd, J = 8.1, 1.8 Hz, 1H, =CHCH(O)CH), 3.56 
(d, J = 1.9 Hz, 1H, CH(O)CHCO), 2.61 – 2.51 (m, 1H, SCH2CH2), 2.43 
(ddd, J = 13.4, 9.0, 6.6 Hz, 1H, SCH2CH2), 2.14 – 2.07 (m, 1H, 
SCH2CH2), 2.04 (s, 3H, CH3S), 1.84 – 1.70 (m, 1H, SCH2CH2), 1.66 (s, 
3H, (CH3)2C), 1.56 (s, 3H, (CH3)2C), 1.06 (s, 9H, (CH3)3Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 163.46, 136.74, 135.48, 133.32, 133.23, 129.79, 
127.76, 124.52, 95.95, 67.07, 63.29, 60.37, 57.89, 55.87, 55.57, 34.33, 
30.84, 26.82, 26.31, 23.04, 19.25, 15.83.
3.6.3.10. Synthesis of the Diepoxy Amide 114
To a solution of epoxy amide 112 (250 mg, 0.46 mmol, 1.0 equiv) 
in dry THF (10 mL) was added dropwise Red-Al 60% w/v (0.3 mL, 1.0 
mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture was 
quenched by addition of a saturated aqueous NH4Cl solution. After 
separation of both layers, the aqueous phase was extracted with EtOAc, 
the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 6 (160 mg, 
























mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 114 (187 mg, 70% 
over two steps) as a pale yellow oil.
Rf = 0.40 [Silica gel, 40% EtOAc in hexanes]. [α]25D = -23.0 (c 1.0, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 7.68 – 7.64 (m, 4H, CH 
aromatic), 7.44 – 7.36 (m, 6H, CH aromatic), 6.05 (ddd, J = 15.4, 4.5, 3.9 
Hz, 1H, CH2CH=CH), 5.56 (ddt, J = 15.4, 7.9, 1.9 Hz, 1H, 
CH2CH=CH), 4.36 – 4.29 (m, 1H, CONCH), 4.23 (dd, J = 4.2, 1.9 Hz, 
2H, SiOCH2), 4.06 – 4.00 (ddd, J = 9.2, 5.3, 1.4 Hz, 1H, OCH2CH), 3.92 
(dd, J = 9.2, 0.8 Hz, 1H, OCH2CH), 3.60 (d, J = 1.9 Hz, 1H, 
CH(O)CHCO), 3.44 (dd, J = 7.9, 1.9 Hz, 1H, =CHCH(O)CH), 3.40 (dd, 
J = 3.3, 2.0 Hz, 1H, CH(O)CHCO), 3.04 (dd, J = 3.3, 2.1 Hz, 1H, 
=CHCH(O)CH), 2.65 – 2.55 (m, 1H, SCH2CH2), 2.49 (dt, J = 12.4, 6.6 
Hz, 1H, SCH2CH2), 2.12 (s, 3H, CH3S), 2.11 – 2.05 (m, 1H, SCH2CH2), 
1.90 – 1.76 (m,1H, SCH2CH2), 1.66 (s, 3H, (CH3)2C), 1.54 (s, 3H, 
(CH3)2C), 1.09 – 1.03 (s, 9H, (CH3)3CSi). 13C NMR (100 MHz, CDCl3), δ 
(ppm): 162.94, 135.79, 135.50, 133.39, 129.77, 127.74, 125.15, 95.98, 
67.08, 63.39, 56.61, 56.01, 55.74, 55.40, 51.31, 34.49, 30.74, 26.82, 
26.24, 22.98, 19.24, 15.86.
3.6.3.11. Synthesis of the Dibromo Alkene 116
To a solution of diepoxy amide 114 (100 mg, 0.17 mmol, 1.0 
equiv) in dry THF (10 mL) was added dropwise Red-Al 60% w/v (0.12 
mL, 0.38 mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction mixture 
was quenched by addition of a saturated aqueous NH4Cl solution. After 





















the organic extracts were washed with brine and dried over MgSO4, and 
the solvent was evaporated under reduced pressure. The resulting crude 
epoxy aldehyde was used for the next step without further purification.
To a solution of CBr4 (115 mg, 0.34 mmol, 2.0 equiv) in CH2Cl2 
(10 mL) was added Ph3P (90 mg, 0.34 mmol) at 0ºC. The mixture was 
stirred at the same temperature for 15 min, and Et3N (0.02 mL, 0.17 
mmol, 1.0 equiv) was added to the resulting mixture at 0ºC. After the 
mixture was stirred at the same temperature for 5 min, the aldehyde 
obtained above, dissolved in CH2Cl2 (5 mL), was added at -78ºC. The 
mixture was stirred at the same temperature for 2 h. After this time, the 
reaction mixture was quenched with saturated aqueous NaHCO3. The 
mixture was diluted with EtOAc, washed with H2O and brine, and then 
dried over MgSO4. Concentration and purification by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) gave the 
corresponding dibromoalkene 116 (40 mg, 40% yield) .
Rf = 0.7 [Silica gel, 10% EtOAc in hexanes]. [α]25D = -35.1 (c 0.7, 
CH2Cl2). 1H RMN (400 MHz, CDCl3), δ (ppm): 7.68 – 7.64 (m, 2H), 7.44 
– 7.36 (m, 8H), 6.16 (d, J = 7.8 Hz, 1H, CH=CBr2), 6.07 – 6.00 (m, 1H, 
CH2CH=), 5.55 (ddt, J = 15.4, 7.8, 1.9 Hz, 1H, CH2CH=CH), 4.23 (dd, 
J = 4.2, 1.9 Hz, 2H, CH2CH=), 3.64 (dd, J = 7.8, 2.0 Hz, 1H, 
(O)CHCH=CBr2), 3.40 (dd, J = 7.9, 2.0 Hz, 1H, CH=CHCH(O)CH)), 
3.07 (dd, J = 3.9, 2.0 Hz, 1H, CH(O)CHCH=CBr2), 2.97 (dd, J = 3.9, 2.1 
Hz, 1H, CH=CHCH(O)CH), 1.06 (s, 9H, (CH3)3CSi). 13C NMR (100 
MHz, CDCl3), δ (ppm): 135.63, 135.57, 135.51, 134.80, 134.47, 129.77, 




3.6.4. Synthesis of the Dialkyne Fragment
3.6.4.1. Synthesis of the Dialkynyl Alcohol 90
Over a solution of 1,4-bis(trimethylsilyl)butadiyne (93) (500 mg, 
2.6 mmol, 1.0 equiv) in Et2O (10 mL) was added MeLi·LiBr at rt. The 
mixture was then stirred at the same temperature for 8 h. Subsequently, 
paraformaldehyde (CH2O)n (78 mg, 2.6 mmol, 1.0 equiv) in Et2O (10 mL) 
was then added at 0ºC, and the reaction allowed to reach rt and then 
stirred over 8 h. The reaction mixture was then diluted with EtOAc and 
quenched with a saturated solution of NH4Cl. The organic phase was 
dried over MgSO4 and the solvent removed under vacuum. The 
corresponding alcohol was used in the next step without further 
purification.
The resulting alcohol was dissolved in MeOH (10 mL) and over 
this solution solid K2CO3 (180 mg, 1.3 mmol, 1.2 equiv) was added, at rt. 
The reaction mixture was stirred over 12 h, and then quenched with 
NH4Cl. Extractions with Et2O and filtration through SiO2 provided the 
corresponding dialkynol 90 that was used in the next step without any 
further purification.
3.6.4.2. Synthesis of the Dialkyne 77
Alcohol 90 (150 mg, 1.9 mmol, 1.0 equiv) was dissolved in 
















mmol, 2.0 equiv)  was then added, followed by TBSOTf (0.4 mL, 3.8 
mmol, 1.2 equiv). The reaction was monitored by TLC and after 3 h, no 
trace of the starting material was detected. The crude reaction was 
quenched by addition of H2O and the aqueous phase extracted with 
EtOAc. The organic phase was then washed with brine, dried over 
MgSO4 and the solvent removed under vacuum. The dialkyne 77 was 
used in the next step without further purification.
3.6.4.3. Synthesis of the Iodo Alcohol 91
For the synthesis of the iodo derivative, KOH (220 mg, 2.6 mmol, 
2.5 equiv) was dissolved in H2O (~ 0.5 mL) and cooled at 0ºC. Dialkynol 
90 was dissolved in MeOH (5 mL) and this solution was added over 
dropwise. After 10 min stirring at the same temperature, I2 (295 mg, 1.2 
mmol, 1.1 equiv) was added portionwise and the reaction mixture allowed 
to reach rt. After 3 h, Et2O and an aqueous solution of Na2SO3 were 
added and the aqueous phase extracted with Et2O. The organic phase was 
then washed with brine and the solvent removed under vacuum. The iode 
alkyne was used in subsequent step withouth further purification.
3.6.4.4. Synthesis of the Silyl Ether 92
Alcohol 91 above obtained was dissolved in CH2Cl2 (10 mL) and 
the mixture cooled at 0ºC. 2,6-lutidine (0.25 mL, 2.1 mmol, 2.0 equiv) 
was then added, followed by TBSOTf (0.28 mL, 1.3 mmol, 1.2 equiv). 
The reaction was monitored by TLC and after 3 h, no trace of the 




















addition of H2O and the aqueous phase extracted with EtOAc. The 
organic phase was then washed with brine, dried over MgSO4 and the 
solvent removed under vacuum. Purification by flash column 
chromatography (silica gel, 10% EtOAc in hexanes) render 92 (230 mg, 
68% overall yield) as a pale yellow oil.
Rf = 0.63 [Silica gel, 40% EtOAc in hexanes]. 1H RMN (400 MHz, 
CDCl3), δ (ppm): 4.41 (s, 2H, CH2), 0.91 (s, 9H, (CH3)3CSi), 0.12 (s, 6H, 
(CH3)2Si). 13C RMN (100 MHz, CDCl3), δ (ppm): 77.96, 73.60, 70.41, 
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In 1991, Matsumoto and colleagues found during a screening 
work from microbial cultures for antitumor agents with detransforming 
activity, a new metabolite that exhibited cell differentiation-modulation 
activity.1,2 The microbial metabolite, isolated from a soil sample collected 
in Okinawa (Japan) identified as the fungus Alternaria brassicicola, RF-328 
exhibited an unprecedented structure containing two epoxide groups 
separated by a double bond which was determined and confirmed by the 
same author by X-ray diffraction analysis of the corresponding bis-(1S)-(-)-
camphanate derivative.2 This novel compound was also isolated from the 
weed pathogen Nimbya scirpicola by Tanaka et al., who demonstrated its 
phytotoxicity toward the host plant of the fungus, Eleocharis kuroguwai, and 
toward other tested plants.3
__________________________________________
The microbial metabolite depudecin is a linear polyketide 
characterized by a highly oxidized 11-carbon chain containing 
two epoxides conjugated through a trans-disubstituted olefin. 
Depudecin was first reported in 1991 by Matsumoto et al. 




Cytoskeletal changes are often a consequence of malignant 
transformation. One of the most characteristic is the loss of actin stress 
fibers, which suggests that the actin-containing microfilament system is a 
critical target during tumorigenesis.4
Several natural products such as herbimycin A,5 radicicol6 or 
azatyrosine7 have been reported to detransforming activity using 
oncogene-transformed cells (v-sis, v-src or v-ras oncogenes as well as other 
cells derived from tumours). Although it remains unclear how these 
compounds show a broad spectrum of detransforming activity in tumor 
cells, there is sufficient evidence suggesting that histone deacetylases 
(HDACs) are likely molecular targets of these agents.8 The broad 
spectrum of detransforming activities displayed by HDAC inhibitors 
implies a role for HDACs in stress fiber formation and cell growth control, 
meaning that HDACs may repress the transcription of  anti-tumor genes.9
In contrast to those previously identified inhibitor of histone 
deacetylase such as trapoxin (117)10,11 and trichostatin A (118)12 or 
largazole (119),13 depudecin (120) possesses a different chemical structure 
that might increase its selectivity towards these biological targets. This fact 
makes depudecin a useful tool to better understand the enzymatic 




Although depudecin can reverse the phenotype transformation of 
ras-oncogene which has been reported to be expressed in many tumours 
and tumour cell lines,15 it does not suppress the expression of the ras gene, 
suggesting that its mode of action does not relate directly to Ras function. 
It also shows a spectrum of detransforming activity, both in v-raf- 
transformed cells and in a human osteosarcoma cell line, MG63. This 
molecule induces production of the flat phenotype of ras-NIH3T3 cells at 
a very low concentration (1.0 µM), revealing that depudecin should 
therefore be involved in the signal transduction after the signal of raf-
oncogene.16
In 1995, Oikawa et al. described its anti-angiogenic activity in vivo 
involving an inhibitory effect on vascular endothelial cell growth,17 with 
and ID50 of 320 ng per egg and a maxima inhibitory activity of 10 µg per 
egg, in the in vivo assay system involving chick embryo CAM. Likewise, it 
inhibited the proliferation of HUVECs in a concentration-dependent 







































vascular endothelial cell growth by depudecin contributes its anti-angionic 
action.
These results indicate depudecin might be a promising anti-
angiogenic and would suggest that an epoxide group could be important 
in the search for a new angiogenesis inhibitor.17
4.1.1. Biosynthesis of Depudecin
Nabeta and co-workers in their interest to understand the 
biosynthesis of depudecin, studied the diferential hydrogen exchange 
occurred in the enzymatic fatty acid elongation process reported 
previously by Saito et al.18 and suggested that although the starter acetate 
unit came from acetyl CoA, the biosynthesis of depudecin may imply 
another mechanism apart of decarboxylative condensation between 
polyacetoacetyl CoA and malonyl CoA, with subsequent decarboxylation 
of  the end carbonyl group and that still remained unknown.19,20
In 2005, Amnuaykanjanasin and co-workers extracted depudecin 
from the fungus Xylaria sp. BCC 1067 together with the polyketide 19-20-




epoxycytochalasin Q, and tried to reveal the PKS (polyketide synthases) 
genes responsible for their biosynthesis.21
But it was not until the year 2009 when Walton et al. identified the 
genes for depudecin biosynthesis and created depudecin-minus mutants in 
order to test whether depudecin was a virulence factor for A. Brassicicola as 
happened to a chemically unrelated HDAC inhibor, HC toxin, that 
exhibits a major virulence factor in the interaction between Cochliobolus 
carbonumand and its host.22 They reported the six-genes cluster of 
depudecin (DEP1 to DEP6), which are predicted to encode a polyketide 
synthase (AbPKS9 or DEP5), a transcription factor (DEP6), two 
monooxygenases (DEP2 and DEP4), a transporter of the major facilitator 
superfamily (DEP3), and one protein of unknown function (DEP1).22 With 
the exception of DEP1, the genes of the depudecin cluster have plausible 
roles in depudecin biosynthesis based in the knowledge of similar genes in 
other secondary metabolite pathways.22
4.1.2. Histone Deacetylase Inhibitors
Histones are small basic proteins rich in amino-acids, lysine and 
arginine, that form the nucleosome core by complexing with DNA. 
Repetitive units of this nucleosome leads to the chromatin, in which all the 
human genome is packaged.
There are two antagonist forms of histones, acetylated or 
deacetylated, and the enzymes that regulate this equilibrium are histone 
acetyl transferases (HTAs), producing the acetylation and histone 
deacetylases (HDACs) which reverse this process.23
Whereas acetylation of histone tails correlates with nucleosome 
remodeling and transcriptional activation, deacetylation induces 




explains this fact due to the neutralization of the positive charge of lysine 
residues in the N-terminal tail during the acetylation process, that implies a 
relaxation in the histone-DNA contacts that facilitates the accessibility of a 
variety of factors to DNA.23 Thought, deacetylation of histone tails causes 
chromatin condensation, electrostatic interactions of neighbouring 
nucleosomes and as a consequence, access of the transcriptional 
machinery to DNA target sequences is blocked.25
Therefore, inhibition of HDACs, potent inducers of growth 
arrest, differentiation and apoptosis of tumour cell lines, represents a novel 
strategy in human cancer therapy because of the key role these enzymes 
plays in regulation gene expression and chromatin assembly.23
4.1.3. Inhibition of Histone Deacetylases by Depudecin
Kwon et al. identified the molecular target(s) of depudecin and 
found evidence that this potential anti-tumor drug belongs to an 
expanding group of pharmaceuticals that inhibit histone deacetylases 
(HDAC): (I) depudecin is a competitive inhibitor of trapoxin, a known 
inhibitor of histone deacetylases, (ii) depudecin inhibits histone 
deacetylases in vitro, and (iii) treatment of cells with depudecin leads to 
histone hyperacetylation in vivo.9
Depudecin induces hyperacetylation of histones in a dose-
dependent manner and inhibit 50% of the purified recombinant HDAC1 
at a concentration of 47 µM.9 This result taken as a whole, provides a 
plausible molecular basis for the actions of depudecin, and suggests, if 
somewhat more tentatively, that changes in gene expression lie behind the 




4.2. Previous Synthesis of Depudecin
The first synthesis of (-)-depudecin was reported by the group of 
Schreiber and co-workers in 1995 according to a strategy that also 
provides access to depudecin-related compounds.26
This synthetic strategy was based on an asymmetric methodology 
that uses a one-pot procedure developed by Sharpless and others for the 
stereoselective conversion of  syn-vicinal diols into trans-epoxides.27-30
The synthesis of the key intermediate 125 started from a D-
threose derivative 121, which was easily transformed into the anti-alcohol 
123 by react ion of the corresponding a ldehyde with 2-
trimethylsilylthiazole. Conversion of the anti-alcohol 123 into the syn 
diastereomer 124 was achieved through an oxidation-reduction sequence 
in a 90% overall yield. Subsequent cleavage of the thistle ring provided 
the aldehyde 125 that represented the left part of depudecin, in 88% yield 
(Scheme 4.1).
Reagents and conditions: (a) Ph3PMeI, tBuOK, 23ºC, 91% (b) TBAF, THF, 
23ºC, 99%. (c) Swern oxidation,  quant. (d) 2-trimethylsilylthiazole, THF, 23ºC, 
then TBAF, 71%. (e) Swern oxidation,  76%. (f) NaBH4, MeOH, -78ºC to -20ºC, 





























99%. (g) TBSCl, imidazole, DMF, 70ºC, 100%. (h) MeI,  MeCN, reflux then CuO, 
CuCl2, CH3CN-H2O, 88%.
Aldehyde 125 was then subjeted to condensation with the 
ketophosphonate derived from 126 affording enone 127 in 88% yield. 
From enone 127, a diastereoselective reduction with sodium borohydride 
in the presence of cerium chloride, followed by deprotection of the silyl 
group and conversion of diol 128 into the tetraol, in a 4 steps sequence 
afforded the key intermediate 130 that contained the complete depudecin 
framework in a 60% overall yield. (Scheme 4.2)
Reagents and conditions:  (a) LiCH2P(O)(OMe)2, THF, 0ºC, 92%. (b) NaH, 
THF, 23ºC, then compound 125, 23ºC, 88%. (c) NaBH4, CeCl3·7H2O, MeOH, 
-78ºC to -20ºC, 96%. (d) TBAF, then separation of stereoisomers, 74%. (e) 
ClCO2CH2CCl3, 2,6-lutidine, CH2Cl2, 23ºC, 99%. (f) HCl (anhyd.), MeOH, 
23ºC, 6 h, 44%. (g) Me2S, benzoyl peroxide (BPO), CH3CN, 0ºC, 34%. (h) 1 M 
LiOH, THF, 23ºC, 93%.
The transformation of the tetraol 130 into the desired diepoxide 
was achieved through formation of the corresponding diacetoxy 
dichloride 131, whose deprotection under excess of mercuric chloride in 








































the presence of calcium carbonate gave depudecin in 52% yield (Scheme 
4.3).
This synthetic strategy proceeded in 22 steps with an overall yield 
of 1.4%. Although the construction of the two epoxide moieties took 
place in a simultaneuos fashion, this strategy presented the drawback of 
using an excess of mercuric chloride. Also the necessity of an oxidation-
reduction sequence to obtain the syn-alcohol made the synthesis longer.
Reagents and conditions: (a) MeC(OMe)3,  cat PPTS, 23ºC. (b) TMSCl, 
Et3N, 23ºC. (c) K2CO3, MeOH, 23ºC, 74% (over 3 steps). (d) 10.0 equiv. HgCl2-
CaCO3, CH3CN-H2O, 23ºC, 3.5 h, 73%. (e) 50.0 equiv. HgCl2-CaCO3, CH3CN-
H2O, 23ºC, 3.5 h, 52%.
The same author analysed the biological activity of the related 
derivatives, mono-methylthiomethyl-protected depudecin 133 and the bis-
methylthiomethyl-protected depudecin 132 and concluded they were both 
inactive at the same concentration, suggesting that the epoxide and 
hydroxyl groups are essential for the detransforming activity of  depudecin.





























4.3. Synthesis of Depudecin
The biological profile exhibited by depudecin indicates that it 
might be a promising anti-angiogenic target and would suggest that an 
epoxide group could be in the search for new angiogenesis inhibitor.22 
Under this premise, we planned the total synthesis of the enantiomer of 
(-)-depudecin, that still remains unknown and might present a similar 
cytotoxicity, employing once again the novel methodology of asymmetric 
epoxidation based on the use of  chiral sulfur ylides.
4.3.1. Retrosynthetic analysis of (+)-Depudecin
Two retrosynthetic strategies for the synthesis of the (+) 
enantiomer of depudecin are presented in Scheme 4.4-A and 4.4-B. 
Both routes relied on the same epoxy alcohol, which was readily available 
from the starting material (-)-ethyl-L-lactate, that provides the only 
stereocenter not generated through this approach. In a first attempt, we 
planned a convergent synthesis of depudecin through the linkage of two 
functionalized epoxide units via a cross metathesis of alkenes 134 and 137 
under the influence of  the Hoveyda-Grubbs catalyst. 





































We planned the synthesis of key fragment 137 from ent-107, 
which was previously obtained during the synthesis of gummiferol. 
Aditionally, epoxy alcohol 135 could be easily synthesized from readily 
commercial starting material such as (-)-ethyl L-lactate (136). 
Unfortunately, the low yields obtained by this way led us to design a 
second approach. Thus, the second strategy consists of a linear sequence 
with the epoxy amide 139 as key intermediate.
It should be highlighted that, in both cases, the epoxides through 
the skeleton of depudecin would be synthesized by using the chiral sulfur 
ylides obtained from sulfonium salt 4.
4.3.2. Towards the Total Synthesis of (+)-Depudecin
4.3.2.1. Convergent Approach
Our initial efforts toward the total synthesis of (+)-depudecin ent-
(120) focused on the convergent approach. To this aim, (-)-ethyl-L-lactate 
was chosen as an appropriate starting material. This compound was first 
converted into the silyl ether and the carboxylic acid reduced into the 
aldehyde by the action of 1.0 equiv of DIBAL-H at -78ºC. The crude 







































aldehyde was then subjected to reaction with the sulfonium salt from L-
methionine (4). However, although several attempts were made to obtain 
the epoxy amide 140, the reaction crude resulted in a complex mixture, 
isolating epoxy amide in a poor yield. Even though the desired product 
was likely to be in the mixture, this could not be confirmed by isolation 
and full characterization which led us to use the Sharpless methodology 
(Scheme 4.5). Thus, the crude aldehyde was subjected to a Wittig-Martin 
reaction to generate the corresponding trans-α,β-unsaturated ester in a 
87% overall yield. The synthesis of the key epoxy alcohol proceeded by 
reduction of the ester 141 into the allylic alcohol 142 by treatment with 
DIBAL-H at -78ºC and Sharpless asymmetric epoxidation with D-(-)-
DET to afford the desired epoxy alcohol 135 in a 90% yield.
Reagents and conditions: (a) TBSCl, imidazol, CH2Cl2, 0ºC.  (b) DIBAL-H, 
CH2Cl2, -78ºC, 1 h. (c) 4, 5.0 M NaOH, CH2Cl2-H2O, 25ºC, 16 h. (d) Super-H, 
THF, 0ºC, 15 min. (e) Bu3PCH2CO2Et, NaOH, toluene-CH2Cl2,  87% (over 3 
steps). (f) DIBAL-H, CH2Cl2, -78ºC, 1 h, 91%. (g) SAE, D-(-)-DET, 90%.
We continued the synthesis of the epoxy alkene 134 from epoxy 
alcohol 135 by a two steps sequence involving oxidation and Wittig 
reaction (Scheme 4.6). For key fragment 137, we planned to start from 
diepoxy amide ent-(107), that was previously obtained for the synthesis of 































gummiferol. Thus, reduction of the mentioned diepoxy amide ent-(107) 
under Red-Al, followed by Wittig reaction, afforded alkene 137 in 50% 
yield over 2 steps.
With the both key fragments in hand, we investigated the viability 
of the metathesis reaction. For the assembly of both epoxy olefins, a cross-
metathesis with Hoveyda-Grubbs 2nd generation was initially atempted. 
However, this reaction afforded the coupling product albeit in a very low 
yield (15%), due to the formation of sub-products during the metathesis 
reactions, such as the homo-coupling product in 60% yield. Different 
conditions and equivalents were tested, including second cycles of 
metathesis but we did not get an improvement of the yield of the desired 
product. However, despite the yield of this reaction was variable and 
generally modest, we were able to prepare 143 in sufficient amounts to 
continue with the synthesis. In this way, selective deprotection step of the 
primary alcohol was accomplished in the presence of TsOH resulting in 
triepoxy alcohol 144, in a 50% yield (Scheme 4.6). Subsequent Apple31 
reaction followed by reductive elimination by treatment of the resulting 
bromo derivative with Zn would led us to the precursor of depudecin. 




Reagents and conditions:  (a) SO3·Pyr,  Et3N, CH2Cl2, DMSO, 0ºC to rt,  4 h. 
(b) Ph3PCH3Br, NaHMDS, 0ºC to rt, 12 h,  50% (over 2 steps). (c) Red-Al, THF, 
0ºC, 45 min. (d) Ph3PCH3Br, NaHMDS, 0ºC to rt, 12 h,  30% (over 2 steps). (e) 
137, Hoveyda-Grubbs 2nd generation catalyst,  CH2Cl2, 45ºC, 72 h, 15%. (f) 
TsOH, 50%. (g) CBr4, Ph3P. (h) Zn (i) TBAF.
4.3.2.2. Linear Approach
As an efficient alternative to the convergent synthesis described 
above, a second route to depudecin, involving the synthesis of the diepoxy 
amide 138 was developed.
To this aim, we first proceeded to obtain the epoxy amide 139 via 
chiral sulfur ylide by a sequence involving: (i) oxidation of epoxy alcohol 
135 into the aldehyde by treatment with SO3-Pyr complex, (ii) a Wittig-
Martin reaction, (iii) reduction to the α,β-unsaturated aldehyde under 
DIBAL-H and (iv) reaction with the sulfur ylide resulting from sulfonium 
salt 4. To our delight, this four-steps sequence was accomplished in a 75% 
overall yield and provided the essential fragment 139 as a single 
diastereoisomer (Scheme 4.7).
























(143) R = OTBS


















Reagents and conditions: (a) SO3·Pyr, CH2Cl2-DMSO, Et3N, 0ºC. (b) 
Bu3PCH2CO2Et, NaOH, toluene-CH2Cl2, 62% (over 2 steps) (c) DIBAL-H, 
CH2Cl2, -78ºC, 1 h. d) 4, NaOH, tBuOH, 12 h, 55% (over 2 steps).
From compound 139, two approaches were explored. In our 
efforts to shorten the number of steps, a straightforward addition of the 
appropriate vinyl Grignard reagent was planned. To this aim, epoxy 
amide 139 was reduced into the corresponding epoxy aldehyde by the 
action of Red-Al, as previously reported, followed by addition of vinyl 
magnesium bromide. Even though several conditions were tested all of 
them resulted in complex mixture and decomposition of the starting 
epoxy aldehyde. This disappointing and unexpected results led us to 
change our initial strategy by synthesizing the triepoxy amide 138 which 
was obtained as a single diasteroisomer in a moderate 30% yield over 2 
steps by reaction of corresponding epoxy aldehyde derived from 139 with 
sulfonium salt 4 employing our two phase method (Scheme 4.8).32 This 
highly valuable tri-epoxide fragment was then converted into the 
corresponding tri-epoxy alcohol 144 by reaction with Super-H in 60% 
yield.




















Reagents and conditions: (a) Red-Al, THF, 0ºC, 45 min. (b) 4, NaOH, 
CH2Cl2-H2O, 30% (over 2 steps). (c) Super-H, THF, 0ºC, 30 min, 60%. (d) CBr4, 
Ph3P. (e) Zn (f) TBAF
With this approach, we have provided a synthetic alternative to 
the synthesis to the tri-epoxy alcohol 144 and have established a valuable 
methodology for the synthesis of the carbon skeleton of depudecin. 
Although three steps remains still unaffordable for completing the total 
synthesis of (+)-depudecin, previously reported conversion of epoxy 
alcohols into vinyl alcohol makes us to be confident on this strategy.33




































4.4. Summary and Concluding Remarks
In this chapter, new approaches towards the synthesis of the non-
natural enantiomer of depudecin were described. Particularly, the 
development of an alternative route to build the oxigenated carbon 
skeleton of depudecin was discussed. In comparison to the synthesis of 
Schreiber, the precursor of the depudecin 144 was synthesized in a 
stereoselective fashion using the chiral sulfur ylide derived from L-Met in a 
sequence involving 12 steps, with an overall yield of 4%. Additionally, a 
more convergent efficient route for the rapid assembly of the building 
blocks 134 and 137 via cross metathesis was described, although 
alternative cross-coupling methods should be tested in order to increase 
the yield of the targeted product. Due to the lack of time, new ways to 
accomplish the total synthesis have to be explored, that could provide an 





4.5.1. General Procedures for the Synthesis of Epoxy  and 
Diepoxy Amides
4.5.1.1. Synthesis of Epoxy Amides
To a solution of sulfonium salt (4 or 6) (1.1 equiv) in tBuOH (~ 
0.08 M) was added a 3.0 M aqueous NaOH solution (1.1 equiv). After 10 
min at 25ºC, a solution of the corresponding aldehyde (1.0 equiv), in 
tBuOH (~ 0.1 M) was added, and the crude reaction mixture was 
vigorously stirred overnight at 25ºC. After this time, both phases were 
separated, and the aqueous layer was extracted twice with EtOAc. 
Combined organic extracts were then washed with H2O and brine, dried 
over anhydrous MgSO4, filtered, and concentrated under vacuum. Flash 
column chromatography (silica gel, EtOAc 30-40% in hexanes) afforded 
the corresponding epoxy amide.
4.5.1.2. Synthesis of Diepoxy Amides
To a solution of the corresponding epoxy amide (1.0 equiv) in dry 
THF (0.08 M) was added dropwise Red-Al 70% w/v in toluene (2.2 equiv) 
at 0ºC. After 1 h at 0ºC, the reaction mixture was quenched by addition of 
a saturated aqueous NH4Cl solution. After separation of both layers, the 
aqueous phase was extracted with EtOAc, the organic extracts were 
washed with brine and dried over MgSO4, and the solvent was evaporated 
under reduced pressure. The resulting crude epoxy aldehyde was used for 





4.5.2.1. Synthesis of the α,β-Unsaturated Ester 141
To a solution of 136 (4.8 mL, 42.3 mmol, 1.0 equiv) in CH2Cl2 
(45 mL) was added, at 0ºC, imidazol (3.5 g, 51.0 mmol, 1.2 equiv) and 
TBSCl (7 g, 46.5 mmol, 1.1 equiv) and the reaction was allowed to reach 
rt. After 5 hours the mixture was quenched with H2O and diluted with 
Et2O. The aqueous phase was extracted with Et2O and the organic layers 
were washed with brine, dried over MgSO4 and the solvent was 
evaporated under reduced pressure. The corresponding silyl ether, whose 
data match with those reported in bibliography, was used in the next step 
without further purification.34
The crude silyl ether dissolved in CH2Cl2 (50 mL) was cooled at 
-78ºC and then treated with DIBAL-H 1.0 M solution in toluene (25.8 
mL, 25.8 mmol, 1.0 equiv) After 20 min, the reaction was quenched by 
addition of EtOAc at -78ºC and the mixture was allowed to reach rt and 
treated with a saturated aqueous Na+/K+ tartrate solution. The resulting 
mixture was vigorously stirred until a clear separation of both organic and 
aqueous phases. The aqueous phase was then separated, the organic 
extract washed with water and brine, dried and the solvent evaporated 
under reduced pressure. The crude of the aldehyde was used in the next 

















A solution of tributyl(ethoxycarbonylmethylene)phosphonium 
bromide (5.8 g, 16.0 mmol, 1.25 equiv) in CH2Cl2 (15 mL) was washed 
twice with a 1.0 M aqueous NaOH solution (30 mL), dried and diluted 
with toluene (20 mL). After removing CH2Cl2, the resulting solution was 
then added to a stirred solution of crude aldehyde and benzoic acid (310 
mg, 2.5 mmol, 0.2 equiv) in toluene (50 mL) at 95ºC. After 30 min the 
solvent was evaporated and the residue was purified by flash column 
chromatography (silica gel 10% EtOAc in hexanes) to provide the 
corresponding α,β-unsaturated ester 141 (2.9 g, 87% over 3 steps) as a 
pale yellow oil.
Rf = 0.73 [Silica gel, 20% EtOAc in hexanes]. [α]25D = + 8.3 (c  0.7, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 6.92 (dd, J = 15.5, 4.1 
Hz, 1H, CH=CHCO2), 5.98 (dd, J = 15.5, 1.8 Hz, 1H, CH=CHCO2), 
4.51 - 4.39 (m, 1H, CH3CH), 4.19 (qd, J = 7.1, 3.1 Hz, 2H, OCH2CH3), 
1.29 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.25 (d, J = 6.6 Hz, 3H, CH3CH), 
0.90 (s, 9H, (CH3)3CSi)), 0.06 (s, 3H, (CH3)2Si), 0.06 (s, 3H, (CH3)2Si)). 13C 
NMR (100 MHz, CDCl3), δ (ppm): 166.85, 151.88, 118.96, 67.70, 60.29, 
25.81, 23.54, 18.21, 14.26, -4.85, -4.87.
4.5.2.2. Synthesis of the Allylic Alcohol 142
A solution of 141 (2.2 g, 8.5 mmol, 1.0 equiv) in CH2Cl2 (50 mL) 
was cooled at -78ºC and then treated with DIBAL-H 1.0 M solution in 
toluene (22 mL, 22.0 mmol, 2.5 equiv). After 40 min, the reaction was 
quenched by adding of EtOAc at -78ºC and the mixture was allowed to 
reach rt and treated with a saturated aqueous Na+/K+ tartrate solution. 













both organic and aqueous phases. The aqueous phase was then separated, 
the organic extract washed with water and brine, dried and the solvent 
evaporated under reduced pressure. The crude was purified by flash 
column chromatography (silica gel, 10% EtOAc in hexanes) to obtain 142 
(1.67 g, 91%) as a colourless oil.
Rf = 0.55 [Silica gel, 20% EtOAc in hexanes]. [α]25D = + 16.4 (c 0.8, 
CH2Cl2). 1H RMN (400 MHz, CDCl3), δ (ppm): 5.78 - 5.71 (m, 2H, 
CHCH=CH and CH=CHCH2), 4.36 - 4.27 (m, 1H, CH3CHCH=), 4.13 
(dd, J = 4.2, 0.9 Hz, 2H, =CHCH2), 1.57 (bs, 1H, OH), 1.21 (d, J = 6.4 
Hz, 3H, CH3CH), 0.89 (s, 9H, (CH3)3CSi), 0.06 (s, 3H, (CH3)2Si), 0.05 (s, 
3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 136.35, 127.30, 
68.48, 63.15, 25.88, 24.32, 18.26, -4.62, -4.75.
4.5.2.3. Synthesis of the Epoxy Alcohol 135 
To a solution of titanium tetraisopropoxide (0.7 mL, 2.3 mmol, 
0.35 equiv) in CH2Cl2 (30 mL) was added D-(-)-DET (0.4 mL, 2.3 mmol, 
0.35 equiv) at -20ºC. After 15 min at this temperature, a solution of alyllic 
alcohol 142 (1.4 g, 6.6 mmol, 1.0 equiv) in CH2Cl2 (40 mL) was added 
dropwise, followed by the addition, after additional 30 min, of a 5.5 M 
TBHP solution in decane (2 mL, 10.5 mmol, 1.6 equiv) at the same 
temperature. After 8 h at this temperature, the reaction mixture was 
quenched with Me2S (2.3 mL, 30.0 mmol, 4.6 equiv) at 0ºC, filtered off 
and the solvent was evaporated under reduced pressure. The crude 
product was purified by flash column chromatography (silica gel, 20% 














Rf = 0.36 [Silica-gel, 30% EtOAc in hexanes]. [α]25D = + 21.0 (c 0.9, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ (ppm): 3.90 (ddd, J = 12.7, 5.5, 
2.5 Hz, 1H, CH2OH), 3.66 - 3.55 (m, 2H, CH3CH and CH2OH), 3.01 
(dt, J = 4.7, 2.4 Hz, 1H, CH(O)CHCH2), 2.95 (dd, J = 5.8, 2.4 Hz, 1H, 
CH(O)CHCH2), 2.29 (t, J = 6.4 Hz, 1H, OH), 1.18 (d, J = 6.4 Hz, 3H, 
CH3CH), 0.88 (s, 9H, (CH3)3CSi)), 0.07 (s, 3H, (CH3)2Si), 0.05 (s, 3H, 
(CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 69.12, 61.51, 60.06, 
56.15, 25.79, 20.34, 18.13, -4.69, -4.87. HRMS (H-ESI) m/e 233.15675 
calcd for C11H24O3Si [M + H]+, found 233.15669.
4.5.2.4. Synthesis of the Epoxy Olefin 134
Epoxy alcohol 135 (220 mg, 0.95 mmol, 1.0 equiv) was dissolved 
in a CH2Cl2/DMSO (1:1) mixture (20 mL) and cooled at 0ºC. At this 
temperature, Et3N (0.4 mL, 14.2 mmol, 3.0 equiv) was added followed by 
SO3·Pyr (270 mg, 1.71 mmol, 1.8 equiv). The mixture was allowed to 
reach rt and 5 hours later was quenched by addition of a buffer solution 
pH = 7 and diluted with Et2O. The aqueous phase was extracted with 
Et2O and the combined organic extracts were washed with water and 
brine, then dried over anhydrous MgSO4 and the solvent removed under 
pressure. The resulting crude of the aldehyde was used in the next step 
without further purification.
Over a solution of Ph3PCH3Br (693 mg, 1.9 mmol, 2.0 equiv) in 
THF (10 mL) was added NaHMDS 2.0 M in THF (0.7 mL, 1.4 mmol, 1.5 
equiv) at 0ºC. The reaction was stirred at the same temperature over 10 
min and then, the crude of the aldehyde above obtained dissolved in THF 













and stirred overnight. The solvent was then removed under vacuum and 
the crude purified by flash column chromatography (silica gel, 10% EtOAc 
in hexanes) to afford 134 (100 mg, 50% over 2 steps) as a pale yellow oil.
Rf = 0.74 [Silica gel, 10% EtOAc in hexanes]. [α]25D = + 35.2 (c 0.4, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 5.58 (ddd, J = 17.3, 
10.1, 7.5 Hz, 1H, CH(O)CHCH=), 5.45 (ddd, J = 17.2, 1.6, 0.4 Hz, 1H, 
CH=CH2), 5.26 (ddd, J = 10.2, 1.5, 0.6 Hz, 1H, CH=CH2), 3.62 (dt, J = 
12.3, 6.3 Hz, 1H, CH3CH), 3.20 (dd, J = 7.5, 2.2 Hz, 1H, 
CH3CHCH(O)CH), 2.85 (dd, J = 5.8, 2.2 Hz, 1H, CH3CHCH(O)), 1.21 
(d, J = 6.4 Hz, 3H, CH3CH), 0.90 (s, 9H, (CH3)3CSi), 0.10 (s, 3H, 
(CH3)2Si), 0.07 (s, 3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 
135.26, 119.22, 69.42, 64.37, 56.28, 25.81, 20.28, 18.16, -4.66, -4.88. 
HRMS (APCI) m/e 229.16183 calcd for C12H24O2Si [M + H]+, found 
229.16194.
4.5.2.5. Synthesis of the Diepoxy Olefin 137
Diepoxiamide ent-107 (350 mg, 0.8 mmol, 1.0 equiv) in dry THF 
(10 mL) was treated dropwise with Red-Al 60% w/v in toluene (0.54 mL, 
1.8 mmol, 2.2 equiv) at 0ºC. After 1 hour at this temperature, the reaction 
mixture was diluted with a saturated aqueous NH4Cl solution. The 
aqueous phase was then separated, extracted twiced with EtOAc and the 
combined organic phase washed with H2O and brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The 
















The crude aldehyde dissolved in THF (10 mL) was cooled at 0ºC 
and over this solution was added NaHMDS 2.0 M in THF (0.6 mL, 1.2 
mmol, 1.5 equiv). The reaction was stirred at the same temperature over 
10 min and then Ph3PCH3Br (590 mg, 1.6 mmol, 2.0 equiv) dissolved in 
THF (5 mL) was added at once. The reaction crude was allowed to reach 
rt and stirred overnight. The solvent was then removed under vacuum and 
the crude purified by flash column chromatography (silica gel, 20% EtOAc 
in hexanes) to afford 137 (70 mg, 30% over 2 steps) as a pale yellow oil.
Rf = 0.33 [Silica gel, 10% EtOAc in hexanes]. [α]25D = - 25.4 (c 0.8, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm): 5.60 - 5.48 (m, 2H, 
CH2=CH and CH2=CH), 5.35 - 5.30 (m, 1H, CH2=CH), 3.88 (dd, J = 
12.2, 2.8 Hz, 1H, CHCH(O)CHCH2), 3.75 (dd, J = 12.2, 4.0 Hz, 1H, 
CHCH(O)CHCH2), 3.37 (dd, J = 7.1, 2.1 Hz, 1H, =CHCH(O)CH), 3.11 
(ddd, J = 4.0, 2.9, 2.1 Hz, 1H, CHCH(O)CHCH2), 3.00 (dd, J = 4.4, 2.1 
Hz, 1H, CHCH(O)CHCH2), 2.92 (dd, J = 4.4, 2.1 Hz, 1H, 
=CHCH(O)CH), 0.90 (s, 9H, (CH3)3CSi), 0.08 (s, 3H, (CH3)2Si), 0.07 (s, 
3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 134.43, 120.17, 
62.07, 57.90, 56.03, 55.96, 53.29, 29.69, 25.84, 18.33, -5.36. HRMS 
(APCI) m/e 257.15675 calcd for C13H24O3Si [M + H]+, found 257.15674.
4.5.2.6. Cross metathesis of Olefins 134 and 137
Alkene 134 (60 mg, 0.27 mmol, 3.0 equiv) and diepoxy alkene 
137 (23 mg, 0.09 mmol, 1.0 equiv) were dissolved in CH2Cl2 (8 mL) and 
Hoveyda-Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 0.2 equiv) 
was added. The flask was then capped and heated at 40ºC overnight, after 















chromatography (silica gel, 5% EtOAc in hexanes) to yield 143 (6 mg, 
15%) as a pale yellow oil.
Rf = 0.57 [Silica gel, 10% EtOAc in hexanes]. [α]25D = + 31.4 (c 0.4, 
CH2Cl2). 1H NMR (400 MHz, CDCl3), δ  (ppm): 5.72 (dd, J = 15.7, 7.0 
Hz, 1H, (O)CHCH=CH), 5.64 (dd, J = 15.6, 7.0 Hz, 1H, 
(O)CHCH=CH), 3.88 (dd, J = 12.2, 2.7 Hz, 1H, (O)CHCH2O), 3.74 (dd, 
J = 12.2, 4.0 Hz, 1H, (O)CHCH2O), 3.63 (dd, J = 6.5, 5.8 Hz, 1H, 
CH3CH), 3.37 (dd, J = 7.1, 2.0 Hz, 1H, =CHCH(O)), 3.23 (dd, J = 7.0, 
2.1 Hz, 1H, CH3CHCH(O)CH), 3.10 (ddd, J = 4.0, 2.8, 2.1 Hz, 1H, 
C H ( O ) C H C H ( O ) C H ) , 3 . 0 0 ( d d , J = 4 . 2 , 2 . 1 H z , 1 H , 
CH(O)CHCH(O)CH), 2.93 (dd, J = 4.2, 2.1 Hz, 1H, =CHCH(O)CH), 
2.86 (dd, J = 5.7, 2.1 Hz, 1H, CH3CHCH(O)), 1.20 (d, J = 6.4 Hz, 3H, 
CH3CH), 0.90 (s, 9H, (CH3)3CSi), 0.89 (s, 9H, (CH3)3CSi), 0.09 (s, 3H, 
(CH3)2Si), 0.07 (s, 3H, (CH3)2Si), 0.07 (s, 3H, (CH3)2Si) 0.06 (s, 3H, 
(CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 132.64, 130.77, 69.16, 
64.68, 61.98, 58.08, 56.07, 54.85, 53.03, 32.06, 29.70, 25.84, 25.80, 
20.26, 18.33, 18.16, -4.67, -4.84, -5.36. HRMS (APCI) m/e 479.26195 
calcd for C23H44O5Si2 [M + H]+, found 479.26208.
4.5.2.7. Synthesis of Triepoxy Alcohol 144
Silyl ether 143 (30 mg, 0.07 mmol, 1.0 equiv) was dissolved in a 
mixture THF-H2O (20:1) (5 mL) and over this solution was added TsOH 
(2 mg, 0.01 mmol, 0.1 equiv) at 25ºC. After stirring for 40 min at the same 
tempearture, the solvent was removed under vacuum and the crude 
mixture purified by flash column chromatography (silica gel, 40% EtOAc 
















Rf = 0.38 [Silica gel, 60% EtOAc in hexanes]. [α]25D = +35.2 (c  0.4, 
CH2Cl2) . 1H RMN (400 MHz, CDCl3), δ  (ppm) (5.73 (dd, J = 15.6, 7.1 
Hz, 1H, CH(O)CHCH=), 5.64 (dd, J = 15.7, 7.2 Hz, 1H, CHCH=CH), 
3.97 (dd, J = 12.9, 2.1 Hz, 1H, CH(O)CHCH2), 3.72 (dd, J = 13.1, 3.2 
Hz, 1H, CH(O)CHCH2), 3.66 – 3.61 (m, 1H, CH3CH), 3.39 (dd, J = 7.2, 
2.1 Hz, 1H, CH=CHCH(O), 3.24 (dd, J = 7.1, 2.0 Hz, 1H, 
CH3CHCH(O)CH), 3.20 – 3.16 (m, 1H, CH(O)CHCH(O)CH), 3.10 (dd, 
J = 4.3, 2.2 Hz, 1H, =CHCH(O)CHCH(O)), 3.03 (bs, 1H, OH), 2.94 (dd, 
J = 4.3, 2.1 Hz, 1H, =CHCH(O)CH), 2.87 (dd, J = 5.7, 2.1 Hz, 1H, 
CH3CHCH(O)), 1.20 (d, J = 6.4 Hz, 3H, CH3CH), 0.90 (s, 9H, 
(CH3)3CHSi), 0.09 (s, 3H, (CH3)2Si), 0.07 (s, 3H, (CH3)2Si). 13C NMR (100 
MHz, CDCl3), δ (ppm): 132.85, 130.55, 69.14, 64.71, 60.44, 57.94, 55.74, 
54.80, 53.00, 29,70, 25.80, 20.26, 18.16, -4.67, -4.84.
4.5.3. Linear approach
4.5.3.1. Synthesis of the α,β-Unsaturated Ester 145
Epoxy alcohol 135 (1.1 g, 4.7 mmol, 1.0 equiv) was dissolved in a  
CH2Cl2/DMSO (1:1) mixture (20 mL) and cooled at 0ºC. At this 
temperature, Et3N (2 mL, 14.2 mmol, 3.0 equiv) was added followed by 
SO3·Pyr complex (1.4 g, 8.5 mmol, 1.8 equiv). The mixture was allowed 
to reach rt and 5 hours later was quenched by addition of a buffer pH = 7 
solution and diluted with Et2O. The aqueous phase was extracted with 
Et2O and the combined organic extracts were washed with water and 

















reduced pressure. The resulting crude aldehyde was used in the next step 
without further purification.
A solution of tributyl(ethoxycarbonylmethylene)phosphonium 
bromide (2.2 g, 4.7 mmol, 1.25 equiv) in CH2Cl2 (10 mL) was washed 
twice with a 1.0 M aqueous NaOH solution, dried over anhydrous 
MgSO4, and diluted with toluene (10 mL). After CH2Cl2 was removed, the 
resulting solution was then added to a stirred solution of the 
corresponding aldehyde (4.7 mmol, 1.0 equiv) and benzoic acid (115 mg, 
0.9 mmol, 0.2 equiv) in toluene (20 mL) at 95ºC. After 30 min, the solvent 
was evaporated and the residue was purified by flash column 
chromatography (silica gel, 20% EtOAc in hexanes) to provide the 
corresponding α,β-unsaturated ester 145 (880 mg, 62% over 2 steps) as a 
pale yellow oil. HRMS (H-ESI) m/e 301.18296 calcd for C15H28O4Si [M 
+ H]+, found 301.18292.
Rf = 0.84 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 3.8 (c  0.5, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ (ppm) 6.65 (dd, J = 15.7, 7.2 
Hz, 1H, CH=CHCO), 6.11 (d, J = 15.7 Hz, 1H, CH=CHCO), 4.18 (q, J 
= 7.1 Hz, 2H, OCH2CH3), 3.72 – 3.62 (m, 1H, CH3CH), 3.33 (dd, J = 
7.2, 1.9 Hz, 1H, (O)CHCH=), 2.91 (dd, J = 5.5, 2.0 Hz, 1H, 
CH(O)CHCH=), 1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.20 (d, J = 6.4 
Hz, 3H, CH3CH), 0.88 (s, 9H, (CH3)3CSi), 0.08 (s, 3H, (CH3)2Si), 0.05 (s, 
3H, (CH3)2Si). 13C NMR (100 MHz, CDCl3), δ (ppm): 165.53, 144.05, 





4.5.3.2. Synthesis of the Diepoxy Amide 139
A solution of 145 (175 mg, 0.6 mmol, 1.0 equiv) in CH2Cl2 (10 
mL) was cooled at -78ºC and then treated with DIBAL-H 1 M solution in 
toluene (0.6 mL, 0.6 mmol, 1.0 equiv) After 20 min, the reaction was 
quenched by addition of EtOAc at -78ºC and the mixture was allowed to 
reach rt and treated with a saturated aqueous Na+/K+ tartrate solution. 
The resulting mixture was vigorously stirred until a clear separation of 
both organic and aqueous phases. The aqueous phase was then separated, 
the organic extract washed with water and brine, dried over MgSO4 and 
the solvent evaporated under reduced pressure. The crude of the aldehyde 
was used in the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (200 g, 0.6 
mmol, 1.1 equiv) and NaOH (3.0 M aqueous solution, 0.2 mL, 0.6 mmol, 
1.0 equiv) according to the general procedure described above for the 
synthesis of diepoxy amides to yield diepoxy amide 139 (80 mg, 55% over 
two steps) as a white solid.
Rf = 0.84 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 28.33 (c 0.5, 
CH2Cl2). mp = 76 - 77ºC. 1H NMR (400 MHz, CDCl3), δ (ppm): 5.83 
(dd, J = 15.7, 7.2 Hz, 1H, (O)CHCH=CH), 5.67 (dd, J = 15.7, 7.5 Hz, 
1H, CH(O)CHCH=), 4.34 - 4.23 (m, 1H, NCH), 4.02 (ddd, J = 9.2, 5.3, 
1.4 Hz, 1H, OCH2CH), 3.90 (d, J = 9.2 Hz, 1H, OCH2CH), 3.71 - 3.57 
(m, 2H, CH3CHCH(O) and CH3CH), 3.53 (d, J = 1.9 Hz, 1H, 
CH3CHCH(O)CH), 3.24 (dd, J = 7.2, 2.1 Hz, 1H, =CHCH(O)), 2.87 (dd, 
J = 5.6, 2.1 Hz, 1H, =CHCH(O)CH), 2.64 - 2.51 (m, 1H, CH3SCH2), 
a. DIBAL-H, -78ºC
b.4, NaOH, tBuOH















2.43 (ddd, J = 13.2, 8.8, 6.7 Hz, 1H, CH3SCH2), 2.10 (s, 3H, CH3S), 2.08 
- 1.99 (m, 1H, CH3SCH2CH2), 1.82 - 1.68 (m, 1H, CH3SCH2CH2), 1.65 
(s, 3H, CH3), 1.54 (s, 3H, CH3), 1.20 (d, J = 6.4 Hz, 3H, CH3CH), 0.89 (s, 
9H, (CH3)3CSi), 0.09 (s, 3H, (CH3)2Si), 0.06 (s, 3H, (CH3)2Si). 13C NMR 
(100 MHz, CDCl3), δ (ppm): 162.98, 133.97, 129.54, 95.99, 69.03, 67.05, 
64.81, 57.02, 55.87, 55.62, 54.64, 34.42, 30.82, 26.28, 25.80, 22.99, 
20.27, 18.16, 15.94, -4.67, -4.83. HRMS (H-ESI) m/e 472.25475 calcd for 
C23H41NO5SSi [M + H]+, found 472.25504.
4.5.3.3. Synthesis of the Triepoxy Amide 138
To a solution of diepoxy amide 139 (65 mg, 0.14 mmol, 1.0 equiv) 
in THF (5 mL) was added dropwise Red-Al (0.09 mL, 70% w/v in 
toluene, 0.30 mmol, 2.2 equiv) at 0ºC. After 1 h at 0ºC, the reaction 
mixture was quenched by addition of a saturated aqueous NH4Cl 
solution. After separation of both layers, the aqueous phase was extracted 
with EtOAc, the organic extracts were washed with brine and dried over 
MgSO4 and the solvent evaporated under reduced pressure. The crude 
diepoxy aldehyde was used for the next step without further purification.
The crude aldehyde was reacted with sulfonium salt 4 (49 mg, 
0.15 mmol, 1.1 equiv) and NaOH (5.0 M aqueous solution, 0.03 mL, 0.14 
mmol, 1.0 equiv) according to the general procedure described above for 
the synthesis of diepoxy amides to yield diepoxy amide 138 (20 mg, 28% 
over 2 steps) as a colourless oil.
a. RedAl
b. 4, NaOH,DCM-H2O
















Rf = 0.25 [Silica gel, 40% EtOAc in hexanes]. [α]25D = + 41.6 (c 0.5, 
CH2Cl2) . 1H NMR (400 MHz, CDCl3), δ  (ppm): 5.75 (dd, J = 15.7, 7.2 
Hz, 1H,CH=CHCH(O), 5.64 (dd, J = 15.7, 7.3 Hz, 1H, 
CH=CHCH(O)), 4.34 – 4.28 (m, 1H, NCH), 4.05 – 3.99 (m, 1H, OCH2), 
3.91 (d, J = 9.2 Hz, 1H, OCH2), 3.66 – 3.61 (m, 1H, CH3CH), 3.59 (d, J 
= 1.9 Hz, 1H, =CHCH(O)CHCH(O)CH), 3.42 (dd, J = 7.3, 1.9 Hz, 
1H,CH=CHCH (O)CH), 3 .39 (dd, J = 3 .1 , 1 .9 Hz, 1H, 
=CHCH(O)CHCH), 3.24 (dd, J = 7.2, 2.0 Hz, 1H, CH(O)CHCH=), 
3.06 (dd, J = 3.2, 2.0 Hz, 1H, CH=CHCH(O)CH), 2.86 (dd, J = 5.6, 2.1 
Hz, 1H, CH(O)CHCH=), 2.59 (ddd, J = 12.9, 7.5, 5.1 Hz, 1H, 
NCHCH2CH2), 2.48 (ddd, J = 13.2, 8.3, 7.3 Hz, 1H, NCHCH2CH2), 
2.13 (s, 3H, CH3S), 2.10 – 2.05 (m, 1H, NCHCH2CH2), 1.87 – 1.76 (m, 
1H, NCHCH2CH2), 1.65 (s, 3H, (CH3)2C), 1.53 (s, 3H, (CH3)2C), 1.20 (d, 
J = 6.4 Hz, 3H, CH3CH), 0.89 (s, J = 3.3 Hz, 9H, (CH3)3CSi ), 0.09 (s, 
3H, (CH3)2Si), 0.06 (s, 3H, (CH3)2Si. 13C NMR (100 MHz, CDCl3), δ 
(ppm): 162.77, 133.17, 130.17, 95.97, 69.10, 67.05, 64.72, 56.63, 55.99, 
55.09, 55.01, 54.77, 51.28, 34.49, 30.72, 26.22, 25.80, 22.96, 20.26, 
18.16, 15.89, -4.67, -4.83. HRMS (H-ESI) m/e 514.26531 calcd for 
C25H43NO6SSi [M + H]+, found 514.26556.
4.5.3.4. Synthesis of Triepoxy Alcohol 144
Triepoxy amide 138 (40 mg, 0.07 mmol, 1.0 equiv) in THF was 
treated with Super-H 1.0 M in THF (0.2 mL, 0.2 mmol, 2. equiv) at 0ºC. 
After 1 h at this temperature, the reaction mixture was diluted with Et2O 
and washed with a saturated aqueous NH4Cl solution. The aqueous phase 
was separated, extracted with Et2O twice and the combined organic layers 


















concentrated under reduced pressure. Purification by flash column 
chromatography (silica gel, 40% EtOAc in hexanes) provided triepoxy 
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5.1. Solid Phase Synthesis of Globomycin
The lipocyclodepsipeptide glomobycin (12) and its congeners 
(Scheme 5.1), isolated from four different strains of actinomycetes in 
1978,1-3 represent an interesting family of natural products distinguished 
by their striking antibiotic activities against Gram-negative bacteria4-6 and 
represent an attractive biological target for the development of new 
antibiotics.
Comparatively, globomycin (12) and SF-1902 A5 (13) display 
greater antibiotic activities when compared to other antibiotics,7 such as 
ampicilllin or streptomycin, against E. coli, Salmonella enteriditis, and 
Enterobacter cloacae. On the other hand, SF-1902 A5 is more active than 
globomycin (MIC against E. coli NIHJJC-2: 6.25 µg/mL for 12, 1.56 µg/
______________________________________________
During the course of this thesis, we also challenged several 
synthetic projects, most of them related to solid phase peptide 
synthesis (SPPS). Consequently, as a result of the above 
mentioned collaborations, the contributions to the synthesis of 
several natural products containing peptidic fragments will be 
briefly discussed throughout this chapter.
____________________________________________
mL for 13), revealing that the lipidic chain plays an important role in the 
biological activity. These biological properties render these 
cyclodepsipeptides as attractive synthetic endeavors in the search for new 
antibiotics.
With the structure of globomycin established by Haneishi et al.3 
and a first total synthesis reported by the Kogen group in 2000,8 our 
research group decided to embark on a research program directed to the 
design of an efficient and readily accesible route toward this class of 
natural products and analogues. Hence, in 2011 the synthesis of 
globomycin and SF-1902 A5 was accomplished utilizing solid phase 
synthesis for the peptidic fragment and the chiral sulfur ylide as 
asymmetric methodology of  epoxidation for the lipidic chain.9
Here we would like to describe the synthesis of the linear peptidic 
chain (151) common to globomycin and SF-1902 A5, that was achieved in 







































(13) SF-1902 A5 
(147) SF-1902 A4a 
(148) SF-1902 A2 





R = CH3, n = 3
R = CH3, n = 5
R = CH3, n = 4 
R = CH3, n = 1
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10 steps by taking advantage of the solid phase methodology and 
revealing a load of  0.6 mmol/g for resin 155 (Scheme 5.2).
Thus, Fmoc-Gly was linked onto the 2-chlorotrityl chloride (CTC) 
resin by esterification with DIPEA to obtain resin 152. After removing the 
Fmoc group by treatment with 20% of piperidine in DMF, the following 
Fmoc aminoacid derivative, Fmoc-L-allo-Thr(TBS)-OH, was loaded onto 
the resulting resin by the action of DIC in the presence of HOBt in DMF. 
To check the loading of the amino acid and to ensure the effectiveness of 
the chosen coupling procedure, we decided to cleave the dipeptide by 
treatment of 153 with CH2Cl2/AcOH/CF3CH2OH (TFE) (7:2:1), which 
gave pure dipeptide 154. The synthesis was continued from 153, 
repeating the procedure of coupling and Fmoc deprotection steps for each 
amino acid being loaded in the following order: (1) Fmoc-L-Ser(Bzl)-OH, 
(2) Fmoc-L-allo-Ile-OH, and (3) Fmoc-N-Me-L-Leu-OH to obtain resin 
155. At this stage, we again checked the overall loading of the resin, and 
thus 155 was treated with CH2Cl2/AcOH/CF3CH2OH (7:2:1) to provide 
pure Fmoc protected pentapeptide 151 in an amount that revealed a load 
of 0.6 mmol/g. Finally, resin 155 was treated with piperidine to remove 





Reagents and Conditions: (a) Fmoc-Gly-OH, DIPEA, DMF, 25ºC, 30 h. (b) 
20% Piperidine in DMF, 25ºC, 30 min; Fmoc-L-allo-Thr(TBS)-OH, HOBt, DIC, 
DMF, 25ºC,  24 h.  (c) CH2Cl2, AcOH, CF3CH2OH (7:2:1), 25ºC, 30 min. (d) 20% 
Piperidine in DMF, 25ºC, 30 min; Fmoc-L-Ser(Bzl)-OH, HOBt, DIC, DMF, 
25ºC, 24 h. (e) 20% Piperidine in DMF, 25ºC, 30 min; Fmoc-L-allo-Ile-OH, 
HOBt, DIC, DMF, 25ºC, 24 h. (f) 20% Piperidine in DMF, 25ºC, 30 min;  Fmoc-
N-Me-L-Leu-OH, HOBt, DIC, DMF, 25ºC, 24 h. (g) 20% Piperidine in DMF 
(Load: 0.6 mmol/g for resin 155).
5.1.1. Experimental Section
5.1.1.1. Fmoc-Gly-OH Loaded 2-Chlorotrityl Resin (152)
A 5 mL polypropylene syringe fitted with polyethylene porous disk 
charged with 2-chlorotrityl chloride resin (300 mg, L = 1.3 mmol/g, 0.39 
mmol, 1.0 equiv), was loaded with a solution of Fmoc-Gly-OH (348 mg, 











































1.17 mmol, 3.0 equiv) and DIPEA (235 µL, 1.37 mmol, 3.5 equiv) in dry 
DMF (3 mL). The resulting suspension was shaken at 280 rpm for 30 h, 
the solution was unloaded, and the resin was washed by shaking with dry 
DMF (5 x 3 mL). The resulting swelled resin was used in the next step.
5.1.1.2. 2-Chlorotrityl-Gly-L-allo-Thr(TBS)-Fmoc resin (153)
The polypropylene syringe loaded with the swelled resin 152 was 
treated with 20% piperidine in DMF (3 x 3 mL x 20 min). After the last 
run, the resin was washed with dry DMF (5 x 3 mL) and loaded with a 
solution of Fmoc-L-allo-Thr(TBS)-OH (355 mg, 0.78 mmol, 2.0 equiv), 
HOBt (107 mg, 0.78 mmol, 2.0 equiv) and DIC (155 µL, 1.0 mmol, 2.5 
equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 
rpm for 24 h, and then, the solution was unloaded, and the resin washed 




The polypropylene syringe loaded with the swelled resin 153 was 
treated with 20% piperidine in DMF (3 x 3 mL x 20 min). After the last 
run, the resin was washed with dry DMF (5 x 3 mL) and loaded with a 
solution of Fmoc-L-Ser(Bzl)-OH (559 mg, .1.18 mmol, 3.0 equiv), HOBt 
(161 mg, 1.17 mmol, 3.0 equiv) and DIC (216 µL, 1.37 mmol, 3.5 equiv) 
in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 
24 h, and then, the solution was unloaded, and the resin washed with dry 
DMF (5 x 3 mL). The resulting swelled resin was used in the next step. 
This sequence was repeated with Fmoc-L-allo-Ile-OH (276 mg, 0.78 
mmol, 2.0 equiv), HOBt (107 mg, 0.78 mmol, 2.0 equiv) and DIC (155 
µL, 1.0 mmol, 2.5 equiv), followed by treatment with 20% piperidine in 




2.5 equiv), HOBt (135 mg, 0.98 mmol, 2.5 equiv) and DIC (195 µL, 1.25 
mmol, 3.2 equiv). Finally, the resin was washed with DMF (5 x 3 mL), 
CH2Cl2 (3 x 3 mL), MeOH (3 x 3 mL) and Et2O (3 x 3 mL). The resulting 
resin was dried under vacuum to recover 626 mg of polymer bound N-
Fmoc protected pentapeptide 155.
5.1.1.4. Fmoc-N-Me-L-Leu-L-allo-Ile-L-Ser(Bzl)-L-allo-Thr(TBS)-
Gly-OH (151)
Relesase of a small amount of peptide from resin x (17.5 mg) by 
treatment with CH2Cl2/AcOH/TFE (1.0 ml, 7:2:1) gave the N-Fmoc 
protected pentapeptide 151 (9.6 mg), which revealed a load of 0.6 mmol/
g for resin 155.
Data for 151 (two rotamers in a 2.9:1 ratio): 1H NMR (400 MHz, DMSO-
d6), δ (ppm) major rotamer,: 8.16 (t, J = 5.0 Hz, 1H), 8.05 (d, J = 7.6 Hz, 
1H), 7.99 (d, J = 9.0 Hz, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.1, 
2H), 7.62-7.70 (m, 1H), 7.41 (t, J = 7.5 Hz, 2H), 7.24 - 7.33 (m, 7H), 
4.65-4.70 (m, 2H), 4.48 (m, 2H), 4.38 (dd, J = 9.0, 7.2 Hz, 1H), 4.25 - 
4.45 (m, 4H), 4.01 (q, J = 6.5 Hz, 1H), 3.77 (dd, J = 17.5, 6.2, 1H), 3.52 - 
3.59 (m, 3H), 2.79 (s, 3/4H), 2.68 (s, 9/4H), 1.73 - 1.84 (m, 3/4H), 1.47 
-1.61 (m, 2H), 1.21 - 1.36 (m, 2H), 1.05 (d, J = 6.2 Hz, 3H), 0.95 - 1.07 
(m, 1H), 0.88 (d, J = 6.6 Hz, 3H), 0.80 (s, 9H), 0.71-0.89 (m, 9H), 0.01 (s, 
3H), 0.03 (s, 3H). FAB HRMS (NBA) m/e 930.5049, calcd for 




5.2. Solid Phase Synthesis of Peptide 157
As part of a collaboration with the Department of Ecology of the 
University of Málaga, the solid phase synthesis of the inhibitor 
AcArgValArgArgCMK, that is currently under biological 
evaluation, was also accomplished according to the retrosynthetic analysis 
depicted in Scheme 5.3.
Thus, for the tripeptide 158, Fmoc-L-Arg(Boc)2-OH was linked 
onto the 2-chlorotrityl chloride (CTC) resin by esterification with DIPEA 
to afford resin 160. Once the Fmoc group was removed by treatment with 
a 20% solution of piperidine in DMF, the following Fmoc aminoacid 
derivative, Fmoc-L-Val-OH, was loaded onto the resulting resin by the 
action of DIC in the presence of HOBt in DMF. To check the loading of 
the amino acid, we decided to cleave the dipeptide by treatment of 161 
with CH2Cl2/AcOH/CF3CH2OH (TFE) (7:2:1), which gave pure 
dipeptide 162. The synthesis was continued by repeating the procedure of 
coupling and Fmoc deprotection steps for Fmoc-L-Arg(Boc)2-OH. The 
treatment with piperidine was accomplished to remove the Fmoc group 
































































prior to the subsequent acetylation with Ac2O and pyridine that afforded 
the acyl resin 164, which was then treated with CH2Cl2/AcOH/
CF3CH2OH (7:2:1) to provide pure tripeptide 158 in an amount that 
revealed a load of  0.3 mmol/g for resin 164.
Reagent and Conditions: (a) Fmoc-L-Arg(Boc)2-OH, DIPEA, DMF, 25ºC, 24 
h. (b) 20% Piperidine in DMF, 25ºC, 30 min; Fmoc-L-Val-OH, DIC, HOBt, 
DMF, 25ºC, 24 h. (c) CH2Cl2, AcOH, CF3CH2OH (7:2:1), 30 min. (d) 20% 
Piperidine in DMF, 25ºC, 30 min; Fmoc-L-Arg(Boc)2-OH, DIC, HOBt, DMF, 
25ºC, 24 h. (e) 20% Piperidine in DMF, 25ºC, 30 min; Ac2O/Pyr, DMF, 25ºC, 24 
h (Load: 0.3 mmol/g for resin 164).
For the preparation of the chloromethyl ketone 159 we followed 
the procedure described by Sun and co-workers,10 in which the protected 









































































amino acid Boc-L-Arg(Mtr)-OH was reacted with diazomethane11 to 
afford diazo ketone Boc-L-Arg(Mtr)-CHN2 (165), which was subsequently 
subjected to the action of HCl in methanol, which provided the desired 
Arg-(Mtr)-chloromethyl ketone 159 as its hydrochloride salt (Scheme 
5.5). The final coupling of 159 with tripeptide 158 by the action of DIC 
in the presence of HOBt in DMF followed by treatment with thioanisol in 
TFA provided the coveted tetrapeptide 157 in 64% yield over 3 steps, as 
depicted in Scheme 5.5.
Reagents and Conditions: (a) (CH3)2CHOCOCl, NMM, CH2N2, THF -20ºC 
to 0ºC, 4 h, 52%. (b) MeOH·HCl, THF, 25ºC, 24 h.  (c) 158, DIPEA, DIC, 
HOBt, CH2Cl2, 25ºC, 24 h. (d) TFA, thioanisol, 25ºC, 20 h, 64% (over 3 steps).







































































5.2.1.1. 2-Chlorotrityl-L-Arg(Boc)2-Fmoc Resin (160).
A 5 mL polypropylene syringe fitted with polyethylene porous disk 
charged with 2-chlorotrityl chloride resin (200 mg, Load = 1.2 mmol/g, 
0.24 mmol, 1.0 equiv), was loaded with a solution of Fmoc-L-Arg(Boc)2-
OH (286 mg, 0.48 mol, 2.0 equiv) and DIPEA (105 µL, 0.6 mmol, 2.5 
equiv) in dry DMF (3 mL). The resulting suspension was shaken at 300 
rpm for 24 h, the solution was unloaded, and the resin was washed by 
shaking with dry DMF (5 x 3 mL). The resulting swelled resin was used in 
the next step.
5.2.1.2. 2-Chlorotrityl-L-Arg(Boc)2-L-Val-Fmoc Resin (161).
The polypropylene syringe loaded with the swelled resin 160 was 
treated with a 20% piperidine solution in DMF (2 x 3 mL x 10 min). After 
the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded 
with a solution of Fmoc-L-Val-OH (163 mg, 0.48 mmol, 2.0 equiv), HOBt 
(66 mg, 0.48 mmol, 2.0 equiv) and DIC (94 µl, 0.6 mmol, 2.5 mmol) in dry 
DMF (3 mL). The resulting suspension was shaken at 300 rpm for 24 h, 
and then, the solution was unloaded and the resin washed with dry DMF 
(5 x 3 mL). The corresponding swelled resin was used in the next step.
5.2.1.3. 2-Chlorotrityl-L-Arg(Boc)2-L-Val-L-Arg(Boc)2-Fmoc Resin 
(163).
The polypropylene syringe loaded with the swelled resin 161 was 
treated with a 20% piperidine solution in DMF (2 x 3 mL x 10 min). After 
the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded 
with a solution of Fmoc-L-Arg(Boc)2-OH (286 mg, 0.48 mmol, 2.0 equiv), 
HOBt (66 mg, 0.48 mmol, 2.0 equiv) and DIC (105 µl, 0.6 mmol, 2.5 




rpm for 24 h, and then, the solution was unloaded and the resin washed 
with dry DMF (5 x 3 mL). The corresponding swelled 163 resin was used 
in the next step.
5.2.1.4. 2-Chlorotrityl-L-Arg(Boc)2-L-Val-L-Arg(Boc)2-acetyl Resin 
(164).
The polypropylene syringe loaded with the swelled resin 163 was 
treated with a 20% piperidine solution in DMF (2 x 3 mL x 10 min). After 
the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded 
with a solution of Ac2O (110 µL, 1.2 mmol, 5.0 equiv) and pyridine (96 
µL, 1.2 mmol, 5.0 equiv) in dry DMF (3 mL). The resulting suspension 
was shaken at 300 rpm for 24 h, and the solution was then unloaded and 
the resin washed with dry DMF (5 x 3 mL). The resulting swelled resin 
164 was used in the next step.
5.2.1.5. Ac-L-Arg(Boc)2-L-Val-L-Arg(Boc)2-OH (158)
The polypropylene syringe loaded with the swelled resin 164 was 
treated with a 20% piperidine solution in DMF (2 x 3 mL x 10 min). After 
the last run, the resin was washed with dry DMF (5 x 3 mL). Release of a 
small amount of peptide from resin 4 (47 mg) by treatment with CH2Cl2/
AcOH/TFE (1.0 mL, 7:2:1) gave the unprotected tripeptide 5 (27 mg) 
which revealed a load of  0.3 mmol/g for resin 158.
1H RMN (400 MHz, CDCl3), δ (ppm) 8.40 (d, J = 31.6 Hz, 2H), 7.62 (d, 
J = 8.0 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.21 (d, J = 7.1 Hz, 1H), 4.55 
(td, J = 8.1, 5.2 Hz, 1H), 4.48 (dt, J = 7.7, 6.0 Hz, 1H), 4.30 (dd, J = 8.6, 
6.4 Hz, 1H), 3.55 - 3.25 (m, 5H), 2.04 (s, 3H), 1.97 - 1.57 (m, 11H), 1.51 - 





Commercially available BocArg(MTr)-OH (165) (500 mg, 1.03 
mmol, 1.0 equiv) was dissolved in THF (10 mL) and cooled at -20ºC. Over 
this solution NMM (0.17 mL, 1.54 mmol, 1.5 equiv) was added, followed 
by isopropyl chloroformate 1.0 M in toluene (1.54 mL, 1.54 mmol, 1.5 
equiv) and the reaction mixture was stirred for 4 h at the same 
temperature. The mixture was then filtered off and an ethereal solution of 
diazomethane11 (4 mL) was added at -20ºC. The reaction was allowed to 
reach 0ºC and after 1 h, the solvent was removed under vacuum and the 
corresponding crude diazo ketone was purified by flash column 
chromatography (EtOAc) to obtain pure diazo 166 (270 mg, 52%) as 
white needles, whose spectral data matched literature values.10
5.2.1.7. H-Arg(MTr)CH2Cl·HCl (159)
BocArg(MTr)CHN2 (270 mg, 0.53 mmol, 1.0 equiv)  was dissolved 
in THF (5 mL) and allowed to react with methanolic HCl 1.8 N (1.5 mL, 
2.6 mmol, 5.0 equiv) at rt until nitrogen evolution ceased (~40 min). The 
solvent was removed by evaporation at rt and the residue was taken up in 
5 mL of 1.8 N methanolic HCl under N2. After stirring the solution for 30 
min at rt, 240 mg of a white solid was obtained by evaporating the solvent. 
The residual solvent was removed in vacuo over a 24 h period and the 




The corresponding acid 158 (27 mg, 31 µmol, 1.0 equiv) was then 
dissolved in dry CH2Cl2 (1 mL) and over this solution HOBt ( 5 mg, 33 




reaction mixture was stirred for 10 min after which the hydrochloride 159 
(15 mg, 33 µmol, 1.0 equiv) dissolved in CH2Cl2 (1 mL) was added, 
followed by DIPEA (23 µL, 132 µmol, 4.0 equiv). The reaction mixture 
was stirred overnight at 25ºC and then diluted with CH2Cl2 and H2O. 
Both phases were separated, and the aqueous layer extracted with CH2Cl2 
twice. Combined organic extracts were then washed with water and brine, 
filtered and concentrated to obtain protected tetrapeptide 167 that was 
used in the next step without further purification.
5.2.1.9. Ac-L-Arg-L-Val-L-Arg-L-Arg-CH2Cl (157)
Tetrapeptide 167 was dissolved in a 95% aqueous TFA solution 
(160 µl) and treated dropwise with thioanisole (8 µL, 66 µmol, 14.0 equiv). 
The resulting dark solution was stirred for 20 h at rt and then 
concentrated under vacuum. The corresponding unprotected peptide was 
purified by preparative HPLC (30% CH3CN/H2O) to afford 3 mg of the 
tris-trifluoracetate salt 157 as a colourless oil (64% yield over 3 steps).
1H NMR (400 MHz, DMSO-d6), δ (ppm): 8.49 (d, J = 6.9 Hz, 1H), 8.37 
(d, J = 6.7 Hz, 1H), 8.35 8.23 (m, 2H), 8.10 (dd, J = 24.7, 7.8 Hz, 2H), 
7.71 - 7.57 (m, 3H), 7.56 7.52 (m, 1H), 7.49 - 6.77 (m, 10H), 4.54 (s, 1H), 
4.34 - 4.15 (m, 4H), 4.13 - 4.05 (m, 2H), 3.15 (d, J = 4.3 Hz, 4H), 3.13 - 
3.10 (m, 2H), 2.03 - 1.87 (m, 2H), 1.84 (d, J = 3.8 Hz, 3H), 1.69 - 1.56 (m, 
3H), 1.54-1.37 (m, 5H), 0.87 - 0.80 (m, 4H); HRMS (ESI) m/e 1002.90 




5.3. Solid Phase Synthesis of Epibestatin
Bestatin analogue [(2R,3R)-3-amino-2-hydroxy-4-phenyl-
butanoyl]-L-leucine (168), also known as epibestatin, was first described by 
Takita et al. who isolated it from a culture of Streptomyces olivoreticuli in 
1976.12,13 Although bestatin, as well as the others analogues, is a dipeptide 
with potent cytotoxicity against aminopeptidase B and leucine 
aminopeptidase, the case of epibestatin is particularly interesting. If the 
inhibitory activity of bestatin is attributable to five-membered chelate ring 
formation by a pair of adjacent amino and hydroxyl groups of bestatin 
and a metal ion of the enzyme, the isomers possessing erythro-AHPA, as 
for the case of epibestatin, do not form the chelate ring, resulting in a loss 
of  the inhibitory activity.12
Nevertheless, epibestatin was recently identified as one of the 
molecules that selectively stabilize the 14-3-3/PMA2 complex,14 involved 
in the regulation of several hundred proteins, among them important 
pharmaceutical targets such as Raf, p53, Cdc25, Cdk2, and histone 
deacetylases (HDACs).15 This remarkable activity makes epibestatin a 
valuable tool in investigating the biology of 14-3-3 protein-protein 
interactions and migh be promising starting points for the development of 
medicinally active agents.14
Although a bunch of synthesis of epibestatin has been already 
described, we decided to apply the solid phase peptide synthesis in 
combination with the chiral sulfur ylide methodology to prepare it in 
efficient, stereoselective and expedient manners. Thus, the route depicted 
in Scheme 5.6 constitutes a straightforward procedure for making 
epibestatin (168) in solid phase. The process involves the linking of the 
starting amino acid Fmoc-L-Leu-OH onto the 2-chlorotrityl chloride 
(CTC) resin by esterification with DIPEA to afford resin 170. Subsequent 
removal of the Fmoc group by treatment with piperidine in DMF and 




epoxidation methodology, by the action of DIC in the presence of HOBt 
in DMF provided resin 172. For the azide opening of the corresponding 
epoxy peptide 172 different conditions were tested and we found that 
opening of the oxirane ring with Mg(N3)2, prepared in situ by combination 
of NaN3 and MgSO4 in DMF at 65ºC seemed to be the most efficient, as 
described by Sharpless et al.16 Despite several attemps were tested to 
reduce the azido group via Staudinger’s reaction, no signicant trace of 
epibetatin was obtained after resin cleavage (Scheme 5.6).
Reagents and Conditions: (a) 20% Piperidine in DMF, 25ºC, 30 min; 171, 
DIC, HOBt, DMF, 25ºC, 16 h. (b) NaN3, MgSO4,  DMF, 65ºC, 16 h. (c) Ph3P, 
THF-H2O (2:1), 25ºC, 16 h. (d) CH2Cl2, AcOH, CF3CH2OH (7:2:1), 30 min.
For the synthesis of the epoxy acid 171, known corresponding 
epoxy amide17 was used as starting material, reduced into the epoxy 
alcohol by the action of Super-H and converted into the carboxylic acid 
under TEMPO/BAIB.

























































We therefore decided to continue with the synthesis even if solid 
phase methodology was discarded. Hence, epoxy acid 171 was coupled 
with protected Fmoc-L-Leu(OBn) by the action of DIC in the presence of 
HOBt, to obtain epoxy amide 174 in 94%. Then the oxirane ring opening 
reaction with Mg(N3)2 proceeded in a regioselective way in 40% yield by 
using the same conditions described above.16 Reduction of the azide 
group and benzyl ester was undertaken in one step by treatment of 
protected azido derivative 175 with H2 in the presence of catalyst to 
afford epibestatin, whose spectral data matched literature values (Scheme 
5.7).12
Reagents and conditions: (a) Fmoc-L-Leu(Obn),  DIC, HOBt, DMF, 25ºC, 16 
h, 94%. (b) NaN3, MgSO4, MeOH, 65ºC, 16 h, 40%. (c) H2, Pd/C, EtOAc, 
25ºC, 16 h, 67%.
5.3.1. Experimental Section
5.3.1.1. Synthesis of Epoxy Amide 174
The epoxy acid 171 (60 mg, 0.33 mmol, 1.0 equiv) and the amino 
acid Fmoc-L-Leu(OBn) (111 mg, 0.5 mmol, 1.5 equiv) were dissolved in 
DMF (5 mL) and treated with DIC (0.1 mL, 0.8 mmol, 2.5 equiv), and 
HOBt (95 mg, 0.7 mmol, 2.0 equiv) at 25ºC. After stirring overnight at 
































this temperature, the crude mixture was diluted with Et2O and washed 
with a saturated aqueous NH4Cl solution. The aqueous phase was 
extracted with Et2O and the combined organic phases were washed with 
brine, dried over anhydrous MgSO4 and the solvent was evaporated under 
vacuum. Purification of the obtained crude product by flash column 
chromatography (silica gel, 30% EtOAc in hexanes) provided epoxy amide 
174 (118 mg, 94%) as a colourless oil.
Rf = 0.65 (Silica gel, 40% EtOAc in hexanes). 1H NMR (400 MHz, 
CDCl3) δ (ppm):7.38 - 7.28 (m, 8H), 7.24 - 7.20 (m, 2H), 6.39 (d, J = 8.9 
Hz, 1H), 5.20 - 5.13 (m, 1H), 4.71 - 4.59 (m, 1H), 3.30 (d, J = 2.1 Hz, 
1H), 3.21 (ddd, J = 6.2, 3.9, 2.1 Hz, 1H), 3.06 (dd, J = 14.8, 3.9 Hz, 1H), 
2.81 (dd, J = 14.8, 6.3 Hz, 1H), 1.75 - 1.58 (m, 3H), 1.52 (dd, J = 9.6, 8.0 
Hz, 1H), 0.92 (d, J = 6.2 Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H). 13C NMR 
(400 MHz, CDCl3), δ  (ppm): 172.19, 168.22, 135.73, 135.24, 129.13, 
128.66, 128.61, 128.46, 128.24, 127.06, 67.14, 59.25, 54.90, 50.07, 41.04, 
37.73, 24.81, 22.84, 21.65.
5.3.1.2. Synthesis of the Azido Alcohol 175
A mixture of epoxy amide 174 (41 mg, 0.1 mmol, 1.0 equiv), 
NaN3 (15 mg, 0.2 mmol, 2.0 equiv) and MgSO4 (15 mg, 0.1 mmol, 1.0 
equiv) was refluxed in MeOH overnight. After removal of the solvent, the 
reaction crude was purified by flash column chromatography (silica gel, 
20% EtOAc in hexanes) to afford 175 (17 mg, 40%) as an amorphous 
white solid.
Rf = 0.60 (Silica gel, 40% EtOAc in Hexane). [α]25D = +7.3 (c 0.7, 
CH2Cl2). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.37 - 7.21 (m, 10H), 6.98 
(d, J = 8.4 Hz, 1H), 4.68 - 4.57 (m, 1H), 4.34 - 4.28 (m, 1H), 3.99 (dt, J = 
10.0, 3.8 Hz, 1H), 3.30 (d, J = 4.8 Hz, 1H), 3.02 (dd, J = 14.2, 3.6 Hz, 




Hz, 6H).13C NMR (400 MHz, CDCl3), δ (ppm): 172.75, 170.16, 137.24, 
129.47, 128.61, 126.89, 73.47, 66.19, 52.41, 50.65, 41.26, 35.01, 24.95, 
22.80, 21.81.
5.3.1.3. Synthesis of Epibestatin 168
Over a solution of the azido alcohol 175 (17 mg, 0.04 mmol, 1.0 
equiv) in EtOAc (3 mL) was added 10% Pd/C (~ 5 mg, 0.04 mmol, 0.1 
equiv). The reaction was stirred under H2 atmosphere overnight, and then 
filtered off through a pad of silica gel. The crude was purified by flash 
column chromatography (silica gel, 5% MeOH in CH2Cl2) to afford 168 
(8 mg, 67% as an amorphous white solid and whose spectral data matched 
literature values.12
Rf = 0.4 (Silica gel, 10% MeOH in CH2Cl2). [α]25D = -1.0 (c 0.6, CH2Cl2). 
1H NMR (400 MHz, D2O): 7.49 - 7.41 (m, 2H), 7.42 - 7.30 (m, 3H), 4.52 
(dd, J = 9.4, 5.4 Hz, 1H), 4.41 (d, J = 3.4 Hz, 1H), 3.57 (d, J = 9.8 Hz, 
1H), 2.95 (dd, J = 13.9, 4.1 Hz, 1H), 2.72 (dd, J = 14.0, 10.1 Hz, 1H), 
1.84 - 1.67 (m, 4H), 1.00 (d, J = 6.1 Hz, 3H), 0.96 (d, J = 6.0 Hz, 3H). 13C 
NMR (101 MHz, CDCl3): 173.20, 129.55, 128.68, 126.62, 124.87, 53.40, 
52.29, 50.61, 29.70, 25.82, 24.96, 22.86, 21.75, 14.20. IR 2936, 2846, 
2110, 1667, 1511, 1464, 1432, 1299, 1117, 1075 cm-1. HRMS (H-ESI) m/




5.4. Solid Phase Synthesis of Celebeside A
Marine sponges belonging to the Teonellidae family have yielded a 
number of unique compounds with a broad spectrum of biological 
activities, including antifungal, antibiotic and antitumoral.18 Among these 
families and despite little has been studied, the genus of Siliquariaspongia 
possesses a wide number of biologically active natural products, such as 
mirabalin,19 a potent antitumor macrolide and mirabamides A-D, 
glycosylated depsipeptides that inhibit HIV-1 fusion.20
Celebesides are a family of unusual cyclodepsipeptides recently 
isolated from the marine sponge Siliquariaspongia mirabilis by Bewley and co-
workers, that contain a polyketide moiety and five amino acid residues. 
This compounds showed activity in HIV-1 neutralization, antifungal, and 
cytotoxicity assays.21 To date six new depsipeptides of two different 
structural classes (celebesides A-C and theopapuamides B-D) have been 
isolated and the absolute configurations elucidated. (Scheme 5.8). 
Interestingly, celebeside A (176) exhibited biological activity as HIV-1 
inhibitor, with an IC50 value of 1.9 ± 0.4 µg/mL as well as cytotoxicity 
against a human colon tumor cell line (HCT-116) with IC50 value of 2.1 
µg/mL. As part of a research programme directed towards the total 
synthesis of celebeside A, we targeted the modified peptidic fragment of 
celebeside A (179), which lacks the methyl group at the Asp residue, in 
order to check the viability of the proposed synthetic strategy. Having 
been described the synthesis of the polyketide chain by Sarabia et al.22 





In this manner, for the synthesis of the tetrapeptide 179, Fmoc-L-
Ser(tBu)-OH was linked onto the 2-chlorotrityl chloride (CTC) resin by 
esterification with DIPEA to afford resin 180. The removal of the Fmoc 
group by treatment of piperidine in DMF, and subsequent peptide 
coupling with Fmoc-L-Asn(Trt)-OH by the action of DIC in the presence 
of HOBt in DMF afforded Fmoc resin 181. A second treatment with 
piperidine in DMF followed by coupling with Fmoc-L-Thr(OTBS), under 
the same conditions, provided Fmoc resin 182. In order to check the 
loading of the amino acid we decided to cleave the tripeptide at this stage 
by treatment of 182 with CH2Cl2/AcOH/CF3CH2OH (TFE) (7:2:1), 
which gave pure tripeptide 183. The synthesis was continued by repeating 
the procedure of Fmoc deprotection and coupling steps for Fmoc-D-
iSer(Bn)-OH. The treatment with piperidine to remove the Fmoc group 
and subsequent cleavage with CH2Cl2/AcOH/CF3CH2OH (7:2:1) 
provided pure tetrapeptide 179 in an amount that revealed a load of 0.2 
mmol/g.







































(176) Celebeside A 





R1 = PO3H2; R2 = C2H5
R1=  PO3H2; R2 = CH3






Reagents and Conditions: (a) Fmoc-L-Ser(tBu)-OH, DIPEA, DMF, 25ºC, 24 
h. (b) 20% Piperidine in DMF, 25ºC, 30 min;  Fmoc-L-Asn(Trt)-OH, DIC, HOBt, 
DMF, 25ºC, 24 h. (c) 20% Piperidine in DMF, 25ºC, 30 min; Fmoc-L-
Thr(OTBS)-OH, DIC, HOBt, DMF, 25ºC, 24 h. (d) CH2Cl2, AcOH, 
CF3CH2OH (7:2:1),  25ºC, 30 min. (e) 20% Piperidine in DMF, 25ºC, 30 min; 
Fmoc-D-iSer(Bn)-OH, DIC, HOBt, DMF, 25ºC, 24 h.































































5.4.1.1. 2-Chlorotrityl-L-Ser(tBu) Fmoc Resin (180)
A 5 mL polypropylene syringe fitted with polyethylene porous disk 
charged with 2-chlorotrityl chloride resin (200 mg, L = 1.2 mmol/g, 0.24 
mmol, 1.0 equiv), was loaded with a solution of Fmoc-L-Ser(tBu)-OH (184 
mg, 0.48 mol, 2.0 equiv) and DIPEA (0.1 mL, 0.6 mmol, 2.5 equiv) in dry 
DMF (3 ml). The resulting suspension was shaken at 300 rpm for 24 h, the 
solution was unloaded, and the resin was washed by shaking with dry 
DMF (5 x 3 mL). The resulting swelled resin was used in the next step.
5.4.1.2. 2-Chlorotrityl-L-Ser(tBu)-L-Asn(Trt) Fmoc Resin (181)
The polypropylene syringe loaded with the swelled resin 180 was 
treated with a 20% piperidine solution in DMF (2 x 3 ml x 10 min). After 
the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded 
with a solution of Fmoc-L-Asn(Trt)-OH (286 mg, 0.48 mmol, 2.0 equiv), 
HOBt (66 mg, 0.48 mmol, 2.0 equiv) and DIC (0.1 mL, 0.6 mmol, 2.5 
mmol) in dry DMF (3 mL). The resulting suspension was shaken at 300 
rpm for 24 h, and then, the solution was unloaded and the resin washed 
with dry DMF (5 x 3 mL). The corresponding swelled resin was used in 
the next step.
5.4.1.3.  2-Chlorotrityl-L-Ser(tBu)-L-Asn(Trt)-L-Thr(TBS)  Fmoc 
resin (182)
The polypropylene syringe loaded with the swelled resin 181 was 
treated with a 20% piperidine in DMF (2 x 3 mL x 10 min). After the last 
run, the resin was washed with dry DMF (5 x 3 mL) and loaded with a 
solution of Fmoc-L-Thr(TBS)-OH (220 mg, 0.48 mmol, 2.0 equiv), HOBt 
(66 mg, 0.48 mmol, 2.0 equiv) and DIC (105 µL, 0.6 mmol, 2.5 equiv) in 




h, and then, the solution was unloaded and the resin washed with dry 
DMF (5 x 3 mL). The corresponding swelled resin was used in the next 
step. Relesase of a small amount of peptide from resin 181 (17.5 mg) by 
treatment with CH2Cl2/AcOH/TFE (1.0 mL, 7:2:1) gave the N-Fmoc 
protected tripeptide 183 (11 mg), which revealed a load of 0.4 mmol/g for 
resin 182.
Data for 183: 1H NMR (400 MHz, CDCl3), δ (ppm): 7.95 (d, J = 7.3 Hz, 
1H), 7.76 (dd, J = 7.6, 2.2 Hz, 2H), 7.58 (t, J = 7.3 Hz, 1H), 7.52 (d, J = 
7.5 Hz, 1H), 7.43 - 7.33 (m, 2H), 7.32 - 7.13 (m, 19H), 6.97 (bs, 1H), 5.71 
(d, J = 7.1 Hz, 1H), 4.88 - 4.74 (m, 1H), 4.59 - 4.46 (m, 1H), 4.41 (dd, J = 
6.4, 3.1 Hz, 1H), 4.36 - 4.29 (m, 2H), 4.21 - 4.11 (m, 2H), 3.75 (dd, J = 
8.8, 4.2 Hz, 1H), 3.44 (t, J = 7.6 Hz, 1H), 3.01 - 2.87 (m, 1H), 2.70 (dd, J 
= 15.4, 6.9 Hz, 1H), 1.13 (s, 9H), 1.12 (d, J = 6.1 Hz, 1H), 0.89 (s, 9H), 
0.10 (s, 3H), 0.07 (s, 3H). 13C NMR (400 MHz, CDCl3), δ (ppm): 172.07, 
171.03, 170.04, 169.85, 156.31, 144.30, 144.04, 143.64, 141.30, 141.26, 
128.72, 127.93, 127.71, 127.67, 127.04, 125.23, 125.15, 119.92, 74.56, 
70.91, 68.14, 67.22, 60.76, 60.04, 52.94, 49.79, 47.12, 38.47, 29.70, 
27.22, 25.87, 19.29, -4.66, -4.92.
5.4.1.4. Fmoc-D-iSer(OBn)-L-Thr(TBS)-L-Asn(Trt)-L-Ser(tBu) 
(179)
The polypropylene syringe loaded with a portion of the swelled 
resin 182 (85 mg) was treated with a 20% piperidine in DMF (2 x 3 mL x 
10 min). After the last run, the resin was washed with dry DMF (5 x 3 mL) 
and loaded with a solution of Fmoc-D-iSer(OBn) (28 mg, 0.07 mmol, 2.0 
equiv), HOBt (10 mg, 0.07 mmol, 2.0 equiv) and DIC (10.0 µL, 0.08 
mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension was 
shaken at 300 rpm for 24 h, and then, the solution was unloaded and the 
resin washed with dry DMF (5 x 3 mL). The corresponding swelled resin 




with CH2Cl2/AcOH/TFE (1.0 mL, 7:2:1) gave the N-Fmoc protected 
tripeptide 179 (20 mg), which revealed a load of 0.2 mmol/g for resin 
184.
Data for 179: 1H NMR (400 MHz, DMSO-d6), δ  (ppm): 8.69 (d, J = 15.1 
Hz, 1H), 8.10 (d, J = 8.6 Hz, 1H), 7.87 (dd, J = 7.5, 2.4 Hz, 1H), 7.69 
(dd, J = 7.7, 3.0 Hz, 1H), 7.50 (dd, J = 14.3, 7.3 Hz, 2H), 7.42 - 7.02 (m, 
26H), 5.00 - 4.86 (m, 1H), 4.66 - 4.54 (m, 1H), 4.51 (d, J = 11.8 Hz, 1H), 
4.42 (d, J = 8.5 Hz, 1H), 4.31 - 4.21 (m, 2H), 4.17 (dd, J = 15.0, 7.7 Hz, 
1H), 4.07 - 3.89 (m, 2H), 3.60 - 3.40 (m, 4H), 3.12 (td, J = 14.3, 13.4, 6.2 
Hz, 1H), 2.75 (d, J = 15.0 Hz, 1H), 2.62 (d, J = 6.3 Hz, 1H), 2.38 - 2.24 
(m, 1H), 1.03 (s, 9H), 0.82 (s, 3H), 0.77 (s, 9H), 0.02 (s, 3H), -0.02 (s, 3H). 
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Conclusions and Future 
Work
In summary, the versatility and utility of the chiral sulfonium salts 
have been demonstrated once again with the synthesis of natural products 
gummiferol and depudecin, and the synthetic epoxy analogues of 
bengamides. The synthetic value of this protocol has been applied to the 
construction of epoxy and di-epoxy key fragments that provide direct 
access to each of the targeted molecules. To this end, a general and 
efficient method for the preparation of enantiopure trans di-epoxides in 4 
steps within moderate to good yields was developed.
Biological evaluation of bengamide analogues 45-46 and 50 did 
not reveal a fumagillin-like interaction with MetAP, as we initially 
assumed. The latter result implicates that the polyol structure of 
bengamides is not amenable to modification, which is in accordance with 
previous reported works.
Additionally, the first steps towards a new type of bengamide 
analogues (aminobengamides) have been established and consolidated 
with the synthesis of the azido derivative 71, in which the azido group can 
be easily inserted by using the Miyashita’s procedure that rendered syn 
azido alcohols.
From a biological point of view, testing of a library of amino 
bengamides analogues with variations in both the caprolactam moiety as 
well as the olefin may provide more potent derivatives in virtue of the 
known affinity of Co+2 for amino groups. Hence, cytotoxicity essays would 
be very helpful in acquiring detailed knowledge regarding the relationship 
between structure and activity. As a continuation of this work, we are 
pursuing efforts to increase the number of new analogues and at present, 
attemps are being made to synthesize 2- and 4- amino bengamides.
The synthesis of the precursor of gummiferol, has been 
completed in 8 steps and 8% overall yield. In this way, an alternative 
formal synthesis to the procedure described by Takamura and co-workers 
has been accomplished. Although the last steps towards gummiferol 
remains still innaccesible, we feel confidents in deprotecting the silyl ether 
and complete the total synthesis.
The synthetic value of the epoxidation protocol based on sulfur 
ylide has been also demonstrated by its application in the concise total 
synthesis of the non-natural enantiomer of depudecin. Although a final 
step still remains unaffordable, we trust that the total synthesis could be 
complete, by conversion of the key fragment triepoxy alcohol 144 into the 
final product. This approach should show broad application in the total 
synthesis of  a range of  depudecin analogues thereof.
In order to achieve further knowledge in other kind of synthesis, 
throughout this time the solid phase peptide syntheses (SPPS) of several 
natural products have been carried out, which has allowed us to gain 
insight into peptide synthesis of molecules such as globomycin, epibestatin 
or celebeside A. This efficient methodology, together with the use of chiral 






La identificación de compuestos capaces de interaccionar de 
forma selectiva con objetivos biológicos específicos y predeterminados, con 
el fin de inhibirlos o activarlos, representa la base para el descubrimiento y 
desarrollo de nuevos fármacos. Además, esta capacidad permite obtener 
una valiosa información para la comprensión del mecanismo de acción 
biológica. Surge así la definida como Biología Química, que incluye el uso 
de compuestos bioactivos como sondas de dianas biológicas, fuente de 
nuevos cabezas de serie en el tratamiento de una determinada 
enfermedad, o como moléculas usadas en la comunicación celular y 
procesos de señalización.
Entre todos los grupos funcionales, el grupo oxirano representa 
uno de los más versátiles en química orgánica, debido a su posible 
funcionalización estereoespecífica y regioselectiva por apertura del anillo 
con diferentes nucleófilos, dando lugar a compuestos bifuncionales, 
resultando muy útil para la síntesis de fármacos y productos naturales.
Dada la importancia química y biológica de la función del anillo 
de oxirano, se han desarrollado múltiples métodos de epoxidación. De 
entre todos los métodos destacan aquellos que generan el epóxido de 
forma enantioselectiva desde compuestos carbonílicos: bien por 
olefinación de Wittig seguida de una oxidación enantioselectiva del doble 
enlace proquiral (métodos oxidativos), o mediante el empleo de un iluro, 
un carbeno o el reactivo de Darzens (métodos no oxidativos) a través de 
una cicloadición enantioselectiva con un carbonilo proquiral.
Dentro de las metodologías oxidativas, la epoxidación asimétrica 
de Sharpless representa uno de los mayores hitos de la síntesis orgánica 
moderna. Sin embargo, los métodos oxidativos presentan ciertos 
requerimientos estructurales (alcoholes alílicos, cis-alquenos, enonas, etc.) y 
limitaciones experimentales (tiempos de reacción elevados, contínua 
adición de agentes oxidantes, excesos enantioméricos moderados, etc.). No 
obstante, a pesar de estas limitaciones, todas estas metodologías siguen 
siendo herramientas sintéticas útiles para obtener epóxidos 
enantioméricamente puros.
En relación a los métodos no oxidativos, de especial interés resulta 
el uso de iluros de azufre, que presentan geometría tetraédrica, y son 
capaces de inducir quiralidad en los compuestos carbonílicos. A pesar de 
ser reacciones en una etapa, no han sido tan ampliamente descritas como 
las metodologías oxidativas, aunque diferentes grupos de investigación han 
contribuído en este área, siendo el grupo del profesor Aggarwal el más 
prolífero.
Especialmente nos centraremos en los iluros de azufre 
estabilizados por amidas, particularmente útiles por tres razones: 1) 
requieren condiciones de reacción suaves y procedimientos simples para 
reaccionar con compuestos carbonílicos, 2) muestran un elevado 
diastereocontrol a favor de los epóxidos trans, y 3) el potencial sintético de 
las amidas glicídicas generadas, que presentan un excelente regiocontrol 
en la posición C2 en las reacciones de apertura con nucleófilos.
Tras los antecedentes sobre la síntesis de amidas glicídicas vía 
iluros de azufre estabilizados, nuestro grupo de investigación abordó la 




diseño y síntesis de una nueva clase de iluros de azufre cíclicos quirales. 
Esta nueva propuesta de iluro de azufre, cuya inducción asimétrica es 
debida al fragmento de amida, preparado desde los aminoácidos 
comerciales L- y D- metionina, originó la síntesis de las correspondientes 
sales de sulfonio, precursoras de los mencionados iluros, según la secuencia 
descrita en el Esquema 1.3, en la que, a través del intermedio de 
cloroacetamida (3) o (5), mediante ciclación en presencia de perclorato 
sódico, y después de recristalización, se obtienen sendas sales de sulfonio 
enantioméricamente puras (4) y (6).
En cuanto a la reactividad, la preparación in situ del 
correspondiente iluro derivado de las sales de derivadas de L- y D- 
metionina (4) y (6), y su posterior reacción con aldehídos, empleando bien 
la metodología en una fase (tBuOH como disolvente y solución acuosa de 
NaOH) o el método de dos fases (mezcla DCM/H2O como disolvente y 
solución acuosa de NaOH), empleado particularmente cuando se 
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encuentran grupos hidroxilo en posiciones adyacentes al carbonilo, 
proporciona sólo uno de los diastereoisómeros posibles de las epoxiamidas, 
con un excelente control estereoquímico como muestra el Esquema 1.4.
Recientemente, se ha realizado la asignación de la configuración 
de estas sales de sulfonio quirales, gracias a estudios de rayos-X. 
Asumiendo que la estereoquímica en el átomo de azufre del iluro 
permanece intacta con respecto a la sal de sulfonio precursora, como 
demostramos experimentalmente por la formación del correspondiente 
iluro de azufre y tratamiento con ácido acético para obtener la sal de 
sulfonio, con similar pureza diastereomérica, racionalizamos la 
estereoselectividad resultante, como se muestra en el Esquema 1.5-B.
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La aproximación por la cara cónvava junto con una disposición 
cisoide entre los reactantes, permitiría al iluro 1 atacar al aldehído por su 
cara re o si. Inicialmente, el ataque hacia la cara si preferida, debería 
proceder a través de los intermedios I y II, tras la rotación del enlace C-C. 
Este mecanismo conduciría a un epóxido tipo cis no detectado debido 
posiblemente a la alta barrera requerida para el cierre del anillo. El ataque 
se produce por tanto por la cara re originando los intermedios I’ y II’, 
siendo el cierre del anillo más favorable en este caso, y proporcionando las 
trans epoxi amidas observadas.
Scheme 1.5-B. Demostración de la estereoquímica en el átomo de azufre de las sales 


































4b (X = AcO)
Me MeX NaOH, tBuOH
AcOH, 0˚ C (cuantitativa)
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De esta forma, tras haber desarrollado recientemente una 
metodología válida para la síntesis de epóxidos, el siguiente paso era la 
aplicación de la misma a la síntesis de productos naturales y análogos que 
presenten una actividad biológica interesante como agentes antitumorales 
y/o antibióticos, como ya se hizo en trabajos anteriores para la síntesis de 
análogos de bengamidas o de los ciclodepsipéptidos naturales 
Globomicina y SF-1904 A5.
El principal objetivo del trabajo desarrollado en esta Tesis 
Doctoral ha sido la síntesis total de productos naturales y/o análogos de 
las familias de bengamidas, gummiferol y depudecina, conteniendo 
grupos epóxido cuya construcción se realizaría aplicando la metodología 
anteriormente descrita. Adicionalmente, durante el transcurso de esta 
investigación se ha llevado a cabo un proyecto paralelo de síntesis orgánica 
en fase sólida, completando la síntesis de las cadenas peptídicas de 
diferentes productos naturales de interés biológico como globomicina, 
epibestatina, y celebésido A, y el tetrapéptido sintético 
AcArgValArgArgCMK, que se encuentra actualmente bajo ensayos 
biológicos de actividad.
Bengamidas
Las Bengamidas, descubiertas en 1986 por Crews y col., 
comprenden una familia de productos naturales aislados de esponjas 
marinas de la familia Jaspidae, con una amplia e interesante actividad 
biológica como agentes antibióticos, antihelmínticos y antitumorales.
La actividad antitumoral está relacionada directamente con la 
inhibición de las enzimas metionina aminopeptidasas tipos I (MetAP1) y II 
(MetAP2), involucradas en la proliferación de células endoteliales y 
angiogénesis. Este mecanismo de acción es similar al exhibido por los 
compuestos fumagilina y ovalicina, agentes antitumorales con actividad 
anti-angiogénica, cuya estructura presenta notables diferencias respecto a 
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la de las bengamides. Particularmente, las bengamides se vinculan con el 
sitio activo de la enzima debido a una interacción hidrofóbica del grupo 
alquílico terminal de la olefina con la cavidad P1, una interacción polar de 
la caprolactama con la región P2 expuesta al disolvente y una 
coordinación entre los grupos hidroxilos C-3, C-4 y C-5 de su cadena 
policétida con iones cobalto presentes en el centro activo (Figura 2.11).
Con el objetivo de diseñar derivados de bengamidas que puedan 
mimetizar la interacción de fumagilina en el centro activo de la enzima, 
mediante una unión covalente al átomo de nitrógeno del anillo de 
imidazol del residuo de His231, tal y como muestra la Figura 2.13, se han 
planteado los epoxi- derivados de bengamida E como interesantes 
analógos. En todos ellos se han sustituído los grupos hidroxilo de la cadena 
policétida de las bengamidas por anillos de oxirano, cuya síntesis se 
plantearía mediante la metodología de epoxidación asimétrica via sales de 
sulfonio quirales. La evaluación biológica de éstos, permitiría completar 








































Por otro lado, se ha planteado una sustitución en la olefina 
terminal de las bengamidas. De esta forma, se ha reemplazado el grupo 
isopropilo característico de la bengamide E, por el grupo alostérico TMS- 
que permitiría nuevas funcionalizaciones en esta posición debida a la 
conocida reactividad de los vinil silanos. Adicionalmente, y aprovechando 
la metodología sintética descrita anteriormente, se ha iniciado la síntesis 
del amino derivado en C4, que puede presentar una mayor interacción 
con los cationes Co (II) presentes en el centro activo de la enzima, 































































Figura 2.13. Epoxi bengamidas como nuevos potentiales inhibidores tipo-fumagilina
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La síntesis de los 2,3:4,5-diepoxi- (45) y 4,5-epoxi- (46) derivados 
de bengamide E se ha establecido desde el reactivo comercial 
isobutiraldehído (49), que proporciona el grupo isopropilo terminal 
presente en la parte olefínica de las bengamidas (Esquema 2.1).
Por otra parte, los silil derivados pueden ser fácilmente obtenidos 
siguiendo un esquema sintético análogo empleando alcohol propargílico 

















Figura 2.14. Amino bengamidas como nuevos inhibidores






































Para la síntesis del amino derivado en C4, se ha diseñado una 
estrategia que involucra la apertura del correspondiente ɣ,ẟ-epoxi éster 
α,β-insaturado (57) utilizando para ello la metodología descrita por 
Miyashita que proporciona syn azido alcoholes, tal y como muestra el 
Esquema 2.3.
Esquema 2.2. Análisis retrosintético de los epoxi- análogos de bengamida E 
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La síntesis de la epoxiamida 58 derivada de isobutiraldehído (49) 
y que representa un precursor común para los análogos 45, 46 y 47 se 
completó tal como muestra el Esquema 2.4, mediante una secuencia de 
reacciones que implica formación y reducción del éster α,β-insaturado, 
posterior oxidación al aldehído y tratamiento con la sal de sulfonio 
procedente de L-metionina (4).
Reactivos y condiciones:  (a) Ph3PCHCO2Et,  DCM, 25ºC, 87%. (b) DIBAL-
H, -78ºC, 30 min, 75%. (c) MnO2, DCM, 25ºC, 12 h. (d). 4,  3 M NaOH, 
tBuOH, 25ºC, 16 h, 58% (sobre 2 etapas).
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Por otra parte, la epoxiamida (64) derivada del alcohol 
propargílico (54) se sintetizó mediante la secuencia de reacciones descrita 
en el Esquema 2.6, con un rendimiento global de 75% sobre 4 etapas.
Reactivos y condiciones: (a) EtMgBr, TMSCl, 0ºC (b) Red-Al, THF, 0ºC, 45 
min. (c) MnO2, DCM, 16 h. (d) 4, 5.0 M NaOH, tBuOH, 25ºC, 75% 
(rendimiento global).
La síntesis de los epoxi- y diepoxi- derivados de bengamida E se 
completó según muestran los Esquemas 2.5 y 2.7. La formación de las 
diepoxiamidas 48 y 53 se completó mediante reducción de las 
epoxiamidas 58 y 64 a los correspondientes epoxi- aldehídos, por acción 
de Red-Al, y posterior acoplamiento con la sal de sulfonio (4) en medio 
básico. La posterior reducción con Super-H rindió los diepoxi- alcoholes 
47 y 52, desde los que se obtuvieron los diepoxi- derivados 45 y 50, 
mediante oxidación del alcohol al ácido carboxílico y posterior 
acoplamiento peptídico con 62. La síntesis de los epoxi- derivados 46 y 51 
requiere un paso adicional de apertura anti del epoxi alcohol bajo 
condiciones de Miyashita, completando posteriormente la síntesis como se 
ha descrito para los diepoxi- derivados.
Esquema 2.6. Sí´ntesis de la epoxiamida 64
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Reactivos y conditiones (a) Red-Al, THF, 0ºC, 45 min. (b) 4, 5.0 M NaOH, 
CH2Cl2-H2O, 25ºC, 85% para 48, 84% para 53 (sobre 2 etapas). (c) Super-H, 
THF, 0ºC, 30 min, 70% para 46, 55% para 51. (d) B(OMe)3,  DBU, MeOH, 
reflux, 12 h. (e) TEMPO/BAIB, ACN-H2O, 25ºC, 16 h. (f) 62, BOP, DIPEA, 
DMF, 25ºC, 16 h, 55% para 45 (desde 52), 30% para 50 (desde 52), 47% para 
46 (desde 52) ,26% para 51 (desde 52).
Una vez obtenidos los epoxi- y diepoxi- análogos 45-46 y 50-51, 
se procedió a evaluar la actividad antitumoral de los tres primeros, para 
determinar la influencia de las modificaciones estructurales realizadas en 
la actividad antiproliferativa. Así, las medidas de IC50 se realizaron frente a 
un panel de diferentes líneas de células tumorales (HL60, MDA-MB-231, 
HT1080, HT20 y BAE), empleando bengamide E (11) y fumagilina (38) 
como control. Desafortunadamente, los resultados biológicos revelaron 
que la sustitución en la cadena policétida por grupos oxirano producía una 














(58) R = (CH3)3CH-
(64) R = TMS-
(48) R = (CH3)3CH-
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(61) R = (CH3)3CH-
(65) R = TMS-
(46) R = (CH3)3CH-
(51) R = TMS-
(45) R = (CH3)3CH-













pérdida total de actividad, indicando que no existe un modo de acción 
tipo fumagilina, como asumimos en un principio.
Por otro lado, para la síntesis de la C4 amino bengamida se 
procedió, desde la epoxiamida 58 a la obtención del epoxi- éster 57 
(Esquema 2.8), desde el cuál, mediante la metodología de Miyashita se 
sintetizó el syn azido alcohol 56 (Esquema 2.9).
Reactivos y condiciones: (a) Red-Al, THF, 0ºC, 45 min. (b) Bu3P=CHCO2Et, 
CH2Cl2, 12 h, 82% (sobre 2 etapas).
Reactivos y condiciones:  (a) TMSN3, Pd(PPh3)4, 25ºC, 5 h, después ácido 
cítrico 10% en MeOH, 82%.
Desde aquí, la síntesis se completa según describe el Esquema 
2.10, mediante reacción de epoxidación asimétrica de Sharpless, y 
posterior apertura con MeOH, oxidación y acoplamiento peptídico, tal y 
como se realizó para los derivados anteriores. De esta forma, tras 
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desprotección del silil éter, se ha sintetizado el azido derivado 71, del que 
se están realizando pruebas de reducción para obtener el amino análogo 
55 (Esquema 2.10).
Reactivos y condiciones: (a) TBSOTf, 2,6-lutidina, CH2Cl2,  25ºC, cuant. (b) 
DIBAL-H, -78ºC, 45 min, 82%. (c) SAE, D-(-)-DET, 10%. (d) B(OMe)3, DBU, 
MeOH, reflujo, 16 h. (e) TEMPO/BAIB, CH3CN-H2O, 25ºC, 16 h. (f) 62, BOP, 
DIPEA, DMF, 25ºC, 16 h,  86% (sobre 3 etapas). (g) TBAF, THF, 0ºC, 40 min, 
55%. h. Staudinger


































































El gummiferol, aislado de las hojas de Adenia gummifera en 1995 por 
Wall et al. presenta en su estructura, además de un sistema triacetilénico, 
dos epóxidos contiguos cuya configuración absoluta ha sido recientemente 
determinada por el grupo de Takamura et al. describiendo además la que 
es la única síntesis total hasta la fecha. Este producto exhibía un valor de 
ED50 de 1.1 µg/ml en el ensayo con células de carcinoma epidermoide 
humano (KB) siendo causa de la actividad citotóxica observada la 
concominante presencia de un sistema altamente insaturado así como los 
anillos contiguos de oxirano. Así, este compuesto exhibe una alta 
citotoxicidad frente a varias líneas celulares, destacando su fuerte actividad 
contra P-388 (leucemia linfocítica de ratón) y U-373 (carcinoma de mama 
humano), lo que le confiere un especial interés por la síntesis tanto del 
producto natural como de sus posibles análogos sintéticos.
Considerando la prometedora actividad biológica como 
anticancerígeno, y como alternativa a la primera síntesis del gummiferol, 
que emplea la metodología de epoxidación asimétrica de Sharpless, se ha 
desarrollado una nueva estrategia sintética, empleando para ello iluros de 
azufre quirales, como se describió anteriormente para la síntesis de los 
diepoxi- análogos de bengamides.
El análisis retrosintético del gummiferol se presenta en el 
Esquema 3.4, donde mediante desconexión del sistema triacetilénico se 
obtienen el diepoxi alquino 94 y el halo derivado 91 como principales 
building blocks, que podrían acoplarse mediante una reacción tipo Cadiot-
Chodkiewicz.
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La síntesis del halo derivado se planteó siguiendo la metodología 
descrito por Fiandenese et al. que permite obtener el yodo alcohol 
protegido 92 en 5 etapas (Esquema 3.5).
Reactivos y condiciones: (a) MeLi-LiBr, Et2O, 0ºC, 8 h. (b) (CH2O)n, Et2O, 
0ºC, 8 h. (c) K2CO3, MeOH, 25ºC,12 h. (d) TBSOTf, 2,6-lutidina, CH2Cl2, 0ºC 
a rt, 3 h. (e) KOH, I2, H2O-MeOH, 0ºC to rt. (f) TBSOTf, 2,6-lutidina, CH2Cl2, 
0ºC a rt, 3 h, 68% rendimiento global.



























(90) X = H; R = H
(91) X = I; R = H
(92) X = I ; R = TBS
(77) X = H; R = OTBS
TBSO OH
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En una primera aproximación, procedimos a realizar la síntesis 
del fragmento 94 desde el D-isopropilidén gliceraldehído (99), utilizando 
para tal fin diferentes sales de sulfonio, obteniendo en todos los casos 
crudos de reacción complejos y rendimientos extremadamente bajos, lo 
que nos llevó a cambiar de metodología.
Debido a los resultados anteriores, desarrollamos un esquema 
sintético que combinara la metodología de epoxidación asimétrica de 
Sharpless (SAE) y la de los iluros de azufre quirales. Se sintetizaron así las 
epoxiamidas 107 y ent-107 en buen rendimiento, y desde las cuáles, se 
accedió a los diepóxidos 108 y ent-108, cuya desprotección, oxidación y 
acoplamiento rendiría el deseado diepoxi alquino 94 y ent-94.
Sin embargo, tras realizar diferentes pruebas de oxidación del 
alcohol resultante de la desprotección de los silil éteres 110 y ent-110, el 
acoplamiento posterior con el reactivo de Ohira-Bestmann no condujo en 
ninguno de los casos a los correspondientes alquinos, por lo que una nueva 
modificación se realizó en el esquema general de la síntesis de los 
dialquinos 94 y ent-94.
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Reactivos y condiciones: (a) PCC, NaOAc, CH2Cl2, 25ºC, 16 h. (b) DIBAL-
H, CH2Cl2, -78ºC, 45 min (c) SAE, 73% para ent-106, 65% para 106 (sobre 2 
etapas).  (d) SO3·Pyr, CH2Cl2, DMSO, 0ºC a rt. (e) 4 or 6, 5.0 M NaOH, CH2Cl2-
H2O, 57% para ent-107,  60% para 107 (sobre 2 etapas). (f) Red-Al,  THF, 0ºC, 45 
min. (g) Ph3PCHCO2Et, CH2Cl2, 25ºC, 57% para ent-108,  60% para 108 (sobre 
2 etapas).  (h) DIBAL-H, CH2Cl2, -78ºC, 45 min, 76% para ent-109, 36% para 
109. (i) Ac2O, Pyr, 25ºC, 12 h, 73% para ent-110, 30% para 110. (j) TBAF (k) 
SO3·Pyr, CH2Cl2, DMSO, 0ºC a rt;  oxidación de Swern; TEMPO/BAIB, 
CH3CN-H2O, 25ºC, 16 h; PCC, NaOAc, CH2Cl2, 25ºC, 16 h. (l) reactivo OB, 
K2CO3.

































ent-(109) R = OH
ent-(110) R = OAc
(108)
a-c
d, e d, e








(109) R = OH








Utilizando esta vez la metodología de los iluros de azufre como 
único método de epoxidación se sintetizaron sendos precursores de (+) y 
(-)-gummiferol, en una secuencia que comprende inicialmente la síntesis 
de las diepoxiamidas ent-113 y 113, y ent-114 y 114 (Esquema 3.9). Para 
tal fin, se emplearon precursores sililados en forma de TBS- y TBDPS-, 
obteniendo los mejores resultados para este último grupo protector 
(Esquema 3.9).
Reactivos y condiciones: (a) PCC, NaOAc, CH2Cl2, 25ºC, 16 h. (b) 4 o 6, 3.0 
M NaOH, tBuOH, 25ºC, 12 h, 40% para ent-111,  40% para 111, 40% para 
ent-112,  40% para ent-112 (sobre 2 etapas). (c) Red-Al,  THF, 0ºC, 45 min to 1 h. 
(d) 4 or 6, 5.0 M NaOH, CH2Cl2, rt,  95% para ent-113, 61% para 113, 95% 
para ent-114, 70% para 114 (sobre 2 etapas).
Posteriormente se procedió a la conversión en el correspondiente 
trialquino y con ello la finalización de la síntesis. Para ello, se emplearon 
las metodologías de Ohira-Bestmann y Corey-Fuchs para instalar el 
alquino terminal, consiguiendo el mejor resultado para ésta última, ya que 
permitió el acoplamiento con el yodo alquino 77, en un 55% sobre 2 
etapas (Esquema 3.10-A y 3.10-B).
















ent-111: R = TBS
ent-112: R = TBDPS
111: R = TBS












c, d c, d
ent-113: R = TBS
ent-114: R = TBDPS
113: R = TBS
114: R = TBDPS
(96a) R = OTBS
(96b) R = OTBDPS
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Reactivos y condiciones: (a) Red-Al, THF, 0ºC, 45 min.  (b) Reactivo Ohira-
Bestmann, K2CO3, MeOH, 25ºC, 16 h. (c) TBAF, THF, 25ºC, 12 h. (d) Ac2O,/
Pyr, 25ºC, 2 h, 5% (d) Ac2O/Pyr, 30% (sobre 2 etapas). (e) Red-Al, THF, 0ºC, 45 
min. (f) CBr4, Ph3P, Et3N, 25ºC, min, 40% (sobre 2 etapas). (g) TBAF, THF, 0ºC, 1 
h. (h) 77, CuI, EtNH2, .(i) Ac2O/Pyr, DMAP, 51% (sobre 3 etapas).
Reactivos y condiciones: (a) Red-Al, THF, 0ºC, 45 min. (b) Reactivo Ohira-
Bestmann, K2CO3, MeOH, 25ºC, 16 h, 44%. (c) TBAF, THF, 25ºC, 12 h (d) 
Ac2O,/Pyr, 25ºC, 2 h (d) Ac2O/Pyr, 25% (sobre 2 etapas). (e) Red-Al,  THF, 0ºC, 







ent-113: R = TBS
ent-114: R = TBDPS
O O
RO
ent-115 R  = OTBS


























113: R = TBS




















115 R  = OTBS




45 min. (f) CBr4, Ph3P, Et3N, 25ºC, min, 40%. TBAF, THF, 0ºC, 1 h. (h) 77, CuI, 
EtNH2. (i) Ac2O/Pyr, DMAP.
Por último, la desprotección del silil éter conduciría a (+) y (-)-
gummiferol. Sin embargo, tras diferentes ensayos con diferentes 
condiciones (TBAF, HF·Pyr) y a pesar de los descrito por Takamura, no se 
ha detectado traza alguna del producto natural y en todos los casos se 
obtuvieron mezclas complejas y productos de descomposición. 
Actualmente, seguimos realizando diferentes pruebas que conduzcan al 
producto natural (Esquema 3.11).
Depudecina
El metabolito microbiano depudecina, descrito por primera vez en 
1991 por Matsumoto et al. es un policétido lineal caracterizado por una 
cadena carbonada altamene oxidada que contiene dos epóxidos 
conjugados a través de un sistema olefínico trans. Este producto natural 
inhibe eficientemente la actividad de la enzima histona deacetilasa tanto in 
vitro como in vivo.
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En comparación a otros inhibidores de histona deacetilasa 
previamente descritos como trapoxina o tricostatina A, depudecina posee 
una estructura química diferente que le permite incrementar su 
selectividad sobre la diana biológica. Este hecho hace de depudecina un 
prometedor compuesto antiangiogénico y una herramienta útil para 
comprender mejor el mecanismo de acción de este tipo de enzimas 
deacetilasas. Bajo esta premisa, se ha diseñado la síntesis total del 
enantiómero de depudecina, aún desconocido, que podría exhibir una 
citotoxicidad similar, empleando para ello la metodología de epoxidación 
asimétrica basada en el uso de iluros quirales de azufre.
Para la síntesis del enantiómero no natural de depudecina ent-
(120)  se planteó, incialmente, una ruta convergente basada en una 
reacción de metátesis cruzada de las olefinas (134) y (137), mediada por el 
catalizador de Hoveyda-Grubbs de 2ª generación. Para tal fin, la olefina 
134 podría ser sintetizada vía iluros de azufre quirales desde el reactivo 
comercial 136, mientras que la olefina 137 se obtiene desde la 
diepoxiamida ent-107, previamente descrita para la síntesis del gummiferol 
(Esquema 4.4-A).






































Desafortunadamente, los bajos rendimientos obtenidos en la 
reacción de metátesis como se detallará más adelante, nos llevaron a 
realizar un cambio en la estrategia, desarrollando así una síntesis lineal, 
como muestra el Esquema 4.4-B.
Cabe señalar que en ambas aproximaciones, los epóxidos 
contenidos en el esqueleto de depudecina se generan vía iluros de azufre 
quirales con la sal de sulfonio 4.
La síntesis del fragmento 135, común a ambas aproximaciones 
sintéticas, procede tal y como muestra el Esquema 4.5. Inicialmente, la 
síntesis del epoxialcohol 135 se planteó por la vía de los iluros de azufre 
para generar la epoxiamida 140; sin embargo, en todas las pruebas 
realizadas se obtuvieron bajos rendimientos y crudos de reacción 
complejos, por lo que se optó por realizar la epoxidación asimétrica de 
Sharpless del alcohol 142, generado desde el éster 141, como muestra el 
Esquema 4.5.
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Reactivos y condiciones: (a) TBSCl,  imidazol,  CH2Cl2, 0ºC. (b) DIBAL-H, 
CH2Cl2, -78ºC, 1 h. (c) 4, 5.0 M NaOH, CH2Cl2-H2O, 25ºC, 16 h. (d) Super-H, 
THF, 0ºC, 15 min. (e) Bu3PCH2CO2Et, NaOH, tolueno-CH2Cl2, 87% (sobre 3 
etapas). (f) DIBAL-H, CH2Cl2, -78ºC, 1 h, 91%. (g) SAE, D-(-)-DET, 90%.
Desde el epoxialcohol 135, se obtiene la olefina 134, mediante 
oxidación al correspondiente aldehído y posterior reacción de Wittig con 
la sal de fosfonio Ph3PCH3Br en medio básico. Por otro lado, la 
diepoxiamida ent-107 se sometió a una reacción de reducción al diepoxi 
aldehído mediada por Red-Al y posterior acoplamiento con la sal de 
fosfonio Ph3PCH3Br, generando así la diepoxi olefina 137. Una vez 
sintetizados ambos fragmentos, se procedió a la metátesis cruzada de 
olefinas catalizada por el reactivo de Hoveyda-Grubbs de segunda 
generación (Esquema 4.6), obeniendo así el triepóxido 143, cuya 
desprotección mediada por TsOH rindió el triepoxi alcohol 144.































Reactivos y condiciones: (a) SO3·Pyr, Et3N, CH2Cl2, DMSO, 0ºC to rt, 4 h. 
(b) Ph3PCH3Br, NaHMDS, 0ºC a rt,  12 h, 50% (sobre 2 etapas). (c) Red-Al, THF, 
0ºC, 45 min. (d) Ph3PCH3Br, NaHMDS, 0ºC a rt, 12 h, 30% (sobre 2 etapas). (e) 
137, catalizador de Hoveyda-Grubbs 2ª generación, CH2Cl2,  45ºC, 72 h, 15%. (f) 
TsOH, 50%. (g) CBr4, Ph3P. (h) Zn (i) TBAF
Desde el triepoxi- alcohol, la síntesis hacia (+)-depudecina se 
completaría mediante reacción de Corey-Fuchs y elminación reductora 
del correspondiente bromoderivado mediada por Zn. Por último, la 
desprotección del silil éter por medio de TBAF, conduciría al producto 
ent-120. Sin embargo, la falta de tiempo ha originado que el esquema no 
haya sido completado aún, y en la actualidad se están realizando pruebas 
para alcanzar el producto natural.
La aproximación lineal, por su parte, comparte con la convergente 
el epoxialcohol 135, que fue transformado en el epoxi éster 145 mediante 
oxidación al correspondiente epoxi aldehído y posterior reacción de 
Wittig-Martin. Desde aquí, la oxidación directa desde el éster al aldehído, 
por medio de 1.0 equivalente de DIBAL-H a 78ºC, seguido de reacción 
























(143) R = OTBS
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con la sal de sulfonio 4 rindió la epoxiamida 139 en un 55% de 
rendimiento sobre 2 etapas (Esquema 4.7).
Reactivos y condiciones: (a) SO3·Pyr, CH2Cl2-DMSO, Et3N, 0ºC. (b) 
Bu3PCH2CO2Et, NaOH, tolueno-CH2Cl2, 62% (sobre 2 etapas) (c) DIBAL-H, 
CH2Cl2, -78ºC, 1 h. d) 4, NaOH, tBuOH, 12 h, 55% (sobre 2 etapas).
Una vez obtenida la epoxiamida 139, se procedió por la vía lineal, 
a obtener la triepoxiamida 138, desde la cuál, por acción de Super-H se 
alcanzó el triepoxi- alcohol 144 (Esquema 4.8).
Esta ruta proporciona una alternativa más eficiente a la 
convergente, en términos de rendimiento, e igualmente se obtiene el 
diepoxi alcohol 144, desde el cuál se están realizando pruebas para su 
conversión en el producto natural (Esquema 4.8)




















Reactivos y condiciones: (a) Red-Al, THF, 0ºC, 45 min. (b) 4, NaOH, 
CH2Cl2-H2O, 30% (sobre 2 etapas). (c) Super-H, THF, 0ºC, 30 min, 60%. (d) 
CBr4, Ph3P. (e) Zn (f) TBAF
Globomicina
El lipociclodepsipéptido glomomicina y sus congéneres 
(Esquema 5.1), aislados de cuatro líneas diferentes de actinomicetes en 
1978, representa una interesante familia de productos naturales debido a 
su actividad antibiótica frente a bacterias Gram-negativa, convirtiéndolo, 
junto con su derivado SF-1902, en una diana para la búsqueda de nuevos 
antibióticos.
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La síntesis de la parte peptídica común a globomicina y SF-1902 
se ha llevado a cabo en fase sólida, siguiendo la metodología Fmoc, 
empleando como resina el cloruro de 2-clorotritilo (Esquema 5.2). De 
esta forma se obtuvo el tetrapéptido 151, en 7 etapas y con un 
rendimiento que revela una carga de 0.6 mmol/g de resina.









































(13) SF-1902 A5 
(147) SF-1902 A4a 
(148) SF-1902 A2 





R = CH3, n = 3
R = CH3, n = 5
R = CH3, n = 4 
R = CH3, n = 1
R = H, n = 3




Reactivos y condiciones: (a) Fmoc-Gly-OH, DIPEA, DMF, 25ºC, 30 h. (b) 
20% Piperidina en DMF, 25ºC, 30 min; Fmoc-L-allo-Thr(TBS)-OH, HOBt, DIC, 
DMF, 25ºC,  24 h.  (c) CH2Cl2, AcOH, CF3CH2OH (7:2:1), 25ºC, 30 min. (d) 20% 
Piperidina en DMF, 25ºC, 30 min; Fmoc-L-Ser(Bzl)-OH, HOBt,  DIC, DMF, 
25ºC, 24 h.  (e) 20% Piperidina en DMF, 25ºC, 30 min; Fmoc-L-allo-Ile-OH, 
HOBt, DIC, DMF, 25ºC, 24 h. (f) 20% Piperidina en DMF, 25ºC, 30 min; Fmoc-
N-Me-L-Leu-OH, HOBt, DIC, DMF, 25ºC,  24 h. (g) 20% Piperidina en DMF 
(Carga: 0.6 mmol/g para resina 155).
Inhibidor AcArgValArgArgCMK
Como parte de una colaboración con el departamento de 
Ecología de la Universidad de Málaga, se ha desarrollado la síntesis del 
péptido de secuencia AcArgValArgArgCMK, que podría presentar una 
importante actividad como inhibidor enzimático de proteasas y que en la 
actualidad se encuentra bajo ensayos biológicos (Esquema 5.3).
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En este caso, y basándonos en la metodología Fmoc, se realizó la 
síntesis en fase sólida del tripéptido 158, en 5 etapas y con un rendimiento 
que revela una carga de 0.3 mmol/g de resina, según muestra el 
Esquema 5.4.
































































Reactivos y condiciones: (a) Fmoc-L-Arg(Boc)2-OH, DIPEA, DMF, 25ºC, 24 
h. (b) 20% Piperidina en DMF, 25ºC, 30 min;  Fmoc-L-Val-OH, DIC, HOBt, 
DMF, 25ºC, 24 h. (c). CH2Cl2, AcOH, CF3CH2OH (7:2:1), 30 min.  (d) 20% 
Piperidina en DMF, 25ºC, 30 min; Fmoc-L-Arg(Boc)2-OH, DIC, HOBt, DMF, 
25ºC, 24 h. (e) 20% Piperidina en DMF, 25ºC, 30 min; Ac2O/Pyr, DMF, 25ºC, 
24 h (Carga: 0.3 mmol/g para resina 164).
Paralelamente, se formó la clorocetona 159 desde el aminoácido 
comercial BocArg(MTr)OH, mediante el empleo de diazometano y 
posterior tratamiento con MeOH·HCl (Esquema 5.5). Finalmente, el 
acoplamiento del ácido 158 y la clorocetona 159, seguido por la 
desprotección de los grupos Boc y MTr con ácido trifluoroacético proveyó 
el tetrapéptido objetivo 157 (Esquema 5.5).
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Reactivos y condiciones:  (a) (CH3)2CHOCOCl, NMM, CH2N2, THF -20ºC 
to 0ºC, 4 h, 52%. (b) MeOH·HCl, THF, 25ºC, 24 h.  (c) 158, DIPEA, DIC, 
HOBt, CH2Cl2, 25ºC, 24 h. (d) TFA, tioanisol, 25ºC, 20 h, 64% (sobre 3 pasos).
Epibestatina
Epibestatina (168), [2S,3R)-3-amino-2-hidroxi-4-fenil-butnoil]-L-
leucina, aislada de cultivos de Streptomyces olivoreticuli, es un dipéptido con 
una potente citotoxicidad contra aminopeptidasa B y leucina 
aminopeptidasa.
Inicialmente se planteó la síntesis en fase sólida, por anclaje del 
aminoácido comercial 169 y acoplamiento del epoxiácido 171 (obtenido 
mediante la metodología de iluros de azufre quirales). Sin embargo, tras la 
apertura regioselectiva mediada por MgSO4, la reducción del grupo azido 






































































al amino en fase sólida, bajo diferentes condiciones de reacción, no pudo 
ser completada, por lo que recurrimos a la síntesis en disolución 
(Esquema 5.6).
Reactivos y condiciones:  (a) 20% Piperidina en DMF, 25ºC, 30 min; 171, 
DIC, HOBt, DMF, 25ºC, 16 h. (b) NaN3, MgSO4,  DMF, 65ºC, 16 h. (c) Ph3P, 
THF-H2O (2:1), 25ºC, 16 h. (d) CH2Cl2, AcOH, CF3CH2OH (7:2:1), 30 min.
La síntesis de epibestatina (168) en disolución pudo ser 
completada desde el azido éster 175, que por reducción con H2, Pd/C 
condujo al mencionado producto natural, en un total de 3 etapas con un 
rendimiento global de 25% (Esquema 5.7).
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Reactivos y condiciones: (a) Fmoc-L-Leu(Obn),  DIC, HOBt, DMF, 25ºC, 16 
h, 94%. (b) NaN3, MgSO4, MeOH, 65ºC, 16 h, 40%. (c) H2, Pd/C, EtOAc, 
25ºC, 16 h, 67%.
Celebésido A
Los celebésidos son una familia inusual de ciclodepsipéptidos 
aislados recientemente de la esponja marina Siliquariaspongia mirabilis por 
Bewley et al., que contienen un sistema policétido y un fragmento 
peptídico de cinco aminoácidos.
Estos compuestos muestran actividad anti VIH, antifúngica, y 
antitumoral. De los 6 miembros aislados de la familia, celebésido A es el 
que presenta un valor más potente de IC50 en su ensayo como inhibidor 
del VIH. Tras haber descrito recientemente la síntesis de la cadena 
policétida, decidimos utilizar la metodología en fase sólida para la síntesis 
de la parte peptídica (Esquema 5.8).
































De esta forma, la síntesis del tetrapéptido correspondiente se 
completó siguiendo un esquema sintético que se detalla en el Esquema 
5.9.







































(176) Celebésido A 





R1 = PO3H2; R2 = C2H5
R1=  PO3H2; R2 = CH3
R1 = H; R2 = C2H5
Péptido modificado
(179)
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Reactivos y Condiciones:  (a) Fmoc-L-Ser(tBu)-OH, DIPEA, DMF, 25ºc, 24 h. 
(b) 20% Piperidina en DMF, 25ºC, 30 min; Fmoc-L-Asn(Trt)-OH, DIC, HOBt, 
DMF, 25ºC, 24 h. (c) 20% Piperidina en DMF, 25ºC, 30 min; Fmoc-L-
Thr(OTBS)-OH, DIC, HOBt, DMF, 25ºC, 24 h. (d) CH2Cl2, AcOH, 
CF3CH2OH (7:2:1), 25ºC, 30 min. (e) 20% Piperidina en DMF, 25ºC, 30 min; 
Fmoc-D-iSer(Bn)-OH, DIC, HOBt, DMF, 25ºC, 24 h. 
Conclusiones
Durante la realización de esta Tesis Doctoral se ha llevado a cabo 
la síntesis tanto de productos naturales como análogos, que contienen 
anillos de oxirano en su estructura. En total, 4 análogos de bengamides 
fueron sintetizados y su actividad biológica evaluada, arrojando nuevos 
datos SAR a los ya conocidos. Se ha establecido además la primera 
estrategia para la síntesis de unos nuevos derivados, las amino 
bengamidas, que pueden presentar mayor interacción con las enzimas 
MetAP.
Se ha completado la síntesis del precursor del gummiferol, 
realizando una síntesis formal que emplea los iluros de azufre para la 
construcción de los epóxidos, ofreciendo una alternativa a la única síntesis 
total descrita por Takamura y basada en la metodología de Sharpless.
Por otro lado, se ha descrito una aproximación sintética hacia la 
depudecina, alcanzando un precursor avanzado de su enantiómero aún no 
descrito, y en la actualidad, seguimos trabajando para completar su 
síntesis total.
Además, se ha trabajado con la metodología de síntesis en fase 
sólida de las cadenas peptídicas de diferentes productos naturales de 







All reactions were performed using oven-dried glassware (200ºC) 
under an atmosphere of dry argon unless using aqueous reagents or 
otherwise stated. All solvents used in reactions were dried and distilled 
using standard procedures. DMF and DMSO were purchased from 
Sigma-Aldrich. THF and toluene were distilled from sodium and CH2Cl2 
and MeOH from calcium hydride prior to use. All other solvents were 
used as supplied unless otherwise stated.
All reagents were purchased from Aldrich, Acros Chimica, Merk 
or Alfa Aesar and were used as supplied or purified using standard 
procedures as necessary. All solutions used in workup procedures were 
saturated unless otherwise noted.
Flash column chromatography (FCC) was performed using E. 
Merk silica gel 60 Ȧ, particle size 230-400 mesh under air pressure. All 
solvents used for chromatographic purification were distilled prior to use. 
Analytical TLC was performed using silica gel 60 F254 ALUGRAM® SII 
G/UV254 plates and visualized by ultraviolet radiation (254 nm), 
potassium permanganate or acidic ceric ammonium molybdate as 
appropriate. Preparative HPLC was performer in reversed-phase with a 
C8 5 µL-Luna column (250 x 10.00 nm) with a flow rate 4.7 mL/min.
Quantities are reported to 3 significant figures and are rounded 
accordingly. Isolated yields are reported to 0 decimal places and “quant.” 
signifies a yield of  99.5% or higher.
NMR spectra were recorded on Bruker DPX-400 (400 MHz). 
Chemical shifts are reported in ppm with the resonance resulting from 
incomplete deuteration of the solvent as the internal standard (CDCl3: 
7.26 ppm, DMSO-d6, 2.49 ppm and D2O, 4.80 ppm). 1H NMR 
assignments were undertaken based on bidimentional NMR experiments 
of COSY (cosyp experiment). 13C NMR spectra were recorded on Bruker 
DPX-400 (100 MHz) spectometer (with complete proton decoupling). 
Chemical shifts are reported in ppm with the solvent resonance as the 
internal standard (13CDCl3: 77.0 ppm, t). Data are reported as follows: 
chemical shift δ/ppm (integration (1H only), multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, br = broad, app = apparent, m = 
multiplet or combinations thereof). 13C signals are singles (unless otherwise 
stated), coupling constants J (Hz, assignment).
High resolution mass spectrometry (HRMS) was performed on a 
Bruker HCT-ULTRA mass spectrometer under Fast Atom Bombardment 
(FAB) conditions and on a ESI-TOF and APCI mass spectrometer in 
positive mode. HRMS signals are reported to 4 decimal places and are 
within ± 5 ppm of  theoretical values.
Infrared spectra were recorded neat on a Perkin Elmer Spectrum 
One FTIR spectrometer and only selected peaks are reported (s = strong, 
m = medium, w = weak, br = broad).
Specific optical rotations were recorded on a Perkin-Elmer 241 
polarimeter with a sodium halogen lamp (𝛌 = 589 nm) and a cell path 
length of  100 nm (c given in g/100 mL).
Melting points were collected using a Gallenkamp or a Griffin 






Cell culture media were purchased from BLBco (GRand Island, 
NY, USA) and Cambrex (Walkersville, MD, USA). Fetal bovine serum 
(FBS) was a product of Harlan-Seralaba (Belton, UK). Supplements and 
other chemicals not listed in this section were obtained from Sigma 
Chemicals Co. (St. Louis, Mo., USA). Plasatics for cell culture were 
supplied by NUNC (Roskilde, Denmark). Bengamides and related 
compounds were dissolved in dimetylsulfoxide (DMSO) and stored at 
-20ºC until use.
Cell culture
Bovine aortic endothelial (BAE) cells were obtained by collagenase 
digestion and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing glucose (1 g/L), glutamine (2 mM), penicillin (50 IU/
ml), streptomycin (50 µg/mL) and amphoterycin (1.25 µg/mL) 
supplemented with 10% FBS. All the cancer cell lines used in this study 
were obtained from the American Type culture collection (ATCC). human 
fibrosarcoma HT1080 cells were maintained in DMEM containing 
glucose (4.5 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin 
(50 µg/ml) and amphoterycin (1.25 µg/mL) supplemented with 10% FBS. 
Human colon adenocarcinoma HT29 cells were maintained in McCoy’s 
5A medium containing glutamine (2 mM), penicillin (50 IU/mL), 
streptomycin (50 µg/mL) and amphoterycin (1.25 µg/mL) supplemented 
with 10% FBS. Human breast cancer carcinoma MDA-MB-231 and 
human promyelocytic leukemia HL60 cells were maintained in 
RPMI1640 medium containing glutamine (2 mM), penicillin (50 IU/mL), 
streptomycin (50 IU/mL), streptomycin (50 µg/mL) and amphoterycin 





The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT; Sigma Chemical co., S. Louis, MO) dye reduction assay in 96-well 
microplates was performed by Drug Discovery biotech S. L. (Málaga, 
Spain), using the method of Mossman. 3.10-3 BAE or 2.10exp3 tumor 
cells in a totla volum of 100 µL of their respective groth media were 
incubated with serial dilutions of the tested compounds. After 3 days of 
incubation (37ºC, 5% CO2 in a humid atmosphere) 10 µL of MTT (5 
mg/mL in PBS) were added to each well and the plate was incubated for a 
further 4 h (37ºC). The resulting formazan was dissolved in 150 µL of 
0.04 N HC/2-propanol and read at 550 nm. all determinations were 
carried out in triplicate. IC50 value was calculated from semilogarithmic 
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13C Spectra (100 MHz)
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13C Spectra (100 MHz)
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13C Spectra (100 MHz)
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13C Spectra (100 MHz)
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13C Spectra (100 MHz)
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1H Spectra (400 MHz)
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13C Spectra (100 MHz)
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1H Spectra (400 MHz)
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